Content
Quantexa News
09/15
Esperion Therapeutics (NASDAQ:ESPR) Rating Lowered to Hold at StockNews.com
StockNews.com lowered shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a buy rating to a hold rating in a research note published on Wednesday. Other equities research analysts also r...
Quantexa News
09/16
Esperion Therapeutics Inc. (NASDAQ: ESPR) Stock: Does It Have More Upside?
In the latest trading session, 0.69 million shares of the Esperion Therapeutics Inc. (NASDAQ:ESPR) were traded, and its beta was 0.99. Most recently the company's share price was $1.85, and it changed...
Yahoo Finance Community
09/16
Comment
Gregg. We have zero position buddy. We actually are rooting for you but we love to put RS, Gary, Charles and Karen in their places. If we could wish it so, we would make it 5 for you by friday. However we will continue to destroy those that pump this junk and try to deceive retail into buying this toxic stock...
Votes:
1
1
Yahoo Finance Community
09/16
Comment
As a patient long, sitting back and watching all “small”, yet to be profitable companies struggling in this market . Will continue until ESPR makes progress on profitability and/or partnership. But given optimistic projections by management, big support of Otsuka, Daiichi and Omers, it is time to buy. I bought at $1.72 and will buy more if it dips. Easy money, just like buys at .80 and below longs preached about....
Votes:
2
0
Yahoo Finance Community
09/16
Comment
Some things to keep in mind (disclosure I am bullish): This is the way it works in the real world, a rep calls on a Dr. multiple times with the marketing message. The Dr agrees with the data or not. The Dr writes an rx and it is or isn’t covered. If it isn’t covered it gives the Dr the perception that it is a hassle to rx. All things being equal coverage is EVERYTHING. The coverage for nexletol has dramatically improved (I personally had no problems getting it covered and have a zero dollar copay).Keep in mind also that this is a chronic medication, most patients are on it for life. So what you will see every quarter is exponential growth from refills. I’ll repeat my premise that the market cap is ridiculously low for a company that has a drug in a multibillion dollar market. Gaining literally 1-2% …...
Votes:
9
0
Yahoo Finance Community
09/17
Comment
Last week Sheldon told Eric To run AI analysis on the sales figures. Eric contacted a data science firm For $150k. The firm reported back to Sheldon that past week Esperion sold three new prescriptions. One in each of three states. Their model predicted greater sales if Sheldon could sell more prescriptions in more states. Sheldon was blown away....
Quantexa News
09/17
Principal Financial Group Inc. Reduces Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Principal Financial Group Inc. reduced its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 29.9% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 20,430 shares of th...
Yahoo Finance Community
09/17
Comment
Where are the billions in revenue? FDA label expansion was so long ago and they are still in the 20 millions of dollars of sales a QTR.What is your definition of blockbuster?Who wants to admit they were manipulated by those pumping posts? Peak Sales by December the chart is saying...
Votes:
1
1
Yahoo Finance Community
09/17
Comment
Look at Europe: it took time to ramp sales. US now has primary treatment added. Takes time for payors to add and doctors to prescribe. Not complicated , but coin flippers like to flip. Then add convertibles being restructured soon, profitability in upcoming quarters, and Japan racing to start up, you can understand why Omers partnered with ESPR, just like Otsuka and Daiichi. Smart money gets it even if small players are momentum trading based on XBI for short term nickels....
Votes:
4
0
Yahoo Finance Community
09/17
Comment
I am glad this stock recovered some of its massive losses incurred yesterday. Yet I can't help thinking that it can never maintain this massive market cap. Most startup pharmaceuticals in its peer group trade at market caps much closer to $20 million....
Votes:
1
2
Yahoo Finance Community
09/17
Comment
There is a pharma called GLMD that traded ip 290% today. Much like Esperion they don't have an encouraging product so maybe Esperion has some hope. On the other hand, they don't have debt mountain and astronomical cash burn that Esperion maintains, so maybe not....
Votes:
2
1
Yahoo Finance Community
09/17
Comment
Djohnson. I never agree with you but i do on this. Selling for tax purposes always is horrible for insiders considering decimation of stock price under their charge. Use money from bloated salary to oay taxes. It does not have to ne stock sales.If you thought stock was going up, they would buy shares and pay cash for tax obligations.CEO is horrible. He hates shareholders....
Quantexa News
09/18
Bokf Na Purchases Shares of 11,905 Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Bokf Na acquired a new stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC...
Yahoo Finance Community
09/18
Comment
Triple pill combo that Daiichi signed up for will bring in revenue to ESPR to 2040+. BA for US is to 2031 with no extensions. They have patents for combos in US as well, which will proceed in time. There are also new applications of BA in file that could extend patents even further. Shorts can’t see past ESPR for a week yet they opine on 2040+. Just shows you the disconnect of ESPR and its stock price and “investors” mentality. But all changes in time....
Votes:
2
1
Yahoo Finance Community
09/18
Comment
Historically, the average one year out analyst prediction has been at about 10X Esperion's current trading price. Today, it is at $7.82 which is only 4.4X current trading price. To adjust to historic averages, the share price would need to be at $.78. I think we will see this correction....
Votes:
1
1
Yahoo Finance Community
09/18
Comment
I used to own this stock and have traded it for years. I’ve been watching it for approximately 8 years, the problem with the stock is that the CEO and all his cronies pay themselves handsomely. Have no inkling or education for running any sort of business. They are using your investments in their stock as their personal piggy bank. I don’t know if you’ve ever heard the CEO talk during earnings or presentations, but he is unable to put a sentence together that makes any sense, but he continues to pay himself and give stock options to all of his cronies on his board, this might as well be a shell company....
Votes:
3
0
Yahoo Finance Community
09/18
Comment
This has 1.5 written all over it.Expect revenues this QTR to be 31 million. Following QTR might hit Peak Sales. Doctors have never heard of it nor do they believe in the benefits. Only investors know about this drug. They sold off European royalties for almost 20 years. No profits EVER...
Votes:
1
0
Yahoo Finance Community
09/18
Comment
What does OMERS, Otsuka, and Daiichi all know to make them want to partner with ESPR and place a valuation over $5b? Easy, look at the market opportunity, sales ramp in Europe, the science, and need for the drug. New studies recently out showing obesity continuing to be a plague on the US and worldwide regardless of weight loss drugs. “Say hello to my little friend”says Sheldon....
Votes:
5
0
Quantexa News
09/19
Esperion Therapeutics (NASDAQ:ESPR) Lifted to Buy at StockNews.com
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday. Get Esperion...
Quantexa News
09/19
Esperion Therapeutics (NASDAQ:ESPR) Lifted to Buy at StockNews.com
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday. A number of...
Yahoo Finance Community
09/19
Comment
No one wants to buy a stock that is only growing 3 mil a QTR. As if that wasn't enough you have the most incompetent management ever. Yes, we said on that last totally unnecessary dilution that the stock was DEAD. We were the only ones to say it was over and legitimate funds LEFT. Guess what? Stock is back at the price where it hit on news of dilution. We are always so correct.Now we made so much in the interim shorting any pops. We have no position because there is no more meat on the bones. Folks there is nothing of value in this stock now. After DSE royalties were signed away for almost 20 years. There is nothing here but losses and incompetence. Chances are there is some kind of IT issue with todays call. Sheldon is incapable of showing any kind of professionalism.Do you remember when …...
Yahoo Finance Community
09/19
Comment
I hope Sheldon discusses lack of insider buying and constant insider selling. They could use cash for tax purposes if they felt the stock was going to go higher. They do not have to sell options to pay tax obligations. Do not fall for the manipulation. They could write a check. Real easy. You use shares if you know it is never going up...
Quantexa News
09/19
Marathon Trading Investment Management LLC Lowers Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Marathon Trading Investment Management LLC reduced its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 81.8% in the second quarter, according to its most recent disclosur...
Quantexa News
09/19
Equities Research Analysts' Upgrades for September 19th (AFLYY, CAL, CGNT, DASH, DLNG, EFX, ELS, ESCA, ESPR, MIND)
Equities Research Analysts' upgrades for Thursday, September 19th: Air France-KLM (OTCMKTS:AFLYY) was upgraded by analysts at BNP Paribas from an underperform rating to a neutral rating. Caleres (NY...
Yahoo Finance Community
09/19
Comment
31 million in Sales this QTR after five years.240 million sharesNo insider buyingTheir interests are not aligned with shareholders sheldon said. He hates you allBeg for a PTLA type dump. No one would pay a dollar for these losses. Most US doctors never heard of this drug and payors make it impossible to prescribe....
Votes:
1
1
Yahoo Finance Community
09/19
Comment
Hey at least CLEAR had a lot of mexicans and women. That should make all you woke folks feel good. Did you hear the CFO say they felt like rock stars at ACC in 23? All they care about is showing up to medical conferences on your dime and feeling important. No mention of NASCAR by them ever. So why waste all of those millions on something they never speak of?Sheldon and his brat kids love NASCAR and so daddy can take them to the PIT and feel like rock stars. You all were played and played pretty well I may add. Tim M was the person to lead this and they fired him and placed Slimy Sheldon....
Votes:
1
1
Yahoo Finance Community
09/19
Comment
James. Did you learn about opportunity lost yet? This is what ESPR is all about. Unnecessary dilutionIncompetent CEOSlow rolling CLEAR data for yearsSlow rolling filing for label changeWasting millions on things that did not matterI could go on and on but look at that chart over 3 years. Then look at chart of any stock we mentioned last 3 years. This is a LOSER...
Yahoo Finance Community
09/19
Comment
That was something folks. Again, no pumping for a month. Longs need time to digest their failure. Stocktwits are reall people with real emotions. Most on here own nothing. They have ZERO emotions, and these kinds of losses would bother all. Evern rich people would be mad....
Votes:
1
2
Yahoo Finance Community
09/19
Comment
Insiders will be selling again next month. All they do is sell and you dummies supposedly buy. Here is the thing. They are burning 240 million a year and they have no profits. So how will they come up with the 500 million needed to keep this going?...
Votes:
1
2
Quantexa News
09/20
Esperion Therapeutics (NASDAQ:ESPR) versus Ainos (NASDAQ:AIMD) Critical Analysis
Ainos ( NASDAQ:AIMD – Get Free Report ) and Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ) are both small-cap medical companies, but which is the superior stock? We will compare the two busin...
Quantexa News
09/20
Comparing Ainos (NASDAQ:AIMD) & Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) and Ainos (NASDAQ:AIMD – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two com...
Quantexa News
09/20
Esperion Therapeutics (NASDAQ:ESPR) Upgraded to Buy by StockNews.com
StockNews.com upgraded shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) from a hold rating to a buy rating in a research report report published on Thursday. Several other analysts also re...
Quantexa News
09/20
Esperion Therapeutics (NASDAQ:ESPR) Upgraded to Buy at StockNews.com
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a research report sent to investors on Thursday morning. ESPR has been the sub...
Yahoo Finance Community
09/20
Comment
What you all have been incapable to understand is this. Even if they grow sales marginally, that is never going to cut it. I do not know why they Sheldon and Antony lied about inflection immediately upon FDA label. Anyone knew it doesn't happen that way. They still have no gotten the VA to authorize. That was two years ago they said that lie and charles fell for it. Low IQ being manipulated. Sheldon has never been called out for saying sales inflection upon FDA label.Now they needed a lot more money to grow sales force and hire competent sales people. The former house cleaners was a generous touch but it failed misterably.They need so much money to ramp sales so why did they do that dilution at the low and before all of the good news? Again, we said on that last dilution He killed the stock forever. We …...
Yahoo Finance Community
09/20
Comment
Daiichi, Otsuka and most recently Omer’s invested billions in ESPR. Easy for big pharma and investment firms to see the value. But Wall Street wants proof. Sort of like when Apple was !5 a share and launched the iPhone, it took time for sales to ramp and Wall Street to jump on. But it always happens regardless of all the tears and crying....
Votes:
2
1
Yahoo Finance Community
09/20
Comment
We told all this was inevitable.We gave the myriad of reasons. They were spot on.Next round of dilution comes next. They need money and lots of it. Nascar costs a lot of money. Same with flying management team around the world. They feel like rick stars eric said yesterday....
Yahoo Finance Community
09/20
Comment
Stocktwits are real investors losing real money. Yahoo longs are all fake. Their tone never changes. Impossible for this many not to care about losing 99% of their investments. Go to ST and forget yahoo. This is not real people. Anyone disagree? Not one person that posts here is mad or believable. It's like a Disney movie. This has FAILED. There is no recovery....
Yahoo Finance Community
09/20
Comment
What is comical is market cap is still almost 400 million. That is a major downsize to non stop dilution. It is still way over priced. US operations is a complete failure. Keesha is a senior manager in charge of marketing and she was an intern at foot locker 2 years ago. This is so sad. They never put together a competent team. They wanted this to fail....
Yahoo Finance Community
09/20
Comment
Cafe Pharma someone recently posted that they are starting to lay people off. Something about a misuse of funds within the company and no money to pay salaries. Do not worry though. Sheldon told all at the recent all hands meeting that he will get all of his before they get theirs. So Sheldon is good...
Votes:
1
1
Yahoo Finance Community
09/20
Comment
XBI down, ESPR is down. At some point ESPR will decouple. How else will ESPR get to $20 preordained share price? ESPR reminds me of Apple in so many ways. I’m already happy knowing the investment payoff is inevitable, but I can’t wait until every single poster on this board is happy. It’s sad when others are sad!...
Votes:
6
2
Quantexa News
09/21
StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to Buy
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Thursday. A number of...
Quantexa News
09/21
Esperion Therapeutics (NASDAQ:ESPR) Upgraded at StockNews.com
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday....
Quantexa News
09/21
StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to Buy
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Thursday. A number of...
Quantexa News
09/21
Inspire Investing LLC Buys Shares of 341,223 Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Inspire Investing LLC bought a new stake in shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) in the 2nd quarter, according to the company in its most recent 13F filing with the Secu...
Yahoo Finance Community
09/21
Comment
I feel sad for Sheldon. I think people in the company told him not to speak at the investor conference last week. They pointed out the damage he does to the share price. Now I think young Ben, the CFO, is plotting a Sheldon overthrow with the board. Keesha in sales is supporting him. There was also a rumor that Dr. Pinderschloss is supporting the ouster because they promised her the Chief Medical Officer position....
Yahoo Finance Community
09/21
Comment
I wonder which big pharma will buy ESPR. It will likely be a bidding war, as I suspect multiple big pharma will jump in. With the new generational molecules looking good, and cfo confirming BA will be a blockbuster in both Europe and US, at least a billion in each market, and IP out to 2040 for Europe and likely the same for US with combinations, this is getting exciting....
Votes:
4
0
Quantexa News
09/22
Esperion Therapeutics (NASDAQ:ESPR) Raised to “Buy” at StockNews.com
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a research note published on Thursday morning. A number of other research anal...
Quantexa News
09/23
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by StockNews.com to Buy
upgraded shares of Esperion Therapeutics ( – from a hold rating to a buy rating in a research note published on Thursday. A number of other analysts have also recently commented on ESPR. Needham & Co...
Quantexa News
09/23
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Stake Raised by XTX Topco Ltd
XTX Topco Ltd grew its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 751.6% during the second quarter, according to the company in its most recent Form 13F filing wi...
Quantexa News
09/23
Market Recap: Esperion Therapeutics Inc. (ESPR)'s Negative Momentum, Closing at 1.68
Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation. 3 Tiny Stocks Primed to Explode...
Quantexa News
09/23
Esperion Therapeutics Inc. (ESPR) Is Another Fantastic Bargain Stock
Esperion Therapeutics Inc. (NASDAQ:ESPR) has a beta value of 1.00 and has seen 0.87 million shares traded in the recent trading session. The company, currently valued at $327.69M, closed the recent tr...
Yahoo Finance Community
09/23
Comment
I’m afraid if European sales keep ramping, Omers will be paid back in 2 years, and ESPR will be receiving over $100m a year from Daiichi’s efforts, quickly escalating to $500m per year. Poor Daiichi, all that work and it will end up going to espr ams buying longs some bigger islands. So sad (i guess)....
Votes:
4
0
Yahoo Finance Community
09/23
Comment
I mean, what is a small company like ESPR going to do with hundreds of millions of revenue coming in, with no costs for manufacturing or distribution or sales. Daiichi sure must love ESPR to do that deal. Talk about dreaming! Why dream when reality is even better....
Votes:
4
1
Yahoo Finance Community
09/23
Comment
Well, did everybody hear the news? United healthcare has now moved Nexletol and Nexlizet to the preventative medicine list for January 2025, did you get that, that’s preventative medicine, that’s your primary prevention. You won’t find the injections on that list, you’ll find statins and this drug, the two that are indicated for primary prevention. Oh boy, I’m glad I’ve been loading up on shares at these cheap prices!...
Votes:
10
0
Yahoo Finance Community
09/24
Comment
We are now ending the 3rd quarter. Claims of blockbuster drug will be tested when US sales are released in November. Anemic growth, again, will send Esperion's very high share price into a tailspin. Anything less than $45 million will be a disaster....
Votes:
1
2
Yahoo Finance Community
09/24
Comment
Next offering might look like this200 million shares at 1 dollar and 300 million warrants at .25 cents.They will need to raise money and it will be extremely tough now with sales abysmal. This type of raise will result in immediate sales by those buying these shares to lock in immediate gains.The stock will hit new all time lows. De listing by Jan 2025...
Yahoo Finance Community
09/24
Comment
After a weekend of a thousand daggers, it looks like the new management structure is now sorted out. Sheldon will remain the CEO for the foreseeable period. Keesha will now be the Global Head of Sales. Eric will stay on as number 2 in the sales organization and will keep his comp package. Ben will become Deputy CEO and retain his CFO title. Only poor Dr. Pinderschloss is still without a position. Poor Greta. On the compensation front, Keesha is petitioning the board of directors for her own corporate jet and Bentley. She feels that not having one at her level is biased. The board is inclined to agree because they are committed to a fair environment that promotes DEI. They are trying to find a jet similar to Sheldon's but with inflation it is difficult to find a jet lease for less than $2 million per month....
Yahoo Finance Community
09/24
Comment
Does anyone actually think this ever sees 2s again???OMERS will take 12 to 15 years to get paid off. That means that royalty stream is not available to ESPR for so long of a time. Otsuka will not provide much if anything first couple of years.It all comes down to US operations and they have been abysmal. Cafe pharma says layoffs are coming to many. The drug is not selling and doctors are no entertaining these reps. The perfect storm if short....
Votes:
1
2
Yahoo Finance Community
09/24
Comment
Well I stand corrected. It made the 2025 preventative drug list with United healthcare and they’re a huge patient population but they actually retro it and made it effective September 1 when they added it it is on the 2024 preventative drug list. also, I don’t see any PCSK9s on that list...
Votes:
5
0
Yahoo Finance Community
09/24
Comment
Something to think about.They were losing money manufacturing the drug for DSE. James so rightly pointed it out before Sheldon admitted it. Does ESPR manufacture the drug for Otsuka? If so, they will lose more money on that endeavor. They need to make sure Otsuka manufactures the drug because only thing sheldon knows is how to lose money. If ESPR manufactures and if they are successful selling in japan, the losses get much bigger. They can't win with the rules they designed. Huge offering coming says the charts and it will be a back breaker for all longs....
Yahoo Finance Community
09/24
Comment
I am happy that this is trading up, for once, today. I am sad that the gain will be short lived as I don't believe Esperion can maintain this astronomical market cap. Most of its peer companies in the speculative start up pharma space have market caps around $20 million and they don't face the financial crisis that Esperion has. The share price will likely revert to about $.10 which would give Esperion a $20 million market cap. Makes sense....
Votes:
1
4
Quantexa News
09/24
Esperion Therapeutics Inc. (ESPR) average volume reaches $5.64M: Is Wall Street expecting a rally?
kicked off on Monday, with Esperion Therapeutics Inc. (NASDAQ: ESPR) stock price down -2.98% from the previous day of trading, before settling in for the closing price of $1.68. ESPR's price has range...
Yahoo Finance Community
09/25
Comment
Keesha, the new global head of sales, had her first meeting with the Esperion marketing team. It was a glum affair. It seems that the team had based their entire strategy around the Lipid Lurker. $5 million was spent on brochures, videos, coffee mugs, even repainting the NASCAR to bear his image. Now the Lipid Lurker is threatening to sue and demanding they remove his image from all Esperion materials. Very sad....
Yahoo Finance Community
09/25
Comment
At the Q2 earnings call, CFO Ben, was optimistic he could refi the $250 million in debt due for repayment in 2025. At the subsequent investor conferences he didn't mention the refi and that means it is not possible. This means that over the next year, poor Esperion faces $500 million in unfunded negative cash flow. Ouch....
Yahoo Finance Community
09/25
Comment
The Board has been trying to accommodate Keesha's demand for a corporate jet. ben spent all day speaking to carious jet finance organizations. The going lease rate is about $2.5 million per month. Ben is fine with that but the leasing people are concerned with Esperion's lack of sales and horrific cash burn. To put it mildly, they are not the best credit risk. They have asked that the loan amount be secured by the drug patents. Ben said he would have to check with the board....
Yahoo Finance Community
09/25
Comment
When ESPR is breakeven in the next quarter or two, which is understandable given the cfo and ceo both stating it will happen and the unprecedented label change and primary treatment given to ESPR, I wonder who will try to buy ESPR. We know Daiichi, but Otsuka and OMERS are two other top choices. Then you have MRK, Amgen, sanofi, PFE, Bayer, etc, the list is really endless. Which company would not want $2b+ of cash flow annually out to 2040+, with next gen drugs looking stellar? Hmmmm...
Votes:
4
1
Yahoo Finance Community
09/25
Comment
Sheldon will wait until stock is again at all time lows for next dilution400 million shares at .75 cents and 1 billion warrants at .5 cents. Folks it is happening. Sales have never materialized and the cash burn is very real. We hope you prepared because the end is coming sooner than you would think...
Yahoo Finance Community
09/25
Comment
Guys please continue to hold this down for me until I get more cash, I know it’s a tough task since we are flying lately, then hopefully we can dilute and or do a reverse split and I can loose again I’m about a week out on shares been banned from options...
Votes:
3
0
Yahoo Finance News
09/25
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Esperion Therapeutics, Inc. Esperion Therapeutics, Inc. Wed, Sep 25, 2024, 4:30 PM 2 min read In This Article: ESPR +1.86% ANN...
Quantexa News
09/26
Rhumbline Advisers Acquires 248,254 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Rhumbline Advisers increased its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 6,560.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange...
Quantexa News
09/26
Rhumbline Advisers Acquires 248,254 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Rhumbline Advisers increased its stake in Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) by 6,560.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchan...
Yahoo Finance Community
09/26
Comment
My guess is Daiichi will buy ESPR soon. By taking over all manufacturing costs($100m+ per year) and taking on triple pill combo to extend patent out to 2040, you can see they want ESPR. Label change was the final straw, as all is aligned perfectly. It only makes sense to buy them. If only Sheldon would agree to their lowball offer ($6b?). But now that Amgen is interested, and PE are kicking the tires, you can see how Daiichi is getting desperate. I would almost say they are sad. Very sad. But maybe not for long....
Votes:
5
0
Yahoo Finance Community
09/27
Comment
Such desperate on here. The realization they missed out on one of the greatest bull runs ever! Opportunity lost is never something one can do over.Look at some if these posts. Befging buyout. Celebrating up a penny when markets moved so much. However the stock is still down a lot this month and year. You were never smarter and it was evident. We loved making a fortune on this....
Votes:
2
4
Yahoo Finance Community
09/27
Comment
I checked the Stocktwits board for the weekly scrip numbers. Please be warned that someone on that board if posting made up numbers. Even the devoted longs are angry that someone would make numbers up. It seems immoral to try to fool investors on that board, who have so little ability to discern fact from fiction, with made up numbers. It all reeks of final days desperation. It is really sad....
Votes:
1
1
Yahoo Finance Community
09/27
Comment
If you are interested in US scripts, I just look at the tremendous ramp in Europe. Europe had a more liberal label and was supported much earlier than US. Now that label change occurred, and unprecedented primary treatment approval was given to BA, you can see a similar trajectory. But instead of 25% of billions of sales, ESPR receives 100% of the billions of sales in US. Then you have Japan rolling in soon which demand will be huge, being a big alternative statin market. You can see why buyout estimates have increased from $5b to $6-8b! Still a steep discount to inclisiran....
Votes:
6
1
Yahoo Finance Community
09/27
Comment
Keesha and Ben are meeting today to go over the finances at Esperion. Keesha thinks they should do the next dilution round now while the share price is still so high. She wants to do it once and get enough money to fund the cash flow through the end of 2025. She thinks 400 million shares should do it....
Quantexa News
09/28
Esperion Therapeutics (NASDAQ:ESPR) Downgraded by StockNews.com to Hold
StockNews.com lowered shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a buy rating to a hold rating in a research note published on Friday. A number of other analysts have also recen...
Quantexa News
09/29
Esperion Therapeutics (NASDAQ:ESPR) Rating Lowered to Hold at StockNews.com
Esperion Therapeutics ( – was downgraded by analysts at from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday. A number of other equities analysts have...
Quantexa News
09/29
Deerfield Management Company L.P. Series C Takes Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Deerfield Management Company L.P. Series C bought a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) during the 2nd quarter, according to its most recent disclosure wi...
Yahoo Finance Community
09/29
Comment
The real question and only important issue now is Q3 sales.it took 5 years and a billion in sales and marketing to get US sales up to $28 million.coverage is now onboard for 100's of million Americans. Sales of any thing leas than $40 million is going to drive the share-price to new all time lows....
Yahoo Finance Community
09/29
Comment
Label change was 4/1/24. Prior to 4/1, bempedoic acid could not be prescribed (reasonably). Drs couldn’t prescribe and payors would not pay (reasonably). Now with the label change the ramp has begun. Europe is a perfect example of the ramp we could expect in US. Pretty simple if you think it through. Unless you’re Kurt, and you would just rather flip a coin....
Votes:
1
0
Yahoo Finance Community
09/29
Comment
I think the real question is what is holding ESPR stock back from skyrocketing upwards with such good news being released. Some suspect it is warrants being exercised to pin the share price down. But there is only a finite amount of pinning that can occur . With profitability coming up, and convertibles to be restructured, the value of ESPR is really being recognized and at some point, ESPR will take off. Given patent extensions to 2040+ for triple pill combo, and likely extensions in other areas, the future is bright for ESPR. And now with next generational molecules being discussed, the long term value has never been better....
Votes:
2
0
Yahoo Finance Community
09/29
Comment
Amgen, Daiichi, Otsuka, PFE, MRK, Sanofi, etc are all looking at European sales. They are all wondering what they could sell with their 5,000 + sales agents in the US vs the 150 newly hired sales agents of ESPR. Common sense. If ESPR’s sales agents can’t do it, you can bet another big pharma will be joining the club soon....
Votes:
1
0
Yahoo Finance Community
09/29
Comment
Keesha is going to start preparing the Esperion troops for the Q3 earnings release coming mid-November. She needs them to double down on the "blockbuster' and '$10 billion dollar buyout' posts. This will help to offset the negative reaction to another quarter of stagnate sales....
Quantexa News
09/30
Renaissance Technologies LLC Has $3.16 Million Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) Posted by on Sep 30th, 2024 A number of other large investors also recently made changes to their positions in ESPR. Bellevue Group AG raised its st
Renaissance Technologies LLC lowered its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 32.8% during the second quarter, according to the company in its most recent filing with th...
Quantexa News
09/30
Renaissance Technologies LLC Sells 694,600 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Renaissance Technologies LLC reduced its stake in shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) by 32.8% during the 2nd quarter, according to the company in its most recent Form...
Yahoo Finance Community
09/30
Comment
Everyone on the Stocktwits board is excited because they have calculated Esperion had 100 sales of BA the other week. Of course, if someone was given a 90 supply, this counts as three prescriptions. With 150 sales people, this is .66 prescriptions per sales person. No wonder it costs $25,000 in sales and marketing spend to generate one new prescription. No one seems to want these pills. It is a very sad situation, perhaps they should consider selling something else?...
Votes:
1
0
Quantexa News
09/30
Marshall Wace LLP Increases Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Marshall Wace LLP lifted its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 94.2% during the 2nd quarter, according to the company in its most recent filing with the...
Yahoo Finance Community
09/30
Comment
I say Sheldon holds out on Daiichi’s soon to be offer until they get to $6b. That will be a good discount to what any other BP would pay. Daiichi should take it and run but I think they will be cheap and we’ll get in a bidding war. Oh well, what can you do as a long but watch the show....
Votes:
2
1
Yahoo Finance Community
09/30
Comment
We have a really identifiable trading pattern here in Esperion. The morning sessions are punctuated with retail investors bidding up the price by 2 or 3%. The afternoons end up erasing this and then another 3=5%. This occurs as institutions continue to exit....
Votes:
1
1
Quantexa News
09/30
Marshall Wace LLP Buys 2,087,635 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Marshall Wace LLP increased its stake in shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) by 94.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securiti...
Yahoo Finance Community
09/30
Comment
I wonder if OMERS has a bigger strategy here with ESPR. Expanding into Canada and other territories in the near term. OMERS acquires and/or invests only in premier companies with the best of opportunities. I sure do like it when smart money takes positions in stocks they I own....
Votes:
2
0
Quantexa News
09/30
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Down 5.8% in September
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) saw a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 38,090,000 shares,...
Quantexa News
09/30
Short Interest in Esperion Therapeutics, Inc. (NASDAQ:ESPR) Drops By 5.8%
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) was the recipient of a significant decrease in short interest in September. As of September 15th, there was short interest totalling 38,09...
Yahoo Finance Community
09/30
Comment
The Stocktwits people post some good information. Someone posted the Q3 analysts revenue estimates for Esperion. The high estimate is $62 million. The low estimate is $43 million. Of course, we all know it will be nowhere close to even the low number. More than likely it will be about $31 million. How devastating these stagnant sales are going to be on the share price. Look out below!...
Quantexa News
09/30
Short Interest in Esperion Therapeutics, Inc. (NASDAQ:ESPR) Drops By 5.8%
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) was the recipient of a significant decrease in short interest in September. As of September 15th, there was short interest totalling 38,09...
Yahoo Finance Community
09/30
Comment
Keesha held a strategy meeting for the C-Suite today. They mulled over many action but decided none of them were likely to boost sales. In the end they all said it would he great if this were a bad COVID season. That helped them ride the first two years of post FDA approval when they also achieved no sales....
Yahoo Finance Community
09/30
Comment
Someone on the SW board calculated a sales increase of 14% for Q3. That is approximately $3.9 million. This figure will be enough to drag the share-price to a new low when earnings are reported. It might actually achieve a new low before then. No one seems to want these pills. Very sad....
Yahoo Finance Community
09/30
Comment
I had a dream last night. There was a poor woman lying on the delivery table just writhing in agony. After hours of suffering she finally delivered the baby. The doctor looked at the baby and said, "Inthink the baby is brain dead, please let's start the morphine". The mother screamed, "No, this baby will survive!" The doctor respected the mothers wish and stood down on the morphine. The baby survived , but sadly, lived out it's days in a very costly vegetative state. The mother loved the child as a mother would. She called the baby Esperion. I think Dr. Pinderschloss delivered the baby....
Quantexa News
10/01
StockNews.com Downgrades Esperion Therapeutics (NASDAQ:ESPR) to Hold
StockNews.com cut shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a buy rating to a hold rating in a report published on Friday. A number of other brokerages also recently weighed in...
Quantexa News
10/01
Esperion Therapeutics (NASDAQ:ESPR) Downgraded to “Hold” at StockNews.com
StockNews.com downgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a buy rating to a hold rating in a research note issued to investors on Friday. A number of other equities an...
Quantexa News
10/01
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Sees Large Decrease in Short Interest
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) was the recipient of a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 3...
Quantexa News
10/02
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Sees Large Decline in Short Interest
NASDAQ:ESPR – Get Free Report ) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totalling 38,090,000 shares, a decrease of 5.8% fro...
Quantexa News
10/02
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Sees Significant Decline in Short Interest
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) saw a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling 38,090,000...
Yahoo Finance Community
10/02
Comment
It would be a good thing if Sheldon eliminated the sales force again as well as all the R&D people. It could save $200 million over the next twelve months and this is so important as they have only $150 million in remaining cash. They could do another dilution round and then try, for a third time, to relaunch the pills. Maybe under a new name....
Yahoo Finance News
10/02
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid Esperion Therapeutics, Inc. Esperi...
Quantexa News
10/02
HC Wainwright Reiterates Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $16.00...
Quantexa News
10/02
Esperion Therapeutics’ (ESPR) “Buy” Rating Reaffirmed at HC Wainwright
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They pres...
Quantexa News
10/02
Esperion Therapeutics' (ESPR) "Buy" Rating Reaffirmed at HC Wainwright
Esperion Therapeutics (NASDAQ:ESPR - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They pres...
Quantexa News
10/02
Esperion's Clinical and Financial Advancements Solidify Buy Rating
H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Esperion ( ESPR – Research Report ) today and set a price target of $16.00. Joseph Pantginis has given his Buy rating due to a comb...
Quantexa News
10/02
Equities Research Analysts' Updated EPS Estimates for October 2nd (AAPL, ADXN, AEO, AMN, BIOL, ESPR, FI, FLYW, FPAY, GNTA)
Equities Research Analysts' updated eps estimates for Wednesday, October 2nd: Get Apple Inc alerts: Apple (NASDAQ:AAPL) had its buy rating reissued by analysts at Citigroup Inc.. The firm currently...
Yahoo Finance Community
10/02
Comment
So 30% + risk reduction and 700% increase in meeting ldl goals! What is not to like. Almost as good as the stock price being up 900%. But that will happen soon enough I guess. Not only will ESPR make longs a ton of money, but it is saving lives. What can be better than that? And no Kurt, winning at the casino does not compare....
Votes:
4
0
Yahoo Finance Community
10/02
Comment
I think Sheldon was fed this line by Daiichi: . “We are very pleased with DSE’s continued progress and look at successes in the growing adoption of bempedoic acid in Europe and other international markets as a potential proxy for the significant market opportunity in the United States.” It only makes sense. So when the deal is announced, only Kurt will be surprised....
Votes:
3
0
Yahoo Finance News
10/03
Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?
Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5? Affan Mir Thu, Oct 3, 2024, 4:56 AM 6 min read In This Article: ESPR +10.20% ^GSPC +0.90% We recently compiled a list of 7 Best NA...
Yahoo Finance Community
10/03
Comment
Anyone here longer than a week knows that most likely this will be down the rest of the week. I predict .06 cent loss today and another .08 tomorrow. Bet we are back in the low 1.70s very soon. Same old bleed out after every rise. Don’t know who is doing it but exactly same as MTTR. Dropped from over 30$ a share to around 1.50 and just sits there despite multiple good news events. Then a lowball 4.50$ buyout after sitting the doing nothing for two year's. Check out the ticker it still trades because the deal hit a couple snags. Exact same chart. Also watch how fast the volume drys up from yesterday to today....
Quantexa News
10/03
Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Reaffirmed by HC Wainwright
HC Wainwright reissued their buy rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a report published on Wednesday morning, Benzinga reports. They currently have a $16.00 target...
Yahoo Finance Community
10/03
Comment
Geez, the longs have been loading up at bargain basement prices. We should be analysts on Wall Street: Esperion Therapeutics (NASDAQ:ESPR) recent financial results indicate a significant upward trend in revenue, which reflects the company’s expanding market presence and product acceptance....
Votes:
6
1
Yahoo Finance Community
10/03
Comment
A market cap under $400m when you have billions of revenue per year in a few years. Look at the investors: Otsuka, Daiichi, Omers! You have to ask yourself, how much longer will ESPR be around with everyone starting to see the value. Profitability is any day now. Daiichi agreed to pay for all manufacturing and distribution costs , estimated at over $100m per year. Who does that??!....
Votes:
10
0
Quantexa News
10/03
Esperion Therapeutics Inc. (NASDAQ: ESPR): Can A Stock Be Down -38.96% YTD, And Still Be A Loser
Esperion Therapeutics Inc. (NASDAQ:ESPR)'s traded shares stood at 1.33 million during the latest session, with the company's beta value hitting 0.97. At the last check today, the stock's price was $1....
Yahoo Finance Community
10/03
Comment
Shorts argue that US sales are weak. Ignoring the fact label change just occurred a few months ago, just look at European sales. A “proxy “ of future US sales. Are you are telling us that Americans, who are obese, eat McDonald’s every day, and don’t exercise ,don’t need ldl lowering meds and are somewhat different than Europeans and the rest of the world? It sounds like an argument Kurt would make....
Votes:
10
0
Yahoo Finance Community
10/03
Comment
Gregg mortgaged the house and buys shares of ESPR and on that day, a rally occurs. Longs across the world are declaring October 2nd Gregg day. A celebration will occur every year, where longs will gather families around the dinner table and explain how Gregg believed in ESPR and in truth, all of us longs. It shall be wonderful and all shall be happy. Tissues will be banned on October 2nd, as no tears shall be shed. And when we are at $20 a share, longs will make the pilgrimage to each other’s islands to continue the celebration of October 2nd. Let it be written. Thank you Gregg....
Votes:
9
0
Yahoo Finance Community
10/03
Comment
Are we all realizing that the 22% reduction event rate occurred at only one year following introduction of Bacid+Z. That’s nearly unheard of with the exception of introduction of a new agent like PCSK9 inhibitors at the time of an acute coronary syndrome. BA was added to other meds, including statins, which makes it more valuable and able to compete with PCSK9 inhibitors which unlike BA don’t have anti-inflammatory effects which have been shown to be very effective IN CAD...
Votes:
5
0
Quantexa News
10/04
Xponance Inc. Takes Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Xponance Inc. purchased a new stake in Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) during the second quarter, according to the company in its most recent Form 13F filing with the Securit...
Quantexa News
10/04
Xponance Inc. Takes Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Xponance Inc. purchased a new stake in Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) during the second quarter, according to the company in its most recent Form 13F filing with the Securit...
Quantexa News
10/04
HC Wainwright Reiterates Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They currently h...
Quantexa News
10/04
Zacks Research Weighs in on Esperion Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:ESPR)
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) – Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for Esperion Therapeutics in a research report issued to clients and...
Quantexa News
10/04
Zacks Research Weighs in on Esperion Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:ESPR)
Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for Esperion Therapeutics in a research report issued to clients and i...
Yahoo Finance Community
10/04
Comment
The cat is sneaking out of James bag. DSE is projecting billions in sales annually. OMERS signed up based on payoff in 3-5 years (likely sooner). This makes sense as ezetimibe sold billions and was not approved for primary treatment, had inferior ldl reduction and limited hscrp reductions. Japan is a major statin alternative market and is just starting up. Milestones will be pouring in. And then you have global territories to follow and the golden goose US rights just getting started. That goose will be flying in no time (why wouldn’t it based on Europe being proxy for future sales)....
Votes:
4
0
Yahoo Finance Community
10/04
Comment
I was reading the posts on the SW board. They are a real troop of true hypsters. Their new trick is trying to add the free prescriptions given away into the sales numbers. It's admirable that they are trying to prop this up, but even so, the market is only going to look at US sales numbers. Going from $28 million last quarter to $31 million this quarter is not going to keep this thing floating. We must all prepare for hard times ahead....
Yahoo Finance Community
10/04
Comment
I am sad, but not surprised, that Esperion is trading down, again. When the sales numbers are released on Fridays, it is always a cosmic slap in the face. So much hype during the week. We hear "blockbuster", "70 million addressable patients in the US along", "cure for cancer", etc. Then Fridays come and we learn that will all this, the team of 150 salespeople have managed to generate 100 new prescriptions. It really is harsh, when you look at reality....
Yahoo Finance Community
10/04
Comment
As we ramp upwards to $20, I hope all longs have loaded up. Once ESPR starts inflecting sales, this ship will have sailed. Japan coming on will quickly ramp. Watch for an upcoming note on convertibles being addressed and we may never see this crazy low valuation again....
Votes:
8
0
Yahoo Finance Community
10/04
Comment
Congratulations to all on this. I as head of the syndicate want to say to people like Gregg and some noble others. I hope this goes to 100. Just remember to donate some to a worthwhile charity. It's been so much fun over the years but you all were so due. Hold til at least 4....
Votes:
7
0
Quantexa News
10/05
Zacks Research Equities Analysts Lower Earnings Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Equities researchers at Zacks Research dropped their Q1 2025 earnings estimates for shares of Esperion Therapeutics in a note issued to invest...
Quantexa News
10/05
Zacks Research Equities Analysts Lower Earnings Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Equities researchers at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a rep...
Quantexa News
10/05
Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by StockNews.com
Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) was upgraded by StockNews.com from a "hold" rating to a "buy" rating in a report issued on Saturday. Several other brokerages have also issued re...
Quantexa News
10/05
Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by StockNews.com
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report issued on Saturday. Get Esperion Therapeutics alerts: Several o...
Quantexa News
10/05
Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by StockNews.com
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Saturday. A number...
Quantexa News
10/05
Esperion Therapeutics Inc. (NASDAQ:ESPR) Up 64.29% Since 52-Week Low; YTD Fall -34.45% – Here's What You Need To Do
Esperion Therapeutics Inc. (NASDAQ:ESPR)'s traded shares stood at 6.15 million during the last session, with the company's beta value hitting 0.97. At the close of trading, the stock's price was $1.96...
Yahoo Finance Community
10/05
Comment
I wonder if the word is hitting the street that Daiichi will buy ESPR? A company does not take over manufacturing and distribution for $100m+ a year, and agree to develop a triple pill combo expected to bring in billions per year until 2040+, while centering the company’s growth plans around a company with a market cap under $500m that can be bought out at anytime. For a small investment of $6-8b , they can pay off the investment in a few years, capture global rights and the golden goose US market, obtain Japan royalties, and capture all IP guaranteeing patent extensions out decades. Of course, they already approached Shelly and he rejected them, but how long before they come back and strengthen their offer? With Amgen, Sanofi, Merck, PFE, Bayer and others all knocking on the ESPR’s door, the last thing Daiichi wants is a bidding war. That could …...
Votes:
5
0
Quantexa News
10/05
Investment Analysts' Updated EPS Estimates for October 5th (AEHR, COLB, COLM, DLNG, ESPR, EVI, GOGL, HNI, LPL, MRCY)
Investment Analysts' updated eps estimates for Saturday, October 5th: Aehr Test Systems (NASDAQ:AEHR) was downgraded by analysts at StockNews.com from a hold rating to a sell rating. Columbia Bankin...
Quantexa News
10/05
Investment Analysts’ Updated EPS Estimates for October 5th (AEHR, COLB, COLM, DLNG, ESPR, EVI, GOGL, HNI, LPL, MRCY)
Investment Analysts’ updated eps estimates for Saturday, October 5th: Aehr Test Systems (NASDAQ:AEHR) was downgraded by analysts at StockNews.com from a hold rating to a sell rating. Get Aehr Test S...
Yahoo Finance Community
10/05
Comment
My little sister has an ear infection so I went with Mom to pick ip her prescription at the pharmacy. There was an old lady in front of us who said her doctor was going to start her on Nexlizet. The pharmacist said we don't carry it anymore because it all went out of date on the shelf. He told her to have her doctor order it through the online Canadian pharmacy. He said it's cheaper that way too because you can get a 90 day supply for just $27. He thought they were also offering a generic for substantially less. What good advice...
Quantexa News
10/05
Esperion Therapeutics (NASDAQ:ESPR) Earns “Buy” Rating from HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a report issued on Wednesday morning, Benzinga reports. HC Wainwright currently has a $16.00...
Quantexa News
10/06
Zacks Research Comments on Esperion Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:ESPR)
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) – Research analysts at Zacks Research decreased their Q1 2025 earnings estimates for Esperion Therapeutics in a research report issued on Tues...
Quantexa News
10/06
Esperion Therapeutics' (ESPR) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a research report report published on Wednesday morning, Benzinga reports. HC Wainwright curre...
Quantexa News
10/06
HC Wainwright Reaffirms “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)
HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research note published on Wednesday, Benzinga reports. The firm currently has a $16.00 ta...
Quantexa News
10/06
American Century Companies Inc. Purchases Shares of 22,518 Esperion Therapeutics, Inc. (NASDAQ:ESPR)
American Century Companies Inc. acquired a new stake in shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) in the 2nd quarter, according to its most recent Form 13F filing with the Se...
Quantexa News
10/06
American Century Companies Inc. Purchases Shares of 22,518 Esperion Therapeutics, Inc. (NASDAQ:ESPR)
American Century Companies Inc. acquired a new stake in shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) in the 2nd quarter, according to its most recent Form 13F filing with the Se...
Quantexa News
10/06
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by StockNews.com to Buy
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a research note published on Saturday. Several other research analysts also re...
Quantexa News
10/07
Esperion Therapeutics Inc. (ESPR) Stock: A Closer Look at the Analyst Ratings
Additionally, the 36-month beta value for ESPR is 0.96. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it...
Quantexa News
10/07
Esperion Therapeutics Inc. (NASDAQ: ESPR) Stock: Does It Have More Upside?
In today's recent session, 1.26 million shares of the Esperion Therapeutics Inc. (NASDAQ:ESPR) have been traded, and its beta is 0.96. Most recently the company's share price was $2.09, and it changed...
Quantexa News
10/08
Esperion Therapeutics (NASDAQ:ESPR) Lifted to Buy at StockNews.com
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a report released on Saturday. Several other research firms also recently weig...
Quantexa News
10/08
Esperion Therapeutics (NASDAQ:ESPR) Upgraded at StockNews.com
StockNews.com upgraded shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) from a hold rating to a buy rating in a research note released on Saturday. Other equities research analysts have al...
Yahoo Finance Community
10/08
Comment
After the euphoria experienced last week from the run up in Esperion's share price caused by retail investor manipulation, it is certainly deflating to watch this sink back to below a dollar shortly. There just seems to be an unending stream of disappointment. At the end, it was never going to rise without US sales increasing substantially, and as we know, this has not happened. Everything else is just noise....
Yahoo Finance Community
10/08
Comment
As Insider Monkey recently reported: In the second quarter, Esperion had a total revenue of $73.8 million, marking an impressive 186% increase from $25.8 million in the same period of 2023. For the first half of the year, revenues surged to $211.6 million, representing a remarkable 322% growth from last year's $50.1 million....
Votes:
1
0
Quantexa News
10/09
Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by StockNews.com
upgraded shares of Esperion Therapeutics ( – from a hold rating to a buy rating in a research report released on Saturday morning. A number of other analysts have also weighed in on the stock. Needha...
Quantexa News
10/09
Esperion Therapeutics (NASDAQ:ESPR) Upgraded to Buy at StockNews.com
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a research note released on Saturday morning. Several other analysts have also...
Quantexa News
10/09
Research Analysts' Recent Ratings Updates for Esperion Therapeutics (ESPR)
Several analysts have recently updated their ratings and price targets for Esperion Therapeutics (NASDAQ: ESPR): 10/5/2024 – Esperion Therapeutics was upgraded by analysts at StockNews.com from a “ho...
Yahoo Finance Community
10/09
Comment
The quiet on this board today speaks volumes. I think it has come as a real shock to the long-suffering investors on this board to see this company firmly on track to less than a dollar, again. I ask you all not to dwell on your losses, but rather reflect on the decision-making process that brought you here. It will help you in the future....
Yahoo Finance Community
10/09
Comment
XBI is down. Ho hum until convertibles announcement is made shortly. Then all will be surprised when we bounce again. I’m just hoping I can pick up some cheap shares along the way. You can always hope but I suspect longs will need to just enjoy the steady rise in the coming days...
Votes:
2
1
Yahoo Finance Community
10/09
Comment
It's just hard on days like these. You look down your list of stocks and you see green, green, and more green. Then you come to Esperion and you see it is down 7.7295%, again. The pain and suffering just never ends. If only they were able to make some sales this would go up. I think since investors have been waiting for the sales "inflection point" for five years now, it just makes it even more painful....
Votes:
2
2
Yahoo Finance Community
10/09
Comment
Shorts are just biding their time to go long, as no one doubts the future of ESPR. So as big shorts try to squeeze a few more pennies and obtain more cheap shares before ESPR runs, longs can sit back and enjoy. But a warning to small shorts. Don’t be on the wrong side of the trade, or you’ll end up like Kurt, knocking on doors for free handouts. Gregg and I both saw him in our trailer park scrounging around for scraps. Don’t be like Kurt....
Votes:
4
1
Yahoo Finance Community
10/10
Comment
In a patriotic fashion, Sheldon has determined to provide each patient in Florida with a free month's supply of BA to avoid treatment breaks if there is supply chain disruption. His assistant has already overnight shipped three bottles of the pills so all patients should have their supply by tomorrow....
Quantexa News
10/10
Zacks Research Weighs in on Esperion Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ESPR)
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) – Investment analysts at Zacks Research lowered their FY2025 earnings per share estimates for shares of Esperion Therapeutics in a research re...
Yahoo Finance Community
10/10
Comment
I popped over to the other board. It's so exciting, Sheldon and Ben have been given transformational leader awards! The article states that over a five-year period they have managed to transform Esperion from a research stage company with 27 million share outstanding and a market cap of $2.7 billion to now, a company with two approved drugs, 200 million shares outstanding and 50 million warrants, and a market cap of $300 million and falling. That is transformational. Only the cash flow is still grotesquely negative, so that has not been transformed....
Yahoo Finance Community
10/10
Comment
I can’t repeat this enough. ESPR is following XBI/market. This is good news as bio market is not favored now. But money in this sector will look for outliers. A soon to be profitable, blockbuster proven drug, in the biggest tam, with huge investors, is a low risk high growth opportunity. Only Kurt does not understand....
Votes:
3
0
Quantexa News
10/11
Equities Analysts Offer Predictions for Esperion Therapeutics, Inc.’s FY2025 Earnings (NASDAQ:ESPR)
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Research analysts at Zacks Research lowered their FY2025 earnings per share (EPS) estimates for Esperion Therapeutics in a note issued to inve...
Quantexa News
10/11
Esperion Therapeutics, Inc. (NASDAQ:ESPR) to Post Q1 2025 Earnings of ($0.16) Per Share, Zacks Research Forecasts
Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Stock analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research...
Quantexa News
10/11
Esperion Therapeutics, Inc. (NASDAQ:ESPR) to Post Q1 2025 Earnings of ($0.16) Per Share, Zacks Research Forecasts
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) – Stock analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a researc...
Quantexa News
10/11
Zacks Research Comments on Esperion Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:ESPR)
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) – Equities researchers at Zacks Research decreased their Q1 2025 earnings per share estimates for Esperion Therapeutics in a note issued to in...
Quantexa News
10/11
Esperion Therapeutics, Inc. (NASDAQ:ESPR) to Post Q1 2025 Earnings of ($0.16) Per Share, Zacks Research Forecasts
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Stock analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research...
Quantexa News
10/12
Equities Analysts Offer Predictions for Esperion Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:ESPR)
Get Esperion Therapeutics alerts: Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) – Zacks Research lowered their Q1 2025 EPS estimates for Esperion Therapeutics in a research note issued on...
Quantexa News
10/13
Q1 2025 EPS Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR) Decreased by Analyst
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) – Analysts at Zacks Research reduced their Q1 2025 EPS estimates for Esperion Therapeutics in a research report issued to clients and investor...
Quantexa News
10/13
Zacks Research Analysts Lower Earnings Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) – Equities research analysts at Zacks Research dropped their Q1 2025 earnings estimates for Esperion Therapeutics in a report issued on Tuesda...
Yahoo Finance Community
10/13
Comment
Think of Daiichi agreeing to take over all manufacturing and distribution costs for BA in its territories and development of triple pill combo. A company does not do that without complete confidence in BA. I’m sure they discussed a buyout but they could not get to ESPR’s price given the depressed market cap. But this will likely change in the coming quarters. Daiichi will want to capitalize on the investment in BA globally, and not just in limited territories. It just makes too much sense. If they delay too long they run the risk of an PE firm or competitor making an offer. ESPR shareholders win soon....
Votes:
7
0
Quantexa News
10/14
Esperion Therapeutics Inc. (ESPR) is destined for greater heights as its last quarter sales were 73,830 K
Esperion Therapeutics Inc. (NASDAQ: ESPR) kicked off on Friday, up 4.23% from the previous trading day, before settling in for the closing price of $1.89. Over the past 52 weeks, ESPR has traded in a...
Quantexa News
10/14
Balance Sheet Insights: Esperion Therapeutics Inc. (ESPR)'s Debt-to-Equity and Long-Term Debt/Eq Ratios
Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth. 3 Tiny Stocks Primed to Explode...
Yahoo Finance Community
10/14
Comment
On ST there’s a mentally deficient user: bportan1.He thinks he’s a genius, But he can not figure out that MILOS and CLEAR are two entirely different types of studies. MILOS had only approximately 900 patients. CLEAR had approximately 12,500 at the end. The more on thinks that MILOS is some sort of data breakthrough. He has no idea what data is....
Votes:
3
0
Quantexa News
10/15
Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by StockNews.com
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. Get Esperion...
Yahoo Finance Community
10/15
Comment
Esperion is so late in announcing the date on which it will report its quarterly loss. The last time they left it so late it was because they co-announced their reorganization with the loss report. I wonder if they are doing the same this time. Last time they announce the layoff of the sales force because they were running out of cash and no one was buying the pills. It could be the same scenario playing out again....
Quantexa News
10/16
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by StockNews.com to “Buy”
StockNews.com upgraded shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) from a hold rating to a buy rating in a research report report published on Tuesday morning. ESPR has been the topic...
Quantexa News
10/16
Esperion Therapeutics (NASDAQ:ESPR) Upgraded to “Buy” by StockNews.com
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a report issued on Tuesday morning. ESPR has been the subject of several other...
Yahoo Finance Community
10/17
Comment
The longer ESPR tracks the XBI the better for longs. None of the positives of the company are recognized by Wall Street yet. That always changes with time as once profitable and sales are ramping up, IP is outlined, convertibles are addressed, there will be nothing holding ESPR back. The science is there and that is what will dictate the ultimate value, likely in a buyout with a capable partner....
Votes:
3
0
Yahoo Finance Community
10/17
Comment
I think the share price going from .7 to 2.10 speaks for itself. Big investors continue to pile up shares, taking from the weak. It makes sense, as who else would sell when ESPR is about to be profitable, has partners with Omers, Daiichi and Otsuka who invested billions, has a proven blockbuster to sell billions per year, with patents out to 2040 in many territories. Poor Kurt is the only one selling. Don’t be a Kurt....
Votes:
2
1
Yahoo Finance News
10/17
Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings
Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings GuruFocus News Thu, Oct 17, 2024, 6:02 PM 3 min read In This Article: ESPR -3.32% Overview of the Recent Transacti...
Quantexa News
10/17
Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings
Overview of the Recent Transaction On September 30, 2024, Millennium Management LLC, a prominent hedge fund, made a significant adjustment to its investment portfolio by reducing its stake in Esperio...
Quantexa News
10/17
Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings
On September 30, 2024, Millennium Management LLC, a prominent hedge fund, made a significant adjustment to its investment portfolio by reducing its stake in Esperion Therapeutics Inc ( NASDAQ:ESPR )....
Yahoo Finance Community
10/17
Comment
If I were a short I would, 1) be afraid everyday that a joint PR is released on a partnership or buyout involving ESPR, 2) be afraid every Friday that scripts will be great again, resulting in more green, 3). Be afraid that Kurt is at the door to ask to stay over since he is now on the streets. I might even be sad. It’s a matter of time before ESPR runs. I’m guessing we are getting close as I think next will be convertibles addressed and/or news on IP. Very exciting!...
Votes:
3
1
Quantexa News
10/18
Esperion Therapeutics (NASDAQ:ESPR) Lifted to “Buy” at StockNews.com
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a report released on Tuesday. ESPR has been the subject of a number of other r...
Quantexa News
10/19
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by StockNews.com to “Buy”
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a research note released on Tuesday. A number of other brokerages have also re...
Quantexa News
10/19
Esperion Therapeutics (NASDAQ:ESPR) Rating Increased to Buy at StockNews.com
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a research report sent to investors on Tuesday morning. Other equities researc...
Quantexa News
10/19
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by StockNews.com to “Buy”
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a research note released on Tuesday. A number of other brokerages have also re...
Yahoo Finance Community
10/19
Comment
With this last dip, I am fully loaded. Have to love ESPR’s position. We know sales are ramping in Europe. RiPA is done. Convertibles are done soon. Daiichi Otsuka and OMERS are partners and all can take another bit of the apple. And then we just have to watch new territories started, Japan ramping, US ramping, new molecules/applications to extend IP and add revenue, profitability in early 2025, milestones received, and possible new partnership and/or buyout. Bio is down but wow, this is a good one....
Votes:
5
0
Yahoo Finance Community
10/20
Comment
With ESPR now with a proven blockbuster with a path to 2040+ IP protection, fda and Ema primary label approval, and new territories being added, it makes sense that big pharma would want to buy ESPR. Thank goodness was Sheldon is seeking valuations that are close to inclisiran buyout. We can still give Daiichi a sweetheart deal of $8b since we are friends....
Votes:
1
0
Yahoo Finance Community
10/21
Comment
It always seems that when shorts get desperate, they post a lot. Usually right before a run up in share price. But we are getting close to a very large run up to $20. I wonder if shorts will post a lot more in the coming days. Let’s wait and see....
Votes:
3
0
Yahoo Finance Community
10/21
Comment
Q3 financials should be interesting. We will get an idea of how revs are ramping up in US and Europe. Should be able to see a path to profitability, as predicted by CEO. Only a few days away but hopefully will show a strong jump and decreased losses. We'll need a strong report to offset weakness in junior bio....
Votes:
6
0
Yahoo Finance Community
10/22
Comment
If Daiichi is expected to sell multiple billions (let’s say $2b) of BA per year out to 2040, what is the current value of BA today? Let’s not even think about our Japan, China, US, Canada, etc. you can see why Daiichi is relentlessly pursuing Sheldon to sell the company now when it is dirt cheap....
Votes:
4
0
Yahoo Finance Community
10/22
Comment
As the institutions continue to unwind their positions in Esperion, it is likely you will see a continued drag on the share price. It would be advisable for management to do a 1 for 10 split on the stock to keep it above a dollar for a while. Maybe they will announce this on the long delayed loss report call....
Yahoo Finance Community
10/22
Comment
I’m nervous for shorts. It’s like pushing down on a big spring. You can huff and puff and push all you want, but we all know it will explode upwards in due time. Longs are patient and love watching all the heavy breathing while we continue to collect cheap shares....
Votes:
2
0
Quantexa News
10/22
Traphagen Investment Advisors LLC Takes $27,000 Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Traphagen Investment Advisors LLC acquired a new position in shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) during the 3rd quarter, Holdings Channel.com reports. The firm acquired...
Quantexa News
10/22
Traphagen Investment Advisors LLC Invests $27,000 in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Traphagen Investment Advisors LLC bought a new stake in Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) during the third quarter, according to the company in its most recent filing with the...
Yahoo Finance Community
10/22
Comment
So much joy and celebration here this morning on a $.03 gain. I feel sad for everyone that this is evaporating in PM trading as is so often the case. It is a repeated pattern now. Retail investors bid this up in the morning on low volume and the institutions use the gains to continue their dumping in the PM....
Yahoo Finance News
10/24
Esperion to Report Third Quarter 2024 Financial Results on November 7
Esperion to Report Third Quarter 2024 Financial Results on November 7 Esperion Therapeutics, Inc. Esperion Therapeutics, Inc. Thu, Oct 24, 2024, 5:00 AM 1 min read In This Article: ESPR +1.94% ANN ARB...
Quantexa News
10/24
Esperion to Report Third Quarter 2024 Financial Results on November 7
ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024....
Quantexa News
10/24
Esperion to Report Third Quarter 2024 Financial Results on November 7
ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024....
Quantexa News
10/24
Esperion To Report Third Quarter 2024 Financial Results On November 7
MENAFN - GlobeNewsWire - Nasdaq) ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens...
Yahoo Finance Community
10/25
Comment
I wonder what sales figure for Q3 would be considered to be good for the US for the period. Would it be $40 million or $45 million? I think there will need to be significant growth over Q2 when it was $28 million. After all the fanfare about blockbuster status, insurance company approvals, etc. and so on, not to mention the $45 million in sales and marketing spent during the quarter, I just don't think $32 million is going to do it....
Yahoo Finance Community
10/25
Comment
I feel sad for the poor long people that post relentlessly on the SW board. They are all working feverishly to explain away the impending disastrous Q3 loss report. They say things like, you can't really look at the quarter because you had the 4th of July holiday and a hurricane somewhere. Anything to distract from the terrible sales and horrific losses after this drug has now been approved for five years. Unlike sophisticated investors, these penny stock people just refuse to look at the writing on the wall. These drugs simply did not find a US market....
Yahoo Finance Community
10/25
Comment
Boom time? Maybe not quite yet, but it is coming. Envision a huge spring being pushed down by all the shorts. But as one short let’s go, the burden on the next in line is doubled. Soon, the spring will leap and all will be happy. Well, most will be happy. This is supported by the science, proven sales, proven milestones owed, key relationships with OMERS, Daiichi and Otsuka, and lack of competition. Think of ESPR’s current price as a gift and opportunity to become wealthy....
Votes:
2
0
Yahoo Finance Community
10/25
Comment
I didn't really follow European sales very much because the royalty stream has been sold off for the next ten or so years until the latest revenue selling deal is completed. One of the few informational posters on the SW board pointed out that DSE is on track to have $230 million in bempedoic acid sales for the full year 2024. He goes on to note that growth in Q3 was the lowest growth in the last two years. This bears out Bank of America's own research that shows sales peaking in Q1 of 2025. It looks like the European/American revenue max for these pills is about $400 million combined. Of course, Esperion will only get the $150 million American market. They need to reduce their expenditures dramatically now that they've maxed out on sales....
Yahoo Finance Community
10/25
Comment
I think Daiichi is sad that Sheldon rejected their $6b offer. You can’t blame Sheldon, as other big pharma are also in discussions so the price will likely go much higher. We are friends with Daiichi and all, but business is business! Ok , maybe I made some of this up, but am I really that far off? Time will tell but I’m watching the news feeds everyday....
Votes:
4
0
Yahoo Finance Community
10/25
Comment
James a year ago 10/26/23 you were telling the same story.. I was buying large blocks at .76 cents when you were telling everyone it was going out of business..very sad.. you said it was going to .20 cents how many people listen to you. Glad I didn’t listen....
Votes:
4
0
Quantexa News
10/25
How will Ecodesign for Sustainable Products Regulation affect printers?
What does the European Union's (EU) Ecodesign for Sustainable Products Regulation (ESPR) mean to you? Your likely answer will probably be, not a lot, but that could be a mistake even if your business...
Yahoo Finance Community
10/25
Comment
So much exuberance when this appeared to be climbing this morning. As always, retail investor meme trading in the morning provides the opportunity for institutions to continue to unwind in the PM at much better prices than they ever thought they could get....
Quantexa News
10/26
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by StockNews.com to “Buy”
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report released on Saturday. ESPR has been the subject of a number of o...
Quantexa News
10/26
StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to Buy
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Saturday. Get Esperion Therapeutics alerts: ES...
Quantexa News
10/27
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Shares Purchased by SG Americas Securities LLC
SG Americas Securities LLC lifted its stake in Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) by 105.9% in the 3rd quarter, Holdings Channel reports. The firm owned 77,049 shares of the bio...
Quantexa News
10/27
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by StockNews.com to Buy
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a research note issued to investors on Saturday. ESPR has been the subject of...
Quantexa News
10/28
Esperion Therapeutics (NASDAQ:ESPR) Stock Rating Upgraded by StockNews.com
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday....
Yahoo Finance Community
10/28
Comment
I am concerned that retail investors are bidding this up in the run up to the loss report call next week. I fear that when management reports $4 million in new prescription revenue for the quarter after having spent $45 million on sales and marketing during that period, disaster will occur. After all, that is $10.50 spent to generate $1 in revenue. What a disaster!...
Votes:
1
0
Yahoo Finance Community
10/28
Comment
I think Esperion ended Q2 with about $180 million in cash. This quarter they should finish up with about $120 million unless there were little hiccups along the way, then maybe $100 million. At the $1 million plus per day cash burn rate, they really need to raise some equity, maybe 200 million shares....
Yahoo Finance Community
10/28
Comment
Wow, last quarter Esperion lost $62 million, and that was with an extra $25 million in revenue received from Daiichi for the sale of future development and distribution rights on the pills. I hope they don't lose that much again. Disaster! They need to sell something else quick....
Quantexa News
10/29
Esperion Therapeutics (NASDAQ:ESPR) Lifted to Buy at StockNews.com
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a report released on Saturday. A number of other brokerages have also commente...
Quantexa News
10/30
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by StockNews.com to Buy
upgraded shares of Esperion Therapeutics ( – from a hold rating to a buy rating in a report issued on Saturday. ESPR has been the topic of a number of other reports. Needham & Company LLC cut their t...
Quantexa News
10/30
Esperion Therapeutics (NASDAQ:ESPR) Upgraded by StockNews.com to Buy
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a research note released on Saturday morning. Several other analysts have also...
Quantexa News
10/30
Market Recap Check: Esperion Therapeutics Inc. (ESPR)'s Negative Finish at 2.08, Up/Down -2.35
Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth. 3 Tiny Stocks Primed to...
Quantexa News
10/30
A Supplier's Guide to the EU Digital Product Passport: Ensuring Sustainable Compliance
Introduction With the EU turning its Green Deal into action, European businesses are required to follow new sustainability regulations. Enter Digital Product Passports (DPPs) - a crucial requirement...
Quantexa News
10/31
Esperion Therapeutics (ESPR) to Release Quarterly Earnings on Thursday
NASDAQ:ESPR – Get Free Report ) is set to issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.14) per share for...
Quantexa News
10/31
Esperion Therapeutics (ESPR) Set to Announce Earnings on Thursday
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earni...
Yahoo Finance News
10/31
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions Esperion...
Yahoo Finance News
10/31
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks Equity Research Thu, Oct 31, 2024, 4:01 AM 5 min read In This Article: ESPR -0.49% JAZZ +0....
Quantexa News
10/31
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Sees Significant Decline in Short Interest
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) was the target of a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 35,39...
Quantexa News
10/31
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Sees Significant Decrease in Short Interest
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) was the target of a significant drop in short interest in October. As of October 15th, there was short interest totalling 35,390,000 share...
Yahoo Finance News
11/04
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
YAHOO FINANCE ELECTION GUIDE What the 2024 campaign means for your wallet Esperion to Participate in Upcoming Jefferies London Healthcare Conference Esperion Therapeutics, Inc. Esperion Therapeutics,...
Quantexa News
11/04
No matter how cynical the overall market is Esperion Therapeutics Inc (ESPR) performance over the last week is recorded -3.33%
On Friday, Esperion Therapeutics Inc (NASDAQ: ESPR) was -0.49% drop from the session before settling in for the closing price of $2.04. A 52-week range for ESPR has been $0.81 – $3.40. Here's Your F...
Quantexa News
11/05
VeChain News: ESPR Law Mandates Detailed Sustainability Reporting for EU Products — VET at the Forefront
VeChain's blockchain enables efficient auditing and secure record-keeping of product sustainability data. The platform's native token, VET, will also see increased adoption as companies seek to fulfi...
Quantexa News
11/05
VeChain News: ESPR Law Mandates Detailed Sustainability Reporting for EU Products — VET at the Forefront
VeChain's blockchain enables efficient auditing and secure record-keeping of product sustainability data. The platform's native token, VET, will also see increased adoption as companies seek to fulfi...
Quantexa News
11/05
Esperion Therapeutics (ESPR) to Release Earnings on Thursday
Esperion Therapeutics ( – ) will post its quarterly earnings results before the market opens on Thursday, November 7th. Analysts expect Esperion Therapeutics to post earnings of ($0.14) per share for...
Quantexa News
11/06
Esperion Therapeutics (ESPR) to Release Earnings on Thursday
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ) is scheduled to be announcing its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce ea...
Quantexa News
11/06
Esperion Therapeutics (ESPR) to Release Earnings on Thursday
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ) is scheduled to release its earnings data before the market opens on Thursday, November 7th. Analysts expect Esperion Therapeutics to post earni...
Quantexa News
11/07
StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to “Buy”
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Thursday. Several other brokerages...
Quantexa News
11/07
Esperion Therapeutics (NASDAQ:ESPR) Rating Increased to Buy at StockNews.com
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday. Get...
Yahoo Finance News
11/07
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update Esperion Therapeutics, Inc. Esperion Therapeutics, Inc. Thu, Nov 7, 2024, 6:00 AM 13 min read In This Article: ESPR...
Polygon News
11/07
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
Esperion reported strong financial results for Q3 2024, with a 52% year-over-year increase in total revenue to $51.6 million. The company saw double-digit growth in prescriptions and continued progres...
Quantexa News
11/07
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
Esperion (NASDAQ: ESPR) today reported financial results for the third quarter ended September 30, 2024, and provided a business update. “The year to date has been transformational for Esperion. We s...
Quantexa News
11/07
Esperion Therapeutics: Q3 Earnings Snapshot STATS Perform dba Automated Insights Nov 7, 2024 22 mins ago
ANN ARBOR, Mich. (AP) — ANN ARBOR, Mich. (AP) — Esperion Therapeutics Inc. (ESPR) on Thursday reported a loss of $29.5 million in its third quarter. The Ann Arbor, Michigan-based company said it had...
Quantexa News
11/07
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y
Esperion Therapeutics, Inc. ESPR incurred a loss of 15 cents per share for the third quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 14 cents. The company had incurred...
Quantexa News
11/07
Investment Analysts' Upgrades for November 7th (AVDX, CLB, CRL, CRSP, CWAN, DDOG, ESPR, FFIC, GFF, HSIC)
Investment Analysts' upgrades for Thursday, November 7th: AvidXchange (NASDAQ:AVDX) was upgraded by analysts at Compass Point from a neutral rating to a buy rating. The firm currently has $15.00 targ...
Quantexa News
11/07
Esperion Therapeutics, Inc. (ESPR) Q3 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2024 Earnings Call November 7, 2024 8:00 AM ET Company Participants Alina Venezia - Director, Investor Relations Sheldon Koenig - President and Chief Ex...
Quantexa News
11/07
Esperion's Strong Financial Performance and Strategic Expansion Drive Buy Rating
Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Esperion ( ESPR – Research Report ), retaining the price target of $16.00. Joseph Pantginis has given his Buy rating due to a co...
Quantexa News
11/07
Esperion's Expanded Medicare Coverage and Revenue Growth Make It a Compelling Buy
Analyst Serge Belanger of Needham maintained a Buy rating on Esperion ( ESPR – Research Report ), retaining the price target of $6.00. Serge Belanger has given his Buy rating due to a combination of...
Quantexa News
11/07
Esperion Therapeutics : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)
November 07, 2024 at 08:42 pm EST espr-20240930 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q For the quarterly period ended September 30, 2024 OR For the...
Quantexa News
11/08
Esperion Therapeutics Sees Significant Revenue Growth in Q3 2024
Esperion Therapeutics ( (ESPR) ) has released its Q3 earnings. Here is a breakdown of the information Esperion Therapeutics presented to its investors. Esperion Therapeutics is a biopharmaceutical co...
Quantexa News
11/08
Esperion's Growth Challenges: Sell Rating Maintained Amid Market Pressures and Competitive Threats
Esperion ( ESPR – Research Report ), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Zemansky from Bank of America Securities reiterated a Sell rating on...
Quantexa News
11/08
Esperion Therapeutics Inc (NASDAQ:ESPR) Shares Are Up 3.43 Percent In A Week – But Can The Gains Continue?
In last trading session, Esperion Therapeutics Inc (NASDAQ:ESPR) saw 11.85 million shares changing hands with its beta currently measuring 0.93. Company's recent per share price level of $2.11 trading...
Quantexa News
11/08
Esperion Therapeutics (NASDAQ:ESPR) Upgraded to Buy at StockNews.com
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a research report sent to investors on Thursday morning. Other analysts have a...
Quantexa News
11/08
Esperion Therapeutics (NASDAQ:ESPR) Upgraded at StockNews.com
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a research note issued to investors on Thursday. ESPR has been the subject of...
Yahoo Finance News
11/08
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Esperion Therapeutics, Inc. Esperion Therapeutics, Inc. Fri, Nov 8, 2024, 1:15 PM 2 min read In This Article: ESPR +8.06% ANN...
Quantexa News
11/09
Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a research report sent to investors on Friday morning, Benzinga reports. The brokerage current...
Quantexa News
11/09
Esperion Therapeutics (NASDAQ:ESPR) Given Buy Rating at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a report published on Friday,Benzinga reports. They currently have a $16.00 price target on...
Quantexa News
11/10
Esperion Therapeutics (NASDAQ:ESPR) Raised to “Buy” at StockNews.com
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a research note released on Thursday. Several other research analysts have als...
Quantexa News
11/10
Esperion Therapeutics (NASDAQ:ESPR) Upgraded at StockNews.com
StockNews.com upgraded shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) from a hold rating to a buy rating in a report issued on Thursday. Several other research firms have also recently i...
Quantexa News
11/10
HC Wainwright Reiterates “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzin...
Quantexa News
11/11
StockNews.com Upgrades Esperion Therapeutics (NASDAQ:ESPR) to “Buy”
StockNews.com upgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a hold rating to a buy rating in a research note released on Thursday. ESPR has been the topic of several other...
Quantexa News
11/11
HC Wainwright Has Positive Estimate for ESPR FY2025 Earnings
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) – Equities research analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for Esperion Therapeutics in a report re...
Quantexa News
11/11
Esperion Therapeutics (NASDAQ:ESPR) Receives Buy Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a report released on Friday, Benzinga reports. They currently have a $16.00 price objective on...
Quantexa News
11/12
What is HC Wainwright's Forecast for ESPR FY2025 Earnings?
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) – Research analysts at HC Wainwright lifted their FY2025 earnings estimates for Esperion Therapeutics in a research report issued on Thursday,...
Quantexa News
11/13
Esperion Therapeutics (NASDAQ:ESPR) Trading Up 13.2% – Still a Buy?
Shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) traded up 13.2% on Monday . The stock traded as high as $2.60 and last traded at $2.58. 5,362,361 shares traded hands during tra...
Quantexa News
11/14
Esperion Therapeutics Inc (NASDAQ: ESPR) Gain Of 60.99% Compared To 52-Week Low; YTD Fall -25.42% – What Should You Do Now?
Esperion Therapeutics Inc (NASDAQ:ESPR)'s traded shares stood at 5.82 million during the last session, with the company's beta value hitting 0.95. At the close of trading, the stock's price was $2.23,...
Quantexa News
11/15
Esperion Therapeutics Inc (NASDAQ: ESPR) Has Advanced 92.66% In 2024; Is The Share Price Attractive Enough At $20?
Esperion Therapeutics Inc (NASDAQ:ESPR)'s traded shares stood at 4.18 million during the last session, with the company's beta value hitting 0.93. At the close of trading, the stock's price was $2.10,...
Quantexa News
11/15
Analysts’ Downgrades for November 15th (AKYA, APPS, ARAY, ARE, BLUE, BNGO, CEVA, CMPX, DRH, ESPR)
Analysts’ downgrades for Friday, November 15th: Akoya Biosciences (NASDAQ:AKYA) was downgraded by analysts at Craig Hallum from a buy rating to a hold rating. Craig Hallum currently has $5.00 price t...
Quantexa News
11/16
Esperion Therapeutics (NASDAQ:ESPR) Downgraded to Hold Rating by StockNews.com
StockNews.com downgraded shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) from a buy rating to a hold rating in a report published on Friday. A number of other research analysts have also...
Quantexa News
11/17
StockNews.com Downgrades Esperion Therapeutics (NASDAQ:ESPR) to Hold
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Friday. G...
Quantexa News
11/17
Esperion Therapeutics (NASDAQ:ESPR) Lowered to Hold Rating by StockNews.com
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a report issued on Friday. A number of other equities analysts also rec...
Quantexa News
11/18
Versor Investments LP Makes New $44,000 Investment in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Versor Investments LP acquired a new position in Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) during the third quarter, Holdings Channel.com reports. The firm acquired 26,400 shares of th...
Yahoo Finance Community
11/18
Comment
People on this board are always looking for a catalyst. This is a proxy that they can use to indicate a good future even when sales fail to materialize after the drugs have been FDA approved for 5 years and label change (the big catalyst) is now six months in the past. The catalyst people are looking at is the $1 million + per day in cash burn. Absolutely terrifying to think how fast the cash is shoveled into the furnace at Esperion....
Yahoo Finance Community
11/18
Comment
I keep going back to Europe being a proxy for US sales. With Daiichi agreeing to take over manufacturing and distribution worth $100m+ per year alone, and committing to the triple pill combo development, and OMERS agreeing to pay $305m upfront for royalty stream for 3 year payback, you can understand that billions of sales is not an if, but a when. And all signs point to sooner rather than later....
Votes:
3
0
Yahoo Finance News
11/18
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific...
Quantexa News
11/18
Esperion Therapeutics Inc (ESPR) volume exceeds 6.48 million: A new investment opportunity for investors
Esperion Therapeutics Inc (NASDAQ: ESPR) on Friday, soared 0.95% from the previous trading day, before settling in for the closing price of $2.10. Within the past 52 weeks, ESPR's price has moved betw...
Quantexa News
11/19
Esperion Therapeutics (NASDAQ:ESPR) Downgraded to “Hold” Rating by StockNews.com
StockNews.com downgraded shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report from a buy rating to a hold rating in a report published on Friday. Other equities analysts have also issued resea...
Quantexa News
11/19
Esperion Therapeutics (NASDAQ:ESPR) Downgraded by StockNews.com to Hold
StockNews.com lowered shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) from a buy rating to a hold rating in a research note published on Friday morning. Other equities analysts have also...
Yahoo Finance Community
11/19
Comment
Why the big drop from 2.6? What will it take to get this above 2.6? 3 million growth per QTR is definitely not going to do it.What do the fake longs see as acceptable growth this QTR in light of a cash raise being a necessity soon? Why has Karen Said OMERs would be paid back in 3 years when the math says 20? Folks you need to read all of her posts about 3 to 5 years then royalties revert back to ESPR. The numbers are not even remotely close to this fantasy. Why does she continually lie about this? What does she have to gain by posting fairy tales to manipulate you? We tell the truth and we do it because we have a good soul. The thing is the numbers are there for all to see and DSE is paying OMERs 8 million per QTR. in order …...
Yahoo Finance Community
11/19
Comment
Shorting at 2.6 was a huge gift for all of us. I hope you took advantage of that spike. We will be covering when the secondary is announced. We expect it to happen this QTR or next. The conditions will be so bad.Twitter Brinks is getting destroyed because of the non stop pumping. People have been saying you have been at it for more than a year and the stock is garbage. Folks Brinks and anthony are husband and wife....
Yahoo Finance Community
11/19
Comment
What do you think is leaking? Favorable convertible restructuring? Partnership for Canada, Israel, Australia, or other territory? Milestone payments? Japan start up? New application or patent extension? Buyout talks with J&J, PFE, MRK, Amgen, Sanofi, others? Script numbers exceeding expectations? The list goes on and on? Poor Kurt. The kid just does not know what he is getting into....
Votes:
3
0
Yahoo Finance Community
11/19
Comment
I hope that Esperion management uses this astronomical share price to raise desperately needed equity capital. At this point, they might fetch as much as $1.10 per share with some free warrants. If they issued just 400 million shares this would fund them through the end of next year....
Quantexa News
11/19
Cascale Puts Sustainability Policy in Spotlight As Brand and Retail Leaders Convene in Brussels
AMSTERDAM, HONG KONG, and OAKLAND, Calif., November 19, 2024 /3BL/ - As the policy landscape evolves at an unprecedented pace, understanding the implications of these changes is more critical than eve...
Yahoo Finance Community
11/19
Comment
Multiple factors. 1. Paradigm shift. Even though burn rate is off the charts, it’s improving with royalties/organ sales locked in, insurance coverage and fair sales. 2. Perception- MAJOR issue: This is now gold. Too many positives to focus on debt/negatives. Seriously. 3. ELY new drug data very positive, but different subpopulation of patients, brings attention to niche. 4. Market euphoria. This is the hottest market I can recall since March 2000. We’ve entered the fear of missing out stage. I expect we’ll scare 4 soon. Little has changed, but everything has changed....
Votes:
5
0
Quantexa News
11/19
Analysts’ Recent Ratings Updates for Esperion Therapeutics (ESPR)
A number of research firms have changed their ratings and price targets for Esperion Therapeutics (NASDAQ: ESPR): 11/19/2024 – Esperion Therapeutics had its “buy” rating reaffirmed by analysts at HC...
Yahoo Finance Community
11/19
Comment
Good thing the board is not full of excitement on this pop. Most have an avg of 50 or even 30 so a pop that will most assuredly give way to lower lows is not something that generates anymore excitement on here.I think it was the almost non existent growth this last QTR. Only 3 million when Karen predicted 50 million two QTRs ago. Again, this person is not real. She has been so far off on her predictions but the question of why needs to be asked.Short at end of day and thank me in morning. It never seems to want to gain and hold. But then again, just look at the non existent sales and that tells all everything. next QTR cash on hand will be what? Do you remember Karen said profitable by years end of 24? Yeah she doesn't say that anymore. She always lied about …...
Quantexa News
11/19
Buy Rating Affirmed for Esperion Due to Bempedoic Acid's Clinical Efficacy in Recent Trials
Esperion ( ESPR – Research Report ), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on the stock and...
Yahoo Finance Community
11/19
Comment
Sheldon looks very scared and fidgety at the investor conference before. It's like he is waiting for the FBI to come in and arrest him during the call, his eyes keep darting from right to left. Ben says they are in active dialogue with the note holders, and they want liquidation to repay the debt. Sheldon says the inflection point in sales has passed, it was 12% quarter over quarter growth. Now it will level off and stagnate. The interviewer wants to know why with all this coverage in place, are prescribers still not pushing this drug, Sheldon says before payor limitations were removed this was the reason. Now that payor coverage is in place, Sheldon says he is still trying to understand why no one wants this drug. He says it is sad....
Quantexa News
11/19
From design to recycling: Navigating ESPR product requirements for a circular economy – policy roundtable
2024-11-19 T-REX Project hosted a policy roundtable on the Ecodesign for Sustainable Products Regulation (ESPR) in Brussels. The event encouraged an open exchange on key issues between stakeholders i...
Yahoo Finance Community
11/19
Comment
Oh, James , please go back and listen to the fireside chat, too many good things to list here to note. James, the burn rate continues to go down and down and they will be reaching probability soon than many think and yes 140, million additional funds will be in before the end of next year with a cash positive company, oh boy, the smart short sellers are already covering . Sheldon is also teasing big Pharma, enticing them to up any buyout offer, talking about rare orphan indications for a no competition and an unmet need in rare kidney and liver disease, we may see short interest drop to .000000000001 percent, just James may be left behind....
Votes:
5
0
Yahoo Finance Community
11/20
Comment
As longs enjoy huge paper gains, it’s important to think long term. Why. settle for 3-5x your investment, when 10x to 20x is right around the corner. Shorts can cry and post for scraps, while we win. There is no better feeling to watch the stock price go up, and our fortunes increase, as they post about nonsense. We care for them but it is sad in a way....
Votes:
1
0
Quantexa News
11/20
Esperion Therapeutics (NASDAQ:ESPR) Given Buy Rating at HC Wainwright
HC Wainwright restated their buy rating on shares of Esperion Therapeutics ( – in a research report report published on Tuesday morning, reports. HC Wainwright currently has a $16.00 target price on t...
Yahoo Finance Community
11/20
Comment
The Jeffries call was excellent. My takeaways: Profitability in next quarter or two, sales are ramping even more strongly, milestones of $140m will be received, COGs will stay same, sales force will not be expanded, DOD contract starts Jan 2025, new drug applications are in the works, patent extension to 2040 is likely, convertibles to be addressed by end of year. Buyout and/or partnership is not off the table and with so many positives, I see it as very probable. But for longs, we want it later for when company is properly valued. Stock price of $20 and buyout for $40. Yum yum...
Votes:
6
0
Yahoo Finance Community
11/20
Comment
My dream was a prophecy. It is giving back all of the gains achieved yesterday. I believe people are starting to filter through the optimistic forward-looking statements and coming to the conclusion that spending $25 million to generate $3 million in new prescriptions is not a model that will work. Especially since the pills have been available now for five years. What a sad ending....
Votes:
1
2
Yahoo Finance Community
11/20
Comment
MIST; $1.75; Upon potential approval of its tachycardia heart drug we should see a market cap of $400 - $600M and a share price of $10 - $15. This reflects a conservative approach, using 3 x US revenue potential and neglecting the pipeline value and outside US market opportunities. A non-dilutive financing to support the launch is already in place. Moreover, we have been in a very narrow trading range of about 1,50$ for 10 months which was just broken with a strong upside move and with increasing trading volume and public visibility. Technically at a golden cross, signaling a major breakout. More buzz on the street will follow, driving the share price appreciation further. No risk for bad news in the near term and solid financials with ample cash on hand....
Yahoo Finance Community
11/20
Comment
I am thinking that when they report Q4 the year end cash position will be at about $110 million, but since they don't report until mid-February, by that time it will have dwindled to about $85 million. Wow, that's just four months of cash burn left! They need to do another equity offering and fast!...
Yahoo Finance Community
11/20
Comment
OMERS handing over $305m to be paid back in 3 years tells it all. Then the royalty stream worth hundreds of millions goes back to ESPR. And then you add in global sales, Japan and US, and you can understand how Sheldon and Ben were stating billions of sales per year is inevitable....
Votes:
2
0
Yahoo Finance Community
11/20
Comment
This is down again after hours. I think the fluff presented during the investor conference is being deciphered by savvy investors. They are going back through investor calls from the past five years and realizing, "Hey, these people have been saying the same thing for the last five years and nothing ever improves". They are correct....
Quantexa News
11/21
Esperion Therapeutics' (ESPR) Buy Rating Reiterated at HC Wainwright
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have...
Yahoo Finance News
11/21
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference Esperion Therapeutics, Inc. Thu, Nov 21, 2024, 7:00 AM 1 min read In This Article: ESPR +0.20% Esperion Therapeutics...
Quantexa News
11/21
Could Esperion Therapeutics Inc (NASDAQ: ESPR) Regain All Of Its Losses Given A -21.85% Dip From High?
During the last session, Esperion Therapeutics Inc (NASDAQ:ESPR)'s traded shares were 0.7 million, with the beta value of the company hitting 0.94. At the end of the trading day, the stock's price was...
Yahoo Finance Community
11/21
Comment
News is getting out that BA works really well alone or with other drugs, ie, statins, ezetimibe, CETP inhibitors, PCSK9s , etc. No wonder why experts believe $20 in 2025 is very reasonable. Imagine billions and billions of annual sales. Triple pill combo out to 2040+....
Votes:
4
0
Quantexa News
11/23
Unlocking Global Potential Strategic Business Implication of Digital
Published: November 23, 2024 Author: TEXTILE VALUE CHAIN Enforced under the Ecodesign for Sustainable Products Regulation (ESPR) , DPPs are crucial for brands and retailers that market products in t...
Quantexa News
11/23
HC Wainwright Reaffirms “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)
HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a report released on Tuesday, Benzinga reports. The brokerage currently has a $16.00 price t...
Yahoo Finance Community
11/24
Comment
Heart disease is the number one cause of death worldwide. LDL levels directly correlate with heart disease risk. Bempedoic acid has proven to reduce risk by 30-40%. That’s why the fda and Ema approved primary treatment prevention for BA, the only non statin to obtain this approval. Daiichi, Otsuka and Omers have invested billions into ESPR. Sales are projected to be billions per year. $20 soon....
Votes:
6
0
Yahoo Finance Community
11/24
Comment
As we approach this season of Thanksgiving, I'd encourage all Esperion investors to focus on those things they have to be thankful for. Family and friends, a productive career, whatever it is that brings you joy. Putting thought into your investment losses is not productive....
Votes:
1
2
Yahoo Finance Community
11/24
Comment
My guess is negotiations between Daiichi and ESPR continue but they can’t meet Sheldon’s asking price (yet). But with the constant ramping of sales and triple pill combo starting up, where 25% of sales goes to ESPR, and Daiichi pays 100% of manufacturing and distribution, and the patent runs to beyond 2040, and sales will be billions per year, it really is just a matter of time....
Votes:
6
0
Yahoo Finance Community
11/25
Comment
As ESPR marches to $20, we should all be thankful to the shenanigans that allowed us to fill up at these hugely discounted share prices. Credit to BOA, Daiichi, and of course, ESPR’s fearless leader, Sheldon. Now that we are all loaded up with shares, $145m cash on hand, $140m cash coming in from milestones, partnership deals in the works for Canada, Israel, Australia, and other territories, and reduced manufacturing and distribution costs worth $100m+ per year, we can let er fly. Any shorts remaining have been warned enough....
Votes:
7
0
Yahoo Finance Community
11/25
Comment
Its been years of struggle for the company to arrive at this level after so many roadblocks and missteps . It has great product suite and solid fundamental which only should go one way up and above. Very low risk and substantial reward waiting for the patient investor....
Votes:
4
0
Quantexa News
11/26
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
ANN ARBOR, Mich., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese Min...
Quantexa News
11/26
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
Esperion Therapeutics, Inc. ANN ARBOR, Mich., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a New Drug Applicat...
Quantexa News
11/26
Esperion Therapeutics (ESPR): Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
November 26, 2024 8:00 AM EST Esperion (NASDAQ: ESPR ) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Lab...
Quantexa News
11/26
Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
ANN ARBOR, Mich., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka) has submitted a New Drug Application (NDA) to the Japanese Min...
Yahoo Finance News
11/26
Esperion Therapeutics' Bempedoic Acid Submitted for Approval in Japan by Otsuka Pharmaceutical
PREMIUM Esperion Therapeutics' Bempedoic Acid Submitted for Approval in Japan by Otsuka Pharmaceutical MT Newswires Tue, Nov 26, 2024, 6:03 AM In This Article: ESPR -2.14% OTSKY +1.57% Esperion Therap...
Quantexa News
11/26
Esperion's Innovative Cholesterol Drug Seeks Approval in Japan
Author Olivia Taylor Updated : 11-26-2024 08:27 AM Esperion's Push for Regulatory Approval in Japan Esperion (NASDAQ: ESPR), a pharmaceutical company based in Ann Arbor, is making significant strid...
Quantexa News
11/26
Esperion announces Otsuka submitted NDA to Japanese MHLW for bempedoic acid
Esperion ( ESPR ) announced that Otsuka Pharmaceutical ( OSUKF ) has submitted a New Drug Application, NDA, to the Japanese Ministry of Health, Labour and Welfare, MHLW, for the manufacture and sale o...
Quantexa News
11/26
Positive Outlook for Esperion Due to Strong Clinical Data and Strategic Expansion
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion ( ESPR – Research Report ), with a price target of Don't Miss our Black Friday Offers: Unlock y...
Quantexa News
11/27
Esperion Therapeutics (NASDAQ:ESPR) Earns “Buy” Rating from HC Wainwright
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They pres...
Quantexa News
11/27
Esperion Therapeutics (NASDAQ:ESPR) Earns “Buy” Rating from HC Wainwright
‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Wednesday, Benzinga reports. They currently have a $16.00 price objective on the biophar...
Quantexa News
11/28
Connor Clark & Lunn Investment Management Ltd. Buys 295,378 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 71.0% during the 3rd quarter, Holdings Channel reports. The ins...
Quantexa News
11/28
Esperion Therapeutics' (ESPR) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright reissued their buy rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a report released on Wednesday, Benzinga reports. The brokerage currently has a $16.00 price t...
Quantexa News
11/28
HC Wainwright Reaffirms “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)
HC Wainwright restated their buy rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a research report released on Wednesday morning, Benzinga reports. HC Wainwright currently has...
Quantexa News
11/29
HC Wainwright Reiterates Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They pres...
Quantexa News
11/29
Esperion Therapeutics Inc (ESPR) Stock: Understanding the Volatility
The stock of Esperion Therapeutics Inc (ESPR) has gone up by 11.33% for the week, with a 29.10% rise in the past month and a 50.27% rise in the past quarter. The volatility ratio for the week is 4.90%...
Quantexa News
11/30
Esperion Therapeutics' (ESPR) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a research note published on Wednesday morning, Benzinga reports. HC Wainwright currently ha...
Quantexa News
11/30
Esperion Therapeutics' (ESPR) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a research note published on Wednesday morning, Benzinga reports. The brokerage currently ha...
Quantexa News
11/30
Esperion Therapeutics Inc (ESPR) Reported a 10.00% Operating Margin Last Year—What's the Real Story?
BofA Securities has recently reduced Esperion Therapeutics Inc (ESPR) stock to Underperform rating, as announced on June 20, 2024, according to Finviz . Earlier, on January 3, 2024, BofA Securities ha...
Yahoo Finance Community
11/30
Comment
I feel sad for the good people that listen to bubba and James and sold. Hopefully we get an update on one of many things going on. Australia, Canada, possibly ROW partnership, DOD, update on DSE manufacturing…that’s over 80 million off expenses coming 2025.Japan updates .do your own DD. But I believe this is a chance of a life time.. stay strong longs crazy trading days are coming.....
Votes:
7
0
Quantexa News
11/30
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Up 8.7% – What’s Next?
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report)’s stock price rose 8.7% during mid-day trading on Friday . The company traded as high as $2.76 and last traded at $2.76. Approximately 2,417...
Quantexa News
12/01
Esperion Therapeutics (NASDAQ:ESPR) Receives “Buy” Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report report published on Wednesday morning,Benzinga reports. The firm currently h...
Quantexa News
12/01
Esperion Therapeutics’ (ESPR) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research note released on Wednesday,Benzinga reports. HC Wainwright currently has a $16.00...
Quantexa News
12/01
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Up 8.7% – Time to Buy?
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report )'s stock price was up 8.7% during mid-day trading on Friday . The company traded as high as $2.76 and last traded at $2.76. Approximately 2...
Quantexa News
12/01
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Up 8.7% – Here's What Happened
Shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) rose 8.7% during trading on Friday . The company traded as high as $2.76 and last traded at $2.76. Approximately 2,417,710 share...
Yahoo Finance News
12/02
Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Treatments to Reduce LDL-C and Cardiovascular Risk
$TSLA NEWS Tesla stock slips after judge again blocks Musk's pay package Esperion Announces New Drug Submissions in Canada for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) T...
Yahoo Finance News
12/02
Esperion Therapeutics Files Applications for Non-Statin Medications in Canada
$TSLA NEWS Tesla stock slips after judge again blocks Musk's pay package PREMIUM Esperion Therapeutics Files Applications for Non-Statin Medications in Canada MT Newswires Mon, Dec 2, 2024, 5:30 AM In...
Yahoo Finance Community
12/02
Comment
In India they just reported a LAI-RECT study testing an affordable(for them) combination of BA-EZE added to rosuvastatin 40 mg (a generic). Results were identical to those of a PCK9 antagonist unaffordable for them, with excellent tolerability....
Votes:
9
0
Yahoo Finance Community
12/02
Comment
Be wary, poor and inexperienced retail investors. You must realize that all meme stocks are driven by a frenzied group of devoted penny stock people. As the market continues to recognize the lack of salable product for both organizations, the price will revert to zero....
Votes:
1
4
Yahoo Finance Community
12/02
Comment
As ESPR proves they can expand globally, their buyout price goes up exponentially. Just a matter of time for a buyout, as a big pharma would drive sales 10-50x higher overnight. Sheldon is smart to partner only Europe and Japan, keeping other territories and US unencumbered....
Votes:
4
0
Yahoo Finance Community
12/02
Comment
Big money is smart. You have the biggest market in the world (heart health), you have a proven mega blockbuster (multiple billion of sales per year), you have BA that is approved by fda and Ema for primary treatment (only statins have same label), and big pharma/investors including Daiichi, Otsuka, and OMERS have partnered for billions. When will ESPR be bought out? Likely 2025 for $5b or more. Look at inclisiran’s buyout for $9.7b. Too easy....
Votes:
4
0
Quantexa News
12/02
Esperion's Global Expansion and Strategic Growth: A Compelling Buy Opportunity
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion ( ESPR – Research Report ), with a price target of Don't Miss our Black Friday Offers: Unlock y...
Quantexa News
12/02
Esperion shares surge on cholesterol drug submissions in Canada
Esperion (NASDAQ: ESPR ) Therapeutics were seen rising as much as 23% on Monday. This notable surge, the largest intraday gain in approximately a year, followed the company's announcement regarding it...
Quantexa News
12/02
Esperion shares surge on cholesterol drug submissions in Canada
Esperion (NASDAQ: ESPR ) Therapeutics were seen rising as much as 23% on Monday. This notable surge, the largest intraday gain in approximately a year, followed the company's announcement regarding it...
Quantexa News
12/02
Esperion shares surge on cholesterol drug submissions in Canada
Esperion (NASDAQ: ESPR ) Therapeutics were seen rising as much as 23% on Monday. This notable surge, the largest intraday gain in approximately a year, followed the company's announcement regarding it...
Quantexa News
12/02
Esperion shares surge on cholesterol drug submissions in Canada
Esperion (NASDAQ: ESPR ) Therapeutics were seen rising as much as 23% on Monday. This notable surge, the largest intraday gain in approximately a year, followed the company's announcement regarding it...
Quantexa News
12/02
Esperion Therapeutics (NASDAQ:ESPR) Reaches New 1-Year High – Still a Buy?
NASDAQ:ESPR – Get Free Report ) reached a new 52-week high on Monday . The stock traded as high as $3.44 and last traded at $3.43, with a volume of 8108749 shares. The stock had previously closed at $...
Quantexa News
12/02
Esperion Therapeutics (NASDAQ:ESPR) Reaches New 1-Year High – Still a Buy?
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) reached a new 52-week high on Monday . The stock traded as high as $3.44 and last traded at $3.43, with a volume of 8108749 shares traded....
Yahoo Finance Community
12/02
Comment
If ESPR can sell $40m per quarter for US with 150 new hires with no sales experience with label just expanded in April, how much could MRK sell ( or similar big pharma) with 10,000 sales people, $250m marketing budget for BA alone, and synergistic drugs already being sold for heart health? We are talking 100x minimum and that is not even addressing patent extensions to sell out to 2040+, and new applications/molecules being generated. Tax write offs and milestone/royalties pay for the buyout. There is a reason territories are under ESPR control and have not been partnered. Show potential, get to break even, then run up share price and slap multiples on for the buyout and everyone is happy....
Votes:
5
0
Quantexa News
12/03
Zacks Research Has Negative Outlook for ESPR FY2025 Earnings
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) – Zacks Research reduced their FY2025 earnings per share estimates for shares of Esperion Therapeutics in a report released on Thursday, Novem...
Yahoo Finance Community
12/03
Comment
We got the close above 3 and a short covering spike to the 52 week high, let the quality buying now drive us through 3.43 to a high enough price that the almost inevitable buyout premium does not look overpriced. However, if we are to achieve a 6Bn offer then it may take a good few more quarters of sales and price appreciation. Bottom line, this is a buy and hold......
Votes:
5
0
Quantexa News
12/03
ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada
Esperion Therapeutics, Inc. ESPR announced that it has filed new drug submissions (NDSs) in Canada to seek approval for its once-daily, oral non-statin drugs Nexletol (bempedoic acid) and Nexlizet as...
Yahoo Finance Community
12/03
Comment
Are the doubters not realizing that Canada has a socialized healthcare system that is very conservative. This country that has problems supporting healthcare decides to approve a very expensive non-statin combination. What will it take to have you believe that this will be profitable medication relatively soon...
Votes:
5
0
Yahoo Finance Community
12/03
Comment
I am a retired physician. After retiring I received my Business degree from NYU and worked with J and J , Pfizer and Lilly business development. When I looked at this companies products and FDA approval, I purchased 10,000 shares and waiting for a buyout!...
Votes:
13
1
Yahoo Finance Community
12/03
Comment
I am concerned about Esperion reaching this astronomical market cap. I don't think it can be sustained. Most of Esperion's peer group in the startup pharmaceutical space have market caps closer to $20 million. Most do not have the severe debt burden either....
Yahoo Finance Community
12/03
Comment
I was just thinking about the last time this went over $3.00 per share. That was the time Sheldon issued 75 million new shares. He needed to because the company was running out of cash like they are now. He'll probably need to do it again. This is prudent....
Yahoo Finance Community
12/03
Comment
OK, been very busy lately, no need to check in on Gregg, Anthony, Cesare, Charles and the rest of the but I’m really worried about James. I feel he’s been misled and being a humanitarian that cares about all, I’m hoping you guys tell me that he switched sides and went long and he’s pumping away here. I don’t have time to scroll all the way down to read all of the messages, he seemed like a pretty sharp lad but he just fell in with the wrong crowd....
Votes:
4
0
Quantexa News
12/04
Esperion Therapeutics (NASDAQ:ESPR) Receives Buy Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. HC Wainwright curre...
Quantexa News
12/04
Parkman Healthcare Partners LLC Has $1.49 Million Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Parkman Healthcare Partners LLC lessened its position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 21.1% during the 3rd quarter, according to its most recent Form 13F filing...
Yahoo Finance Community
12/04
Comment
Esperion market cap should be 1.5 billion minimum.. I believe they will be receiving 1.5 billion in milestone payments from Otsuka and Daiichi.. just think about that. Can’t wait to find out who’s partnering up with Esperion/Canada. What will they pay....
Votes:
7
1
Quantexa News
12/04
Parkman Healthcare Partners LLC Has $1.49 Million Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Parkman Healthcare Partners LLC trimmed its position in Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) by 21.1% during the third quarter, according to the company in its most recent 13F fil...
Yahoo Finance Community
12/04
Comment
ESPR is still under the radar considering its great fundamental and proven alternative to Statins ; the market is huge in USA and internationally. The sales is increasing and the SP won't stay at this level . The recent upward move is the beginning of a new stage. Excellent Risk Reward proposition....
Votes:
9
0
Quantexa News
12/04
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Update
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) was the target of a significant drop in short interest in November. As of November 15th, there was short interest totalling 31,250,000 sha...
Quantexa News
12/04
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Update
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) was the recipient of a significant decrease in short interest in the month of November. As of November 15th, there was short interest tota...
Yahoo Finance Community
12/04
Comment
I hope there is not more bad news lurking. It seems like whenever there is a run up in the stock price, there is some equally deflating news to cause it to tank again. It could be lackluster sales, but we already know about them. Maybe the note holders are not going to do a deal, and Esperion will have to issue another 200 million shares to pay them off. Something like that could be it....
Yahoo Finance Community
12/04
Comment
I suspect Sheldon already rejected low ball buyout offers. I recall him stating ESPR was a takeover target, throwing it out there during a call. But I also believe Sheldon understands that a few billion dollar takeout will not be supported. You don’t have the ceo stating “mega blockbuster “ , reducing overhang (ripa, convertibles) if looking for a quick sale. He has also kept most territories, including US, free from a partnership. This is set up to run in 2025 and then slap on 50-100% premium for a buyout. That could be over $20-30 price depending on ramping across territories. Putting it differently, ESPR doesn’t need to sell but big pharma needs billions in sales per year to 2040+. It works either way for longs....
Votes:
9
0
Quantexa News
12/04
Check out this: Esperion Therapeutics Inc (ESPR) could be on the verge of a big rally
Esperion Therapeutics Inc (NASDAQ: ESPR) is 8.70% higher on its value in year-to-date trading and has touched a low of $1.35 and a high of $3.44 in the current 52-week trading range. The question beco...
Yahoo Finance Community
12/04
Comment
Not sure where this goes, but congrats to anyone making money. I changed my opinion after the election due to macro issues, and now this is on the bubbling market radar. Clearly the insurance coverage and new country potentials contribute. I’m highly fearful of a new stock offering and dilution in January like last year, as many similar companies have been doing after run ups. Obviously the buyout theory is intact at some point....
Votes:
5
1
Quantexa News
12/04
Esperion Therapeutics (NASDAQ:ESPR) Reaches New 12-Month High – Still a Buy?
Esperion Therapeutics, Inc. ( – ) shares hit a new 52-week high during trading on Monday . The company traded as high as $3.44 and last traded at $3.43, with a volume of 8108749 shares changing hands....
Yahoo Finance Community
12/05
Comment
ESPR turned heads today with its Canadian approval filing for NEXLETOL and NEXLIZET. These innovative cholesterol-lowering treatments could make waves in a market desperate for non-statin options. It’s a bullish setup if they can capitalize on the need for better heart disease solutions. Meanwhile, MYNZ is quietly gaining momentum post-split, with chatter about a big reveal—worth watching closely....
Quantexa News
12/05
Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They presently...
Quantexa News
12/05
Esperion Therapeutics' (ESPR) Buy Rating Reiterated at HC Wainwright
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They current...
Yahoo Finance Community
12/05
Comment
The only thing that has me wondering is why not plan for triple pill combo in US? Start the plans now. It’s a home run, even though it would be costly. Daiichi has already started it for Europe, with a 2027 year end date. If needed, get a partner to cosponsor it. My only guess is that will be addressed with a big pharma partner /buyer but why the analysts don’t jump on this amazes me....
Votes:
1
0
Yahoo Finance Community
12/05
Comment
Looks like some profit taking. I think this is now a FOMO story, so doubt a very low bottom ($3 max near term). I’m really hoping they don’t announce a/the next dilution/cash raise until January, seems inevitable looking at burn rate. Probably last time this will be needed, this should be on autopilot and at mercy of general market Beta until takeover....
Votes:
1
0
Yahoo Finance Community
12/05
Comment
No updates on conference call besides Department of Defense will be in affect 1/29/2025. 8 million people plus family. I don’t understand why no PR on that. This is tremendous news. Nothing about Canada. Disappointed in conference but holding long. Stay strong longs this is part of the game.. this will turn fast.....
Votes:
7
0
Yahoo Finance Community
12/05
Comment
So you have a proven blockbuster, sales going through the roof in Europe as evidenced by Daiichi agreeing to an added $100m annual cost for taking on manufacturing and distribution and OMERS agreeing to pay $305m upfront for 3 year payback, and fda, Ema unprecedented primary treatment approval with Japan following soon, so what do you decide to do with US operations ? You stay with the 150 person sales team?...
Votes:
5
0
Yahoo Finance Community
12/05
Comment
I believe part of this run was from November conference call when Sheldon mentioned contract with Department of Defense.. I still can’t believe he didn’t give us any info on that Today or wasn’t asked any hard questions on that.. no hard questions on deal with Canada. I believe if he puts out a PR on DoD this will be over $5.00.....
Votes:
7
0
Quantexa News
12/05
Short Interest in Esperion Therapeutics, Inc. (NASDAQ:ESPR) Drops By 6.6%
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 31,250,000 shares,...
Quantexa News
12/06
Esperion Therapeutics' (ESPR) Buy Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a research note issued to investors on Tuesday morning, Benzinga reports. They currently hav...
Quantexa News
12/06
HC Wainwright Reiterates Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)
HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a research report released on Tuesday morning, Benzinga reports. They currently have a $16.0...
Quantexa News
12/06
Esperion Therapeutics Inc (ESPR) 14-day ATR is 0.25: This Stock is Set to Soar Above its Peers
Esperion Therapeutics Inc (NASDAQ: ESPR) started the day on Thursday, with a price decrease of -8.74% at $3.34, before settling in for the price of $3.66 at the close. Taking a more long-term approach...
Yahoo Finance Community
12/06
Comment
Esperion was up over 50% from November conference call. Now yesterday conference call Sheldon talked about winning contract with DoD and the 8 million people plus family members. I believe piper will be buying after that news or talking about it. Stay strong longs. Monster runs are coming...
Votes:
4
0
Yahoo Finance Community
12/06
Comment
What it really comes down to is a big pharma getting the intro to Sheldon to partner and make this the huge return it should be. Is the intro from blackrock, Omers, Needham, or some other big player…..who knows. But it is just a matter of time. This will be a cash cow and at these multiples you can pay 10x the stock price and still make money in the long run. Investors will pressure the buyout and all will fly off on their private jets. Maybe they will even buy some islands....
Votes:
5
0
Quantexa News
12/06
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap Up – What’s Next?
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) shares gapped up prior to trading on Friday . The stock had previously closed at $3.34, but opened at $3.49. Esperion Therapeutics shares la...
Quantexa News
12/06
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap Up – Time to Buy?
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report )'s stock price gapped up before the market opened on Friday . The stock had previously closed at $3.34, but opened at $3.49. Esperion Thera...
Yahoo Finance Community
12/06
Comment
I'm sorry I seem to have misled people. NO and NO again, My gout was not caused by any medicine from ESPR or any manufacture. I came down with the GOUT all on my own. I'm sorry I gave people the wrong impression. And yes I'm a long term holder of ESPR....
Votes:
4
0
Quantexa News
12/07
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 6.8% – What's Next?
Shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) dropped 6.8% during trading on Thursday . The stock traded as low as $3.38 and last traded at $3.41. Approximately 3,604,589 sha...
Quantexa News
12/08
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap Up – What’s Next?
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report)’s share price gapped up prior to trading on Friday . The stock had previously closed at $3.34, but opened at $3.49. Esperion Therapeutics sh...
Quantexa News
12/08
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap Up – Should You Buy?
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $3.34, but opened at $3.49. Esperion Therapeutics shares last trad...
Quantexa News
12/08
Anson Funds Management LP Acquires New Shares in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Anson Funds Management LP acquired a new stake in Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutio...
Quantexa News
12/08
Anson Funds Management LP Makes New Investment in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Anson Funds Management LP bought a new position in shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) during the third quarter, according to its most recent disclosure with the Securi...
Quantexa News
12/08
Will The Long Awaited Breakout For Esperion Therapeutics Hold?
Suddenly, the weight of the overhangs for Esperion Therapeutics (NASDAQ: ESPR ) got a little lighter. The stock made an important technical achievement by breaking out above a year-long trading range....
Quantexa News
12/09
56,904 Shares in Esperion Therapeutics, Inc. (NASDAQ:ESPR) Bought by Intech Investment Management LLC
Intech Investment Management LLC bought a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) in the third quarter, according to the company in its most recent filing wit...
Yahoo Finance Community
12/09
Comment
As shorts become more and more desperate, it’s good to know the only overhang for ESPR are the convertibles. They will be addressed by year end and experts believe this is an easy lift that will extend due dates well into the future that can be addressed by free cash flow. Profitability is close with sales ramping in US, Japan coming on line, $140m milestones from Otsuka, new territories being added, possible new partnerships, etc. Great days ahead. Of course, unless you’re short....
Votes:
5
0
Quantexa News
12/09
Evaluating the Impact of 4.19 Increase on Esperion Therapeutics Inc's (ESPR) Stock
The stock of Esperion Therapeutics Inc (ESPR) has seen a 24.29% increase in the past week, with a 57.47% gain in the past month, and a 104.71% flourish in the past quarter. The volatility ratio for th...
Yahoo Finance Community
12/09
Comment
Oh no. Someone called and the person was so sad they couldn’t speak. A lot of sobbing. The type that really gets you moved. They hung up before I could offer help. But then I clicked on a page listing islands for sale and I started feeling much better....
Votes:
5
0
Yahoo Finance Community
12/09
Comment
FOMO continues. There really is no way to value this given anemic sales which are now rapidly accelerating w insurance coverage, indications, etc. Round number resistance but should be minimal to 5. 3.3-5 looks good. I still believe risky holding in January given the need for capital/dilution and new prognosis favorable into eventual buyout. ESPR has been consistent in burning shareholders w every light in the tunnel, no reason to expect different until the buyout....
Votes:
3
0
Yahoo Finance Community
12/09
Comment
Nuvig partners (Sheldon’s other venture) received $161m funding last week. A lot of big pharma players involved. ST has the post over on that board. Perhaps time for Sheldon to move on to his new hobby. Sell ESPR in 2025 and play with Nuvig. Sorry , james, but you were not mentioned by Sheldon in his post....
Votes:
4
0
Quantexa News
12/10
Esperion Therapeutics (NASDAQ:ESPR) Hits New 12-Month High – What’s Next?
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) shares reached a new 52-week high on Monday . The stock traded as high as $3.82 and last traded at $3.82, with a volume of 3018645 shares ch...
Yahoo Finance Community
12/10
Comment
I love Wall Street. The herd jumps on such nonsense. NAMS and their CETP inhibitor provided decent results, but nothing earth shattering. ESPR primary prevention showed 30-40% risk reductions. NAMs g came out with about a 21% risk reduction on similar patient group after 1 year. In 4 to 5 years, let’s talk. CETP inhibitors have a long history of failure and I’m not convinced of anything....
Votes:
7
1
Yahoo Finance Community
12/11
Comment
There is a lot of knowledge and experience on the message board regarding ESPR. A 20% move to the downside and no one her has identified new information to drive the sustained selloff. Either there are better informed investors out there or this was orchestrated? Looking at the daily chart it was not people running for the doors but a steady forced decline. I did not think this would happen again and I am slightly taken aback at the ability to pull this down by 20% but here we are. I am still happy if we are around 3.40 by end of week. That said this sort of price move is damaging as the unexplained volatility keeps new investors away....
Votes:
6
0
Yahoo Finance Community
12/11
Comment
For those that stayed with Esperion for so long, it can be difficult to accept that its drugs are being replaced with better new alternatives. Especially since after five years they seemed to be getting some early acceptance. Even so, we must try to be happy for the patient population. They will have a new and more effective pill to take, free from the worry of gout....
Yahoo Finance Community
12/11
Comment
Nams is only one clinical stage with 0 revenue and over 2 billion market cap at a price of $26 . it has a long way to go to catch up with Espr. Remember Espr in the clinical stage, had over $100 price per share? What a similar scenario! It's a big funds game before the real action....
Votes:
2
0
Yahoo Finance Community
12/11
Comment
Way too much reaction for NAMS effect at this point. Massive hedge fund or other liquidation- must be leak of impending dilution, or some fraudulent component. Anyone who traded a lot back in 1999/2000 can recall every other Nasdaq stock having similar up and down 20-40% moves. I once had $1000 EXTR put that was $19k the next day. This type of volatility is only seen at market extremes. Irrational exuberance, ot irrational pessimism. Reality in between....
Yahoo Finance Community
12/11
Comment
Oh, my goodness, over 13 million shares unloaded in the first two hours of trading. Investors are really scrambling for the door here at any price. I try to discern the thoughts driving this mass exit and the top two reasons seem to be the belief that another mass dilution will occur and the belief that bempedoic acid will be a short-lived product because of new and better alternatives rapidly approaching availability. Makes sense....
Yahoo Finance Community
12/11
Comment
I only have one regret, that I could not purchase more shares on this two day running of all the stops giving the shorts a way out. I have seen a lot in biotech over the years, DNDN the first immunotherapy the stops were run 20 mins before the stock was halted for FDA approval. Last two days has been totally abnormal trading and the daily charts are very clear - automated sell off...
Votes:
3
1
Quantexa News
12/11
Esperion's Strategic Pipeline Advancements and Market Recovery Drive Buy Rating Amidst Cholesterol Competition
Dennis Ding , an analyst from Jefferies, maintained the Buy rating on Esperion ( ESPR – Research Report ). The associated price target is $5.00. Pick the best stocks and maximize your portfolio: Di...
Yahoo Finance Community
12/11
Comment
Amsterdam: Although exploratory at this point, the difference in major adverse cardiovascular events (“MACE”) at one year in BROADWAY supports our belief that obicetrapib could provide greater than expected CV risk reductions through mechanisms beyond LDL-C lowering.Well they need a large long study before going to FDA...
Votes:
1
0
Quantexa News
12/11
Esperion Therapeutics (NASDAQ:ESPR) Sets New 52-Week High – Here's What Happened
Shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) reached a new 52-week high on Monday . The stock traded as high as $3.82 and last traded at $3.82, with a volume of 3018645 shar...
Polygon News
12/12
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
Esperion Therapeutics has entered into a licensing agreement with Neopharm Israel to exclusively commercialize its cardiovascular drugs NEXLETOL and NEXLIZET in Israel. Esperion will receive upfront a...
Quantexa News
12/12
Esperion entered into licensing agreement with Neopharm Israel Esperion (ESPR) Therapeutics announced it has entered into a licensing agreement with Neopharm Israel for the exclusive rights...
Esperion (ESPR) Therapeutics announced it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to commercialize NEXLETOL and NEXLIZET in Israel. Under the terms of the...
Quantexa News
12/12
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales – – Israel-Based Commercial Organization Brings Successful Track Record Commercializing...
Quantexa News
12/12
Esperion Therapeutics (ESPR) Partners with Neopharm to Commercialize NEXLETOL and NEXLIZET in Israel
December 12, 2024 8:01 AM EST Esperion Therapeutics (NASDAQ: ESPR ) today announced it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to commercialize NEXLETOL®...
Quantexa News
12/12
Esperion Partners with Neopharm to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Israel
– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales – – Israel-Based Commercial Organization Brings Successful Track Record Commercializing...
Yahoo Finance News
12/12
Esperion Therapeutics Signs Licensing Deal for Nexletol, Nexlizet in Israel
PREMIUM Esperion Therapeutics Signs Licensing Deal for Nexletol, Nexlizet in Israel MT Newswires Thu, Dec 12, 2024, 9:47 AM In This Article: ESPR -12.11% Esperion Therapeutics (ESPR) said Thursday it...
Yahoo Finance Community
12/12
Comment
I hope the management team at Esperion was able to negotiate a deal with the Israelis that provides enough royalty revenue to cover manufacturing and shipping the drug. As management points out, they are still losing money on every pill sold in Europe. This is very bad since sales have now peaked....
Quantexa News
12/12
Esperion entered into licensing agreement with Neopharm Israel
Esperion ( ESPR ) Therapeutics announced it has entered into a licensing agreement with Neopharm Israel for the exclusive rights to commercialize NEXLETOL and NEXLIZET in Israel. Under the terms of th...
Quantexa News
12/12
Esperion's Strategic Expansion and International Growth Justify Buy Rating
In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion ( ESPR – Research Report ), with a price target of Pick the best stocks and maximize your portfol...
Quantexa News
12/12
Esperion Partners with Neopharm to Commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) in Israel
– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with Tiered Royalties on Product Sales – – Israel-Based Commercial Organization Brings Successful Track Record Commercializing...
Polygon News
12/13
Esperion Announces $210 Million Convertible Debt Financing
Esperion announced a $100 million convertible notes offering, including $57.5 million in exchange for existing notes and $42.5 million in new cash. The new notes will mature in 2030 and pay 5.75% inte...
Quantexa News
12/13
Esperion Announces $210 Million Convertible Debt Financing
Esperion Therapeutics, Inc. ANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscrip...
Quantexa News
12/13
Esperion Therapeutics (ESPR) Announces $210M Convertible Debt Financing
December 13, 2024 6:15 AM EST Esperion (the “Company”) (NASDAQ: ESPR ) today announced that it entered into privately negotiated exchange and subscription agreements (the “Agreements”) with certain h...
Quantexa News
12/13
Esperion Announces $210 Million Convertible Debt Financing
ANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscription agreements (the “Agreeme...
Quantexa News
12/13
Esperion Announces $210 Million Convertible Debt Financing © 2021, The Oxford Eagle
ANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscription agreements (the “Agreeme...
Quantexa News
12/13
Esperion Announces $210 Million Convertible Debt Financing
ANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscription agreements (the “Agreeme...
Quantexa News
12/13
Esperion Therapeutics : ANNOUNCES $210 MILLION CONVERTIBLE DEBT FINANCING Form 8 K
December 13, 2024 at 06:46 am EST ESPERION ANNOUNCES $210 MILLION CONVERTIBLE DEBT FINANCING ANN ARBOR, Mich., December 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the "Company") (NASDAQ: ESPR) today ann...
Quantexa News
12/13
Esperion Announces $210 Million Convertible Debt Financing
ANN ARBOR, Mich., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Esperion (the “Company”) (NASDAQ: ESPR) today announced that it entered into privately negotiated exchange and subscription agreements (the “Agreeme...
Yahoo Finance Community
12/13
Comment
SEC should be contacted. What a scam. I’ve been alerting about risks of share issuance/dilution, but something more ominous here re: the incredible multipart dilution now involving multiple entities here and abroad. Needs to be sold before it’s time to pay the piper....
Yahoo Finance Community
12/13
Comment
I’m see 2 major problems (besides stock price): 1) $157 million cash paid out- so they retired much of this debt, but now cash DEPLETED; 2) Can kicked down the road, with smaller Convertible at higher rate. HOWEVER, NOW there is markedly reduced cash for operations next year. I predict a share issuance in January, now at remarkably similar terms to last January $1.5/share. The clarity of this House of Cards, and obvious insider action and now market realization, is right out of Billions. Needs a fire sale at $4 soon....
Yahoo Finance Community
12/13
Comment
Investing in start-ups is always risky. Early investors are always subject to losing money and/or dilution of their original value (additional stock/debt offering or reverse splits). Net net: You’re last for consideration but always first when they want your money!...
Votes:
2
1
Yahoo Finance Community
12/13
Comment
Folks. This is what happens when insider trading and Wall Street clarity become a lightbulb moment. Undoubtedly those involved with the Convertible financing (and inevitable share issuance in 2025) dumped shares or led to cascade of sales from 3’s to 1’s. Harsh reality....
Yahoo Finance Community
12/13
Comment
People! The issue here is that debt was refinanced with more debt, of course! If you believe in the drug and that sales will pick up then you should not worry, and for those talking abou dilution, you should learn how to read press releases in a proper manner....
Votes:
2
1
Yahoo Finance Community
12/13
Comment
Guys. I urge you to review previous years graphs and news. There will be a near term bounce off these catastrophic sell lows. But the new share dilution in January (my speculation) will crush any bounce attempt, and reset the bottom .25-.5 above the share issuance price. Sure, this is can be traded, take some cents from your buds. But until there are actual sales exceeding all these royalties and obligations, it’s Whack a Mole....
Yahoo Finance Community
12/13
Comment
I think the new lenders are opening their short positions on the stock as a hedge against their very high-risk loans. After all, they've just refinanced a company whose sales have peaked and burns through a million in cash per day. Prudent to hedge. ....
Votes:
1
0
Yahoo Finance Community
12/13
Comment
Almost 50% wiped out in days.Sheldon is the destroyer of shareholder value. Please no more talk of retiring or buying an island. The market has spoken. This is a pump and dump. A scam. Sheldon does not care one bit about you all. In fact, he hates you all....
Yahoo Finance Community
12/13
Comment
We just went from roughly 750 million in market cap to below 400 million in market cap and can anybody answer the question why? The answer would be because this company is totally mismanaged and they are losing money and nobody thinks that they will be making money anytime in the near future if at all....
Yahoo Finance Community
12/13
Comment
As I always said, it was inevitable that this would crash. A firm such as Esperion should never have a market cap at this level (currently $400 million). Its peer group in the penny pharma stocks, typically have market caps much closer to $20 million....
Votes:
1
1
Yahoo Finance Community
12/13
Comment
Many are failing to grasp what is occurring. They believe the illusion that a simple Convertible refinancing has occurred, and there is no correlation with a near 50% stock drop. This was insider leaked details, telegraphing a $157 million cash debt buy down, which necessitates another major stock dilution for cash operations in 2025. Yes, the mortgaged royalties from Japan, Canada, etc, help, but simply not enough, and cash is now needed. History repeats. Super high risk except for day trading through Feb....
Votes:
1
0
Yahoo Finance Community
12/13
Comment
Ok, the 2025 debt is going down by 210m. The question is they don't have any more cash for the remaining 54m of 2025 debt. Also their current liability is high too. Are they going to do another debt financing or issuing shares to raise money, or they believe the revenue growth is enough to cover everything?...
Votes:
1
2
Yahoo Finance Community
12/13
Comment
These convertible offerings almost always lead to rampant shorting as a hedge. I wouldn't be surprised if they push this down below $1 again and ultimately, if the drug doesn't take off, the debt holders will end up with what's left of the company. I considered selling in the 3's, which would've been a double for me, but I didn't and now I'll stick around for morbid curiosity with my 10,000 shares. If this drug doesn't pick up steam, I don't see how they can service the debt and fund operations. And if the convertible holders short it into oblivion, that will be lights out. Definitely hoping for the best, but not too optimistic....
Votes:
1
2
Yahoo Finance Community
12/13
Comment
Interesting how Jeffries was the sole listing agent last January when they issued $85 million of common shares . And Jeffries had main press release the other day saying the main reason for the initial ESPR selloff was response to new NAMS drug research report (which actually was same type data from November). Truly a travesty. Watch for another Jeffries linked offering in 2025 (maybe after Jan since so close to this debacle)....
Yahoo Finance Community
12/13
Comment
Have to say, with next round of dilution in 2025, and probable general market correction, this is setting up for a potential drop below 1, and then a reverse split. Probably a 5 or 10 to one. Sitting at 3.9 a few days ago, I warned of dilution potential, but missed the forest through the trees on their dire finances....
Yahoo Finance Community
12/13
Comment
Anthony said they would be profitable by end of this year. LIEAnthony said OMERS would be paid back within 3 years. LIEAnthony said this would be 20 by time debt restructured. LIE.Anthony has cost so many so much.If you listened to me, you are making so much. Remember to donate to a worthy charity....
Votes:
1
0
Yahoo Finance Community
12/13
Comment
Let me help all out.If they spend 240 million a year and Ben said 25 would be the same.If they are doing 31 million per QTR and growing around 3 million per QTR. How many years before they are profitable?Folks this is easy math and the stuff some of you post is bizarro. They might get profitable the moment patent expires. NAMS drug goes to market or oral PCSK9 is here. This was always a loser. Shocked more didn't see it that way.They are not closer than most think when it comes to being profitable. Next round of dilution is coming. They need so much more money....
Quantexa News
12/13
Esperion Therapeutics (NASDAQ:ESPR) Given Buy Rating at Needham & Company LLC
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “buy” rating reissued by Needham & Company LLC in a report issued on Friday, Benzinga reports. They presently have a $6.00 price...
Quantexa News
12/13
Esperion Therapeutics (NASDAQ:ESPR) Given Buy Rating at Needham & Company LLC
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “buy” rating reaffirmed by Needham & Company LLC in a research note issued on Friday, Benzinga reports. They presently have a $6....
Yahoo Finance Community
12/13
Comment
The killer is the refinancing liquidation of $157million in cash, which basically eliminates cash for operations after the first quarter or so. An absolute kick in nuts. Rates were too high to roll whole thing over. The well is dry. At these low prices will need another 25-30% dilution from here. Grim....
Quantexa News
12/13
Investment Analysts' Updated EPS Estimates for December 13th (AAPL, ABSI, ACON, BIRK, BLBD, COST, EDIT, ELEV, ESPR, FOLD)
Investment Analysts' updated eps estimates for Friday, December 13th: Apple (NASDAQ:AAPL) had its overweight rating reaffirmed by analysts at Morgan Stanley. Morgan Stanley currently has a $273.00 ta...
Yahoo Finance Community
12/13
Comment
Please no pumping for the remainder of the month. Let longs process just how much they have lost and the fact that it is never coming back.13 Jan is the date pumpers can start to talk this loser up again. Many have lost everything. Let them self analyze where their thoughts were flawed.Never ever invest in anything sheldon is connected to. You short Everything and anything Sheldon is around....
Yahoo Finance Community
12/13
Comment
Listen, as a long term holder, am I happy. No. Is there a cost of money. Of course. Have I lost a dime yet? No, only Kurt has. If ESPR is bought out next week for $10 will this be worth it. You know the answer. You can visit me as my island that will be half the size of Bermuda. Nothing has changed except timing. Europe is ramping beyond expectations. Japan is starting. Milestones due. US is the gold goose. Nams is years out. Oral pcks9s will have the same risk reductions issues. Be smart and don’t be Kurt who shorted at $1.75....
Votes:
3
0
Yahoo Finance Community
12/13
Comment
Feel bad for people who bought at $3 looking for a momentum trade ( think Kurt), but this a long term holder. Many longs purchased under $1, and some under .8. Think where ESPR will be in -1 year, 2 years. What is the end game. If you think 150 sales newbies will be selling in Us, you are as naive Kurt/Omar/Bubba. For me, it makes sense....
Votes:
1
0
Yahoo Finance Community
12/13
Comment
I want to give someone that posts regularly my overachiever award. This person has been posting non stop and all of his posts have been mostly accurate. If you listened to him you should have a Merry Xmas.This person is James. James has been so energetic and accurate and he has zero shares. He shares his insight because James is a man of the people. He is a gentlemen. The world needs more people like James. James I and the syndicate appreciates all of your hardwork in keeping people aware of this scam and constantly reminding that Sheldon is their enemy....
Yahoo Finance Community
12/13
Comment
James so long ago stated something that was unreal. Esperion was losing money on every pill DSE sold. No one believed it until Sheldon admitted during a call. Now, how much will they lose with Japan, Canada and Israel? It makes zero sense to engage in partnerships where the more successful that partner is, the more ESPR losses. This is why the chart looks the way it does. Shame on anyone that didn't sell 70% when this almost hit 4. Fools are abound...
Yahoo Finance Community
12/13
Comment
Board needs to fire Sheldon and bring back Tim M. Only then would this have a chance. WS despises slimy Sheldon for that so unnecessary dilution at 50% off the stock price.When asked why he gave such a steep discount. He said his interests were not aligned with shareholders so he didn't care whom he hurt....
Quantexa News
12/13
Esperion's Strategic Debt Refinancing Boosts Financial Stability and Investor Appeal
Analyst Serge Belanger from Needham maintained a Buy rating on Esperion ( ESPR – Research Report ) and keeping the price target at $6.00. Pick the best stocks and maximize your portfolio: Discover...
Yahoo Finance Community
12/13
Comment
To hold this overnight. You risk the chance of waking up to a PR about massive dilution. Sheldon has proven before he will dilute at discounted prices when there was no need to dilute. Holding a Sheldon stock overnight is a huge gamble. He could dilute monday or next month. He does not care about shareholders....
Yahoo Finance Community
12/13
Comment
How was this ever called a potential blockbuster? Where are the billions in revenue a year?They are doing 31 million a quarter. Where is that inflection?You all were scammed and manipulated. IF you bought this, you are the sheep and sheldon is the wolf. You believed his lies as he diluted and you kept losing....
Quantexa News
12/14
Esperion's Strategic Debt Refinancing Boosts Financial Stability and Investor Appeal
Analyst Serge Belanger from Needham maintained a Buy rating on Esperion (ESPR – Research Report) and keeping the price target at $6.00. Serge Belanger’s rating is based on Esperion’s recent strategic...
Yahoo Finance Community
12/14
Comment
I've never been more confident in an investment. Their PowerPoint slides radiate a level of excellence that proves they’re not just working hard—they’re working smart. And let’s not forget the organic cotton lab coats. That kind of sustainable innovation shows they care about every detail. This is why I’ve committed my entire portfolio. Some people just don’t see the vision....
Votes:
7
0
Quantexa News
12/14
Esperion Therapeutics' (ESPR) “Buy” Rating Reiterated at Needham & Company LLC
Needham & Company LLC reissued their buy rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a research report report published on Friday morning, Benzinga reports. Needham & Comp...
Quantexa News
12/14
Esperion Therapeutics Secures $150 Million Term Loan in Recent Credit Agreement
On December 12, 2024, Esperion Therapeutics, Inc. (NASDAQ: ESPR) finalized a credit agreement with GLAS USA LLC and several initial lenders for a $150,000,000 term loan to refinance a portion of its e...
Yahoo Finance Community
12/14
Comment
Do not be jealous. Do not hate those that make money on this stock.To have 200% to 300% gains and not sell any is beyond greed and recklessness. It was stupid. You paid for your low IQs. All of these years of holding and pumping and you are back to the low 2s. That must sting so bad. Rule #1 is management must be trusted. So many funds sold and never came back after sheldon did that last dilution. They are smarter than you all. This will never see 4 again. The sales just are not there and never will be with 150 lazy unqualified DEI hire sales people.Do you know how much sales have grown since that label expansion? Its not much folks. Anthony touted immediately inflection will occur. Fools...
Yahoo Finance Community
12/14
Comment
The deal was done to maximize current and future value by pushing payback to 2030. Short term the milestones and or small territory partnerships will easily pay the remaining 2025 convertibles and remaining cash will fund operations until profitability occurs in a quarter or two. This perfectly preserves ESPR as an attractive bigger partner or acquisition target as predicted. No dilution. Of course, if a special event occurs, longs will be sailing to their island with the news. Wall Street herd will understand and reverse course soon. Which shorts are shorting now? Let’s get it on paper so we can track results....
Votes:
4
0
Yahoo Finance Community
12/14
Comment
Longs have to love this deal. All risk is removed. There is a zero chance of failure for this stock. Nams is not a player until 2028 and good luck getting primary treatment approval when it is a “me too” add on to statins, not bringing anything new to the party. CETP inhibitors have all failed. All current prospective drugs (pcsk9s) do not have the same ancillary benefits as BA (inflammation reduction). That is why Daiichi, Otsuka and OMERS have invested billions. Expect acquisition in 2025....
Votes:
6
0
Yahoo Finance Community
12/14
Comment
Remember on the conference call Sheldon said Esperion won the contract for Department of Defense with 8 million plus family members. No news on that. I believe Sheldon gave us longs a heads up on that before it’s announced. Nobody knows this but us. I added 3 times on Friday....
Votes:
1
0
Yahoo Finance Community
12/14
Comment
So it seems almost all catalysts uave come and gone and stock price is back at low 2sNow it comes down to sales. Nothing else to pump for you all.They are growing at an anemic 3 million per QTR and BoA says peak sales are so close.For those that bought at 52 week lows and to have not sold on that runup. Amateur hour.To make money like a pro you hVe to trade like a pro. They brought price up to lure you in and they dumped it.I would not be shocked if sheldon sold millions via the ATM last two weeks. Sheldon should start to fear for his life. If they coupd hit the CEO on UNH. Sheldon is much more deserving of that fate....
Yahoo Finance Community
12/14
Comment
Some lost 45% this week. Please no pumping.There are no more upcoming catalysts. It is now all sales based. They have said 4th QTR is always their slowest. Is this where peak sales start to come into play?Crazy this was 4 dollars Monday and hit a low of 1.87 Friday. Penny stocks move like this. Manipulated stocks move like this. Sheldon led stocks act like this.You have to be asking why did it go up and then immediately down?????? Who was buying and who was shorting....
Votes:
1
0
Yahoo Finance Community
12/14
Comment
It’s all about setting positions before the herd moves. Many longs here set enormous positions under $1. You can then understand how we can sit and laugh at the machinations of small shorts trying to make a living. The game of large funds covering positions on positive news in small bio is always the same. Longs have won. This battle is over. It’s just a matter of when we collect and the final return. Those entering now will be smart to follow the money prior to the run up. If you’re trying to put food on the table for the holidays, good luck shorting with Kurt....
Votes:
2
0
Yahoo Finance Community
12/14
Comment
You could have bought just about any stock over the last year and you would be up about 30%Only you all would buy and celebrate making NO MONEY. When markets correct, this will be below a dollar yet again. Who regrets ever buying this or being manipulated to buy more shares of garbage?...
Votes:
1
1
Yahoo Finance Community
12/14
Comment
For years I have been reading about billions in milestones. What happened to those? Why is ESPR always cash poor? There was a poster who lied so much. James what was her name?She said billions in milestones would pay off all debt and they would be paid by now.She also said OMERS would be paid off in 3 years. DSE is only paying 8.9 million per QTRShe also said billions in revenues and they are ONLY doing 31 million.She also said it would be bought out for 40 by nowShe also said this would be a blockbusterShe also said it would make everyone rich. Read all message boards yesterday. Everyone that invested is poor.She also said shorts would lose. Shorts are the only ones winning. How could a female be so wrong for so long???? James do you think she is lying on purporse or just really bad at this …...
Votes:
1
3
Yahoo Finance Community
12/14
Comment
Ben said to break even they need 225 million in US sales. They are doing 120 million. Where do you all get that they will be profitable soon? How dumb or naive must you be to think at 3 million per QTR growth before plateau that they will be profitable before patent expires? You all have not made any money not because of bad luck but because you are just not smart at figuring out what matters, what are facts and what are false opinions. This has failed and will aways fail because Drs just do not care about alternatives to statins. Statin intolerance is the same as the fify religions out there. No one believes...
Yahoo Finance Community
12/14
Comment
FYI, Sales have shown consistent improvement month over month, reflecting positive momentum. The current price presents an exceptional opportunity for long-term investors. ESPR is poised for significant growth as we enter the new year, with next quarter’s earnings expected to be impressive....
Votes:
4
0
Quantexa News
12/15
Esperion Therapeutics' (ESPR) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a research note released on Thursday morning, Benzinga reports. HC Wainwright currently has...
Quantexa News
12/15
Needham & Company LLC Reiterates “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “buy” rating reaffirmed by equities research analysts at Needham & Company LLC in a research note issued on Friday, Benzinga repo...
Yahoo Finance Community
12/15
Comment
Now ESPR has complete control of their future. No dilution and 5 years of growth to pay off nominal debt. Quite amazing and when Wall Street covers all of their short positions, ESPR will run and run until they are bought out. All will make tons of money and be happy. Well, all but a very few....
Votes:
3
0
Yahoo Finance Community
12/15
Comment
I talked to a doctor last night at my Mom's Christmas party for the neighbors. I asked if she was prescribing bempedoic acid but she hadn't heard of it. I asked what she does when her patients have muscle pain. She said it was very rare, maybe 1 in 100. She says she usually tries another statin or adjusts the dose and this usually does the trick. She's sent a couple of patients on for injections but not many....
Yahoo Finance Community
12/15
Comment
Everyone on here and ST is acting like the convertible news was a positive. Folks the stock sold off big time on high volume. I get you all are not nearly smart enough to determine anything let alone if something is good or bad for your investment. Look to see what the stock does to determine. Funds are pros and they are in the game to make their clients money. ESPR sold off 45% in a week. Friday was brutal sell off on crazy volume. The convertible news was horrible. It ensures so much more dilution. That is how the markets interpreted it. ESPR is so weak right now and the markets sense it. Remember it is not what pumpers feel. The stock price tells everyone everything. It is going lower because Sheldon has proven one thing. Given the choice, he always picks wrong....
Yahoo Finance Community
12/15
Comment
IF my house was burnt to the ground. Would I be elated that the fire company put out the fire and I view it as a success? My house was destroyed, and I have nothing left but sure, lets commend the fire dept for putting out the remaining ashes. You all have no clue. Sheldon is destroying this company day by day. He started with 18 million shares. Now it is close to 330 million. Your piece of the pie is getting smaller and smaller with each move they make. Guess what? They are still unable to meaningfully grow sales. 31 million and they need to be doing 75 million a QTR. There is no plan to grow sales. They are just moving pieces around the board to deceive the low IQ easily manipulated. You can tell who is intellectually challenged by their posts as it pertains to stock price …...
Yahoo Finance Community
12/15
Comment
You all make me laugh. You know nothing, lost a lot of money, yet think you are winning. Do you know what we call that? Accepting of being a loser. You gave up trying to win and know you just want to feel like all of those years and all of those losses mean something. Do not have children. You would teach them to be losers like you. The world needs leaders and winners. Esp America. MAGA...
Yahoo Finance Community
12/15
Comment
No insider buys because they know its fools gold. They are doing everything to keep the ship alfoat. They love their jobs and salary.! Their goal is to keep this going until generics and tuen the gig is up. Ben said as long as he is CEO the spend will remain the same. Its not about growing but keeping this scam going.75 million per QTR was their goal. They know its never happening. Peak sales are here soon. WS knows its. Sheldon knows it. Its why he took a horrible debt deal....
Yahoo Finance Community
12/15
Comment
FYI, Sales have shown consistent improvement month over month, reflecting positive momentum. The current price presents an exceptional opportunity for long-term investors. ESPR is poised for significant growth as we enter the new year, with next quarter’s earnings expected to be impressive....
Votes:
5
0
Quantexa News
12/16
Esperion Therapeutics' (ESPR) Buy Rating Reiterated at Needham & Company LLC
Needham & Company LLC restated their buy rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a research note published on Friday morning, Benzinga reports. They currently have a $...
Quantexa News
12/16
Needham & Company LLC Reaffirms “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)
Needham & Company LLC reaffirmed their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report released on Friday morning,Benzinga reports. Needham & Company LLC...
Yahoo Finance Community
12/16
Comment
Candlestick chart indicator show a bullish reversal pattern Hammer candlestick with long lower shadow after a gap down. Reversal to upside may be imminent. If we close up today which is confirmation of the reversal buy aggressively. Or buy immediately if we open green on high volume...
Votes:
2
0
Yahoo Finance Community
12/16
Comment
FYI, Sales have shown consistent improvement month over month, reflecting positive momentum. The current price presents an exceptional opportunity for long-term investors. ESPR is poised for significant growth as we enter the new year, with next quarter’s earnings expected to be impressive....
Votes:
4
0
Yahoo Finance Community
12/16
Comment
On Friday Esperion lost 11.76% in one trading session. I sure hope it doesn't lose 11.76% again today. That will leave the share price at $1.98. That would be sad. I hope they start making some sales of this "blockbuster" drug. Hard to believe after five years they only have 25,000 patients in the US. It makes me think the Bank of America analyst was correct when he said sales were peaking this quarter....
Votes:
1
4
Yahoo Finance Community
12/16
Comment
ESPR is up for the month. Sure everyone wants huge paper gains but in reality, ESPR is in better shape and shorts are covering . Those run ups will become more and more common. Fun times ahead. That’s what you get when a small company becomes profitable with a mega blockbuster drug....
Votes:
4
0
Yahoo Finance Community
12/16
Comment
ESPR is ready to bloom. Like a rose bush just prior to spring. With debt addressed, sales ramping, Japan coming on line, Europe exploding, US ramping, new territory partnerships, milestones, and new molecules and applications, you now know why sheldon is maintaining his high asking price ( I think it is $8b). 2025 will be the best year yet for ESPR, and with Kurt betting against it and james crying, it will be very exciting....
Votes:
7
0
Yahoo Finance Community
12/16
Comment
For the first three quarters, Esperion had a loss from continuing operations of $161 million. I suspect they will need to book a loss on the debt restructuring of about $50 million during Q4. When you combine that with the standard $35 million per quarter operating loss, the full year loss should come in at around $250 million....
Yahoo Finance Community
12/16
Comment
Karen said ESPR would be profitable this year. She has a few days left to be true. This would be 100 straight lie of hers,Now to be profitable Ben said they need 225 million in US revenues. they are at 120 million. How is this considered close when sales are stagnant? They might get to be profitable right around patent expiration. Sheldon and Ben do not believe their lies which is why they have not bought 1 share. If this rises to 2.5 I will put the short back on. Now I just use this to pass time as I collect other winners. ESPR was so good to me and my firm. We made so much shorting this. I want it to pop again to short it into next dilution....
Yahoo Finance Community
12/16
Comment
Can anyone give an example of something Karen said or predicted over 5 years that actually came true?We have listed so many lies over the years. Absolutely no need to lie to you all. What is her end game? The truth is a much better weapon in the war or wins and losses.In 5 years of Anthony/Karen investing on here. She has only had a LOSS. Never sold a share for a gain. Buying from 30 down. I know this much. 5 year chart is horrendous. Sales are not and never were going to inflect like she said. When asked, she said sales would inflect immediately after CLEAR outcomes. I could go back and list the 100 lies but no need. The stock price action is proof for all to see.Sheldon and Ben never buying a share is proof. They have ZERO desire to increase sales or they would dedicate …...
Yahoo Finance Community
12/16
Comment
I’m not sure what longs should be most excited for: Japan starting up, US sales ramping, Daiichi sales ramping, Daiichi taking over manufacturing and distribution,new partnerships, milestone payments, profitability, or new molecules applications/patent extensions. Just so much good news....
Votes:
2
0
Yahoo Finance Community
12/16
Comment
Need 2.5 to short. That little pop today wasnt enough. No recovery. Going lower it seems. So weak this one isThe technical damage down 45% in a week does to a stock is hard for many to comprehend. Sales or bust and sales are not picking up enough to matter to WS. Sure you losers celebrate a small uptick QTR over QTR but the losses are daunting. Where are the billions in milestones i jeard about? Where are the billions in sales?...
Yahoo Finance Community
12/16
Comment
Closer to the open price then the high. Bearish. This after being destroyed last week. If this was up 15% maybe longs have a reason to celebrate. Anyone happy is just happy its not down 25% per the norm.When is any long going to get a ROi? Years of sadness. Years of lost opportunities. Longs are so good at being content losers...
Yahoo Finance Community
12/16
Comment
This is one of a few stocks that lives at all time lows and many seem happy about it. Very strange. Markets been all time highs for so long and this stays in penny stock land. Remember they need lots of cash. How long dies cash on hand last burning 30 million per month?We see February as month of next dilution. No insider buys nor funds adding.This scam has been well orchestrated and they are taking advantage of the low IQ types . You all believe everything they say. Bet opposite like i did and would have made millions...
Quantexa News
12/17
Cantor Fitzgerald Starts Esperion Therapeutics (ESPR) at Overweight
December 17, 2024 6:03 AM EST (Updated - December 17, 2024 6:32 AM EST) Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Esperion Therapeutics (NASDAQ ... This is a premium only artic...
Quantexa News
12/17
Esperion initiated with an Overweight at Cantor Fitzgerald Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Esperion (ESPR) with an Overweight rating and $8 price target....
Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Esperion (ESPR) with an Overweight rating and $8 price target. The company markets the oral ATP-citrate lyase inhibitors, Nexletol and Ne...
Yahoo Finance News
12/17
Cantor Fitzgerald Initiates Esperion Therapeutics at Overweight With $8 Price Target
BREAKING Fed cuts interest rates by a quarter point in final 2024 decision PREMIUM Cantor Fitzgerald Initiates Esperion Therapeutics at Overweight With $8 Price Target MT Newswires Tue, Dec 17, 2024,...
Quantexa News
12/17
Cantor Fitzgerald Begins Coverage on Esperion Therapeutics (NASDAQ:ESPR)
Research analysts at Cantor Fitzgerald started coverage on shares of Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report in a research report issued to clients and investors on Tuesday, Benzinga rep...
Quantexa News
12/17
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Down 6.9% – Here’s What Happened
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) shares dropped 6.9% during mid-day trading on Wednesday . The stock traded as low as $2.81 and last traded at $2.83. Approximately 1,300,263...
Quantexa News
12/17
Esperion initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Kristen Kluska initiated coverage of Esperion ( ESPR ) with an Overweight rating and $8 price target. The company markets the oral ATP-citrate lyase inhibitors, Nexletol and...
Quantexa News
12/18
Esperion reinstated with a Neutral at Goldman Sachs Goldman Sachs reinstated coverage of Esperion (ESPR) with a Neutral rating and $4 price target Post the label...
Goldman Sachs reinstated coverage of Esperion (ESPR) with a Neutral rating and $4 price target Post the label expansion, Nexletol and Nexlizet uptake has started to pick up but key opinion leader feed...
Quantexa News
12/18
Esperion Therapeutics (NASDAQ:ESPR) Now Covered by Cantor Fitzgerald
Cantor Fitzgerald began coverage on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a research note published on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an ove...
Quantexa News
12/18
Cantor Fitzgerald Initiates Coverage on Esperion Therapeutics (NASDAQ:ESPR)
Cantor Fitzgerald began coverage on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a report released on Tuesday, MarketBeat Ratings reports. The brokerage issued an overweight rating a...
Quantexa News
12/18
Paul Choi Assigns Hold Rating to Esperion Due to Market Uncertainty and Pipeline Challenges
Paul Choi , an analyst from Goldman Sachs, has initiated a new Hold rating on Esperion ( ESPR Pick the best stocks and maximize your portfolio: Discover top-rated stocks from highly ranked analysts...
Quantexa News
12/18
Goldman Sachs Reinstates Esperion Therapeutics (ESPR) at Neutral
Goldman Sachs analyst Paul Choi reinstates coverage on Esperion Therapeutics (NASDAQ: ESPR ) with a Neutral rating and a price target of $4.00. The analyst comments "Post label expansion, Nexletol/Ne...
Polygon News
12/18
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
Esperion announced a $150 million senior secured term loan and a $100 million convertible note to repay a significant portion of its existing $265 million convertible debt. The new financing will prov...
Quantexa News
12/18
Esperion closes refinancing transactions Esperion (ESPR) has closed on a series of financing transactions that will support the Company’s repayment of a...
Esperion (ESPR) has closed on a series of financing transactions that will support the Company’s repayment of a portion of its existing $265M convertible debt facility. The transactions included a $15...
Quantexa News
12/18
The first step toward business compliance amidst the ESPR’s DPP mandate: The data minefield
Lars Rensing, CEO of Protokol, explores the measures businesses can take to prepare for compliance with ESPR’s Digital Product Passport (PPD) mandate, enhance sustainability, and strengthen operationa...
Quantexa News
12/18
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
Esperion (NASDAQ: ESPR) today announced that it has closed on a series of financing transactions that will support the Company's repayment of a portion of its existing $265 million convertible debt f...
Quantexa News
12/18
Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions
Esperion Therapeutics, Inc. 9 min read In This Article – $150 Million Senior Secured Term Loan Credit Facility and New $100 Million Convertible Note to Repay Significant Portion of Existing $265 Mi...
Quantexa News
12/18
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Rating of “Moderate Buy” by Analysts
NASDAQ:ESPR – Get Free Report ) have been assigned a consensus recommendation of “Moderate Buy” from the four ratings firms that are covering the company, Marketbeat.com reports. One research analyst...
Quantexa News
12/18
Esperion reinstated with a Neutral at Goldman Sachs
Goldman Sachs reinstated coverage of Esperion ( ESPR ) with a Neutral rating and $4 price target Post the label expansion, Nexletol and Nexlizet uptake has started to pick up but key opinion leader fe...
Yahoo Finance Community
12/18
Comment
Europe is absolutely exploding. Daiichi agrees to pay all manufacturing and distribution costs saving ESPR projected 80m+ in one year. OMERS agrees to a 3 year loan for $305m upfront with no strings attached to Europe royalties. We know 150 sales people are not sufficient for US, especially since they lack synergistic meds and open channels to deliver. So why the slow play in US, and globally? Preserve it so big pharma can swoop in and run trials for triple pill while collecting the billions until then. Pretty straightforward....
Votes:
6
0
Quantexa News
12/19
XTX Topco Ltd Sells 208,381 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)
XTX Topco Ltd cut its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 57.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchang...
Yahoo Finance Community
12/19
Comment
I still can't believe many of you did not sell a share when this was at 4 last week. Those that did not, really need to do a mutual fund. You do not have the required skill set to make money. This is down 50% in two weeks and yet you still pump. It is mindboggling yet reaffirms what I always thought. Many are paid to pump and to pump lies. You do not own any shares. I am absolutely certain of this. This stock loves to life at the lows. It closed the day on the low like I predicted at lunch time yesterday. This is so easy to see....
Yahoo Finance Community
12/19
Comment
How bad must things be to have that loan at 9% interest rate? That is equivalent to the payday loan type deals. WOW. 9% is horrendous. Who outside of you all with your low credit scores does this? No other financing deal on WS has a 9% interest rate. Go find one and report back to me. This is so funny. Sheldon and Ben are really trying to destroy this in 2025. I can't wait to see what those payments look like and how fast that small cash pile is depleted. This is all part of their plan for the next massive raise. They need 400 million and they will sell so many share at around 1 dollar to get it....
Quantexa News
12/19
Cantor Fitzgerald Begins Coverage on Esperion Therapeutics (NASDAQ:ESPR)
Investment analysts at Cantor Fitzgerald started coverage on shares of Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) in a report released on Tuesday, Marketbeat Ratings reports. The brokerage...
Yahoo Finance Community
12/19
Comment
I wonder when Canada and Australia deal are announced. Wonder if OMERS will become more of a partner. They really could be an acquirer and collect the cash from the company over many years, while investing in operations. I wouldn’t be surprised if blackrock is looking at ESPR as well. Big pharma better get moving as ESPR’s uber depressed valuation makes it a target (as the ceo previously stated)....
Votes:
3
0
Yahoo Finance Community
12/19
Comment
One of the great cons I have seen in awhile. insiders buy ZERO shares only sell. They get extremely generous paychecks and can show nothing for it. Make mistake after mistake but pay pumpers on message boards to keep the euphoria going.Only goal of theirs is not to sell the drug but to keep the scam going because management is getting rich while delivering nothing. I love how this board stays so euphoric in light of the stock only knowing red except the one time it was in their benefit to make it rise. Short all you can and enjoy the riches to accompany. Sheldon is a morally and ethically broken person. To turn off all comments on social media platforms tells everyone everything. Tomorrow the pumpers will be at it like the norm.At least ST you can read their resentment in buying this garbage and being manipulated....
Yahoo Finance Community
12/19
Comment
Even if, (and it is a big if) the oral PCSK9 and CETP inhibitors work, they don’t have the proven benefit of BA with regards to inflammation reduction. Many experts believe this is the secret sauce of statins and BA. So however you look at the competition in 3-5 years, they will be combined efforts with BA to reduce risk. ESPR is not going anywhere. Of course, they could very well be bought out....
Votes:
3
0
Quantexa News
12/19
Esperion Therapeutics (NASDAQ:ESPR) Now Covered by The Goldman Sachs Group
The Goldman Sachs Group began coverage on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research note issued to investors on Wednesday morning, MarketBeat.com reports. The brokerage...
Yahoo Finance Community
12/19
Comment
Foregone conclusion that it ends red. Question is by how many % points? Down 50% in two weeks.WOW. AAOI just did a convertible restructuring that was announced today. I guarantee it is not going to be nearly as toxic as ESPR. 9% interest rate and 20% added dilution. I mean wow, and they think they are doing such a great job....
Yahoo Finance Community
12/19
Comment
You can have all of the upgrades in the world. IF the CEO is deadset on increasing sales, it is going much lower. He learned how to make a lot of money from the PTLA fiasco. Same playbook. Same people. Funny is people on ST talk all day how shady this is and yet they stay long. That makes zero sense. You short a stock with a shady CEO....
Quantexa News
12/19
Cantor Fitzgerald Begins Coverage on Esperion Therapeutics (NASDAQ:ESPR)
Analysts at Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report in a research report issued on Tuesday, Marketbeat Ratings reports. The firm set an “o...
Yahoo Finance Community
12/19
Comment
I just fear that when Q4 earnings are reported, with a major loss on the toxic debt restructuring reported, plus cash having dwindled to less than $100 million and sales having increased by only $2-3 million, we're going to be right back to $.70. That will be a sad day, but they were just never able to generate any interest in their pills. Even after five years....
Quantexa News
12/19
Esperion Therapeutics (NASDAQ:ESPR) Now Covered by Analysts at The Goldman Sachs Group
The Goldman Sachs Group began coverage on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a report released on Wednesday morning, MarketBeat Ratings reports. The firm issued a neutral r...
Quantexa News
12/20
Wellington Management Group LLP Acquires 241,512 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Wellington Management Group LLP boosted its holdings in Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) by 66.8% in the 3rd quarter, according to its most recent filing with the Securities a...
Quantexa News
12/20
Esperion Therapeutics (NASDAQ:ESPR) Research Coverage Started at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a research note published on Tuesday morning, MarketBeat.com reports. The firm issued an overweight...
Quantexa News
12/20
The Goldman Sachs Group Initiates Coverage on Esperion Therapeutics (NASDAQ:ESPR)
Equities research analysts at The Goldman Sachs Group started coverage on shares of Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report in a research note issued on Wednesday, MarketBeat Ratings rep...
Quantexa News
12/20
The Goldman Sachs Group Initiates Coverage on Esperion Therapeutics (NASDAQ:ESPR)
Research analysts at The Goldman Sachs Group assumed coverage on shares of Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report in a report released on Wednesday, Marketbeat.com reports. The firm set...
Yahoo Finance Community
12/20
Comment
NO fear whatsoever being short. Look at that chart. Look at number of shares added every six months. Look at revenue stagnation. End of QTR is almost here. How much more in revenues did they add? 2 million? 3 million?Time is running out until patent expiration. They do not care because they know no one wants to buy a drug that is not selling. Their goal is to bank enough money that in 5 years when generics come, they laugh and move to florida. You all are being scammed....
Yahoo Finance Community
12/20
Comment
Many long term investors in Esperion will feel a deep sense of despair at the horrible performance of the company. It may put one off buying into pharmaceuticals. But you must look at players like the global pharma super mega nova, Eli Lilly. They are up today by 7% even as Epserion continues to decline. EL show you that a company that develops great products where a real need exists, then executes flawlessly can go from strength to strength. If you have none of these qualities, you are Esperion....
Yahoo Finance Community
12/20
Comment
I guess the market is saying numbers this week were not impressive. This QTR is going to be so funny. they have already started to give excuses for this lackluster QTR. Listen to last fireside chats. They make a point of saying 4th QTR is always the weakest. Yeah ever since launch, every QTR is weak. Literally they have only been able to grow since label expansion a few million a QTR. That is so pathetic. It really is and that ensures this ceiling of the 2s. It only went up this month, because they needed it for that horrendous debt restructuring. You all got played and had no idea. Smart money (me) was shorting and laughing knowing this was going to drop....
Yahoo Finance Community
12/20
Comment
Its just always except when they manipulated the low IQs on that pop to 4. AGain, if I was you all. I would be so mad that they keep doing this to shareholders. They give hope and promise and always then just punch in face. They made no bones about hating longs. To say, our interests are not aligned with shareholders yet so that is basically why I did that horrendous dilution 50% below stock price. Wow...
Yahoo Finance Community
12/20
Comment
Let me help all new traders.This stock has been dead for years. It has only known lows of the day. They let it run ONCE over 5 years because they needed the price up for that 9% interest debt restructuring deal. Short of that one time, it has never went up. There is no reason.Sales are horrible. They gave away the only thing of value in the DSE royalties for the next 15 to 20 years. There is nothing of value as it relates to the US. In five years, the patent runs out and they will have NOTHING left. There is nothing to invest on this one. This is like road kill on the side of the road. Sure some scavenger might take a bite but by in large, no one wants to near it because it starts to stink and the meat goes rotten.Sheldon is the destroyer of …...
Yahoo Finance Community
12/20
Comment
down close to 50% in a few days and even now, no buyers. This is so overvalued.31 million a QTR five years into selling the drug. They lose so much money a week and yet no interest in changing anything about this continual failure. They said NO changes to anything. Sheldon does not want the stress and pressure of delivering. He loves things to stay as they are....
Yahoo Finance Community
12/20
Comment
Thoughts on what will move this? Not sales. Not milestones. Not sheldon. Not anylst upgrades. Not mad moneyIt just keeps going lower and lower. Soon under 2.Folks dilution will happen because revenues are not picking up. How much and at what low of a price will it be?...
Yahoo Finance Community
12/20
Comment
Wow markets are now up so much. Every stock is bonkers green.Remember they said espr would be profitable this year. They stopped saying that when they saw they cannot grow sales at all.They lie and lie and when that lie is exposed. Instead of saying sorry. They just change the lie so the lie can live on.Folks, this will never be profitable. They need to be selling more than double what they are now and consistently. Its a pipe dream. This is never going above these levels. They are planning next round of dilution.For 5 years this stock lives at its lows. Zero insider buysA clueless CFO and an incompetent CEO gives you esperion stock chart.I love this short because its meant to be shorted because its the worst of everything.Why is it not moving in line with XBI and markets? Because they refinanced debt and no one wants 9% …...
Votes:
1
1
Yahoo Finance Community
12/20
Comment
I say this QTR sales were flat and that is why they already started with excuses. 4th QTR sales did not grow. Markets know this. This will be 1.5 on earnings and then dilution to follow.500 million more shares will be sold at bargain price of .75 cents. Think i am wrong. You do not know Sheldon...
Yahoo Finance Community
12/20
Comment
Does anyone on this board remember when bubba was telling us to short all you can at .90cents. He said it was never going over a dollar.. he took a very large loss.. he’s basically posting all the same stuff. The way he’s posting he must be trading with very scared money. Very sad....
Votes:
1
0
Quantexa News
12/20
The ESPR Conundrum: Why Esperion Therapeutics Inc's Stock Is Making Headlines Again
Goldman has recently initiated Esperion Therapeutics Inc (ESPR) stock to Neutral rating, as announced on December 18, 2024, according to Finviz . Earlier, on December 17, 2024, Cantor Fitzgerald had i...
Quantexa News
12/20
Analysts Predict Esperion Therapeutics Inc (NASDAQ:ESPR) To Reach 8 In 12 Months
In last trading session, Esperion Therapeutics Inc (NASDAQ:ESPR) saw 3.6 million shares changing hands with its beta currently measuring 1.04. Company's recent per share price level of $2.17 trading a...
Yahoo Finance Community
12/20
Comment
Djohnson is such a fool. I mean so many of you have been wrong almost every time.He says they will have no futher need to dilute ever. They have 188 million cash on hand. Their debt is 150 million in 9% covertible and 54 million in past debt. They burn 30 million a month. How long does that cash last when they are UNABLE or UNWILLING to increase revenues?They will never allow themselves to come close to being out of money again. Dilution is most certainly going to happen within 3 to 4 months. At which they time, they will have around 70 million in cash. When they cannot grow sales then they will need to dilute. You guys are such clowns and never learn a thing. Why is the stock not moving after convertible news? Because WS knows the next thing they will do is another dilution. The price …...
Yahoo Finance Community
12/20
Comment
I own all of you. I have been so right and so knowledgeable on everything related to ESPR. I know what happens and what will happen long before you and the rest. The stock is showing dilution is coming and coming soon. That debt deal was done out of desperation. They desperately needed that 50 some million to add to their cash piles. That is why they did a 9% because no one was going to hand Ben and Sheldon anything without making them pay a huge premium. they are in desperation mode. That deal ensures no one is looking to buy or partner. They did the absolutely worst kind of deal one could make. Look at AAOI who just did the same thing and their numbers were so nice and generous. Ben and Sheldon are clueless and lose on everything they do....
Yahoo Finance Community
12/20
Comment
How you can spot a fool. Anytime someone says ESPR has great fundamentals. They have lost money everyday they have been a company. They have never made a profit. They have massive debt. Their revenues are non existent and close to peak sales. They settled milestone dispute for pennies and thenndid a massive dilution. They had 18 million shares not long ago and close to 300 million now.Fundamentally they are a mess and you are a clown....
Quantexa News
12/21
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $8.13 Consensus Target Price from Analysts
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) have been assigned a consensus rating of “Hold” from the five research firms that are covering the stock, MarketBeat reports. One...
Quantexa News
12/21
Esperion Therapeutics (NASDAQ:ESPR) Earns Neutral Rating from Analysts at The Goldman Sachs Group
The Goldman Sachs Group began coverage on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The brokerage iss...
Quantexa News
12/21
Public Employees Retirement System of Ohio Buys New Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Public Employees Retirement System of Ohio purchased a new position in Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) in the third quarter, according to the company in its most recent Form...
Yahoo Finance Community
12/22
Comment
Sheldon has now wrapped up for the year. On Thursday the Esperion jet flew him down to West Palm Beach. He'll spend the holidays with his mother, Zelda and retake the helm at Esperion in January. This will be his first Christmas in five years without Dr. greta Pinderschloss, so it will be a little sad for him. They had a falling out when Sheldon appointed Keesha to the position of Chief Medical Officer....
Votes:
1
1
Yahoo Finance Community
12/22
Comment
ESPR soon to be profitable, no CMO even though they are soon to launch new molecules and/or applications, 150 sales reps in biggest market in the world, limited sales effort which can be taken over by a big pharma, hundreds of millions from milestones owed, royalties owed from 20-30% in key markets, manufacturing paid for by Daiichi, triple pill combo out to 2040+, and tax write offs for years, with product in the biggest TAM. ESPR is the perfect acquisition target and I suspect 2025 will be a good year....
Votes:
5
1
Yahoo Finance Community
12/22
Comment
Would not be surprised to see MRK buy ESPR to get rid of competition by combining oral PCSK9 and bempedoic acid. MRK’s pcsk9 trial still slated to end in late 2029. What better way to enter the space than buy ESPR. Shelly has ties there as well. Or, what about Amgen getting into the game to compliment Repatha. Writing is on the wall for Repatha. Ironically, no big pharma really cares about NAMS as CETP inhibitors we’re all shut down in past for reduced risk reduction. Just ask MRK- Anacetrapib....
Votes:
3
1
Quantexa News
12/23
Fmr LLC Trims Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Fmr LLC cut its holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 7.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 71,164 shares of th...
Quantexa News
12/23
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $8.13 Consensus Target Price from Analysts
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) have earned a consensus rating of “Hold” from the five brokerages that are presently covering the firm, Marketbeat reports. One eq...
Quantexa News
12/23
Analysts Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $8.13
Shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) have been given a consensus rating of “Hold” by the five analysts that are presently covering the company, MarketBeat.com report...
Yahoo Finance Community
12/23
Comment
Young Ben, CFO will now be out until after the New Year. His parents are taking him to the Magic Kingdom. With Sheldon off with his mother in West Palm, this leaves poor Keesha at the helm of the entire Esperion organization. That's a lot of responsibility for a 24 year old....
Yahoo Finance Community
12/23
Comment
This morning we had the Christmas assembly at school and now I am finished up until the 2nd of January! I checked the board here when I got in and it sure is quiet. I mentioned it to my mom who is also off now and she said we need to remember that most of the poor souls that post on the board will be working mandatory overtime shifts in their retail or Amazon jobs. I guess this makes sense. I remember Anthony said he was in charge of the hotdog roaster at 7-11....
Votes:
1
3
Quantexa News
12/23
Esperion Therapeutics Inc (ESPR) Shares Up Despite Recent Market Volatility
Esperion Therapeutics Inc (NASDAQ: ESPR)'s stock price has gone rise by 2.28 in comparison to its previous close of 2.19, however, the company has experienced a -3.86% decrease in its stock price over...
Yahoo Finance Community
12/24
Comment
Oh no, imagine if ESPR is up another nickel today? The name calling will not be appropriate before Christmas. Please shorts, be appropriate and try to enjoy the run up of ESPR’s stock price with the holidays. It’s best we all get used to it for 2025....
Votes:
8
0
Yahoo Finance Community
12/24
Comment
Oh no, is this the start of ESPR’s move upwards? We all know it will happen soon. Even the shorts are trying to time it just right, but as we know, it’s difficult to time these sudden increases. When all the shorts start covering , sitting short on the holidays can be quite scary. No name calling here, just best wishes to everyone!...
Votes:
4
1
Quantexa News
12/25
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Recommendation of “Hold” from Analysts
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) has been given a consensus recommendation of “Hold” by the five brokerages that are presently covering the stock, MarketBeat.com reports....
Quantexa News
12/25
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of “Hold” by Analysts
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) has been given a consensus recommendation of “Hold” by the five ratings firms that are covering the company, MarketBeat.com reports. One r...
Yahoo Finance Community
12/26
Comment
XBI is a good proxy for bio but it is better for larger bio. Fact is small bio will struggle until clarity for drug pricing and big Pharma consolidation plans start coming to fruition. But now is the time to buy a strong, soon to be profitable small bio like ESPR. It’s like buying energy stocks when Covid hit and pummeled the sector, or gold in 2019 prior to the run up with inflation. You buy now in anticipation of the inevitable returns. Big pharma need to replace sunsetting patents. ESPR is proven with the clear outcomes study and payors buy in. We know 150 reps will not do it in US but Japan and Europe are queued up to deliver. Collecting now for the inevitable payout....
Votes:
3
1
Yahoo Finance Community
12/26
Comment
Looks to me that a bigger pivot to more “risky” bio is the move at recent depressed market prices . Big pharma is not going away and demand from baby boomers will only increase. If inflation does subside more and economy does well, bio may finally find favor in a market where there are some pretty high valuations in other sectors. ESPR is a natural good buy and should fly regardless with so many positives....
Votes:
3
0
Yahoo Finance Community
12/26
Comment
Look at Europe! Please explain how sales are projected to be billions a year, and OMERS agreed to a no strings upfront payment of $305m based off royalties (figure a 3 year window to payoff) and ESPR is not valued over $2b market cap? Europe alone would make ESPR grossly undervalued at current valuation. Don’t even consider US, Japan, Israel, Australia, Canada, and all other territories. It’s just simple math....
Votes:
2
1
Yahoo Finance Community
12/27
Comment
Keesha has brought in an independent accountant to review the astronomical spending. She hopes that if she can control spending, she'll have a job longer. She doesn't want to go back to being a care assistant in her local nursing home. Also, care assistant jobs don't come with a corporate jet. The accountant was in the Ann Arbor office bright and early, but unfortunately most of the spending records are not available....
Votes:
1
2
Yahoo Finance Community
12/27
Comment
CMO Keesha flew up to Ann Arbor early this morning in preparation for her meeting with Greta. She was shocked to see the offices empty and covered with dust. The security guard explained to her that no one had been in the office since the pandemic, and once a month the courier was sent to retrieve any mail. She asked how a company could operate like this, and the security guard explained that most employees had given up about 3 years ago and were just riding the work from home wave. Most, he explained, had relocated to Florida where some had started new businesses. They attend the team calls but other than that there is really not much to do....
Yahoo Finance Community
12/27
Comment
It was my hope that Esperion might end the year over $2.00. This now seems unlikely. I think the issue is that the share price has always been supported by penny stock investors. Most are overextended from the holidays, so this is reducing the constant inflow of retail money as the institutions continue to exit....
Votes:
1
2
Yahoo Finance Community
12/27
Comment
I’m just glad we have Gregg wrapped in his vest watching the ticker. Also, soon to be profitable with a number of announcements with partnerships and possible buyout doesn’t hurt either. Nor does sales ramp, milestones or new molecules/applications....
Votes:
3
1
Yahoo Finance Community
12/27
Comment
It looks like the positive scripts data will bring us green again. That’s what happens when you have exponential growth of sales, or how you Canadians like to refer to as “hockey stick” ramp of sales. So easy to hold a stock that will soon be $20....
Votes:
3
0
Yahoo Finance Community
12/27
Comment
I would seriously consider starting a rumor that either a big pharma or investment fund would be interested in taking over or partnering with ESPR, but I don’t think rumors are needed at this point. With OMERS, Otsuka and Daiichi investing billions already, the value is clear to astute investors and experts. A few shorts will be caught by surprise, but they are adrenaline seekers and I suspect they like the thrill of seeing how long they can roll the dice without getting hit hard....
Votes:
4
1
Yahoo Finance Community
12/27
Comment
I still think Daiichi buys out ESPR. It is logical, as they already invested billions, have until 2040+ with triple pill combo, and have to pay 25% to ESPR of billions per year. On top of that they owe milestones and can expand into other territories or sell off those rights while collecting royalties from Japan and other territories. Only problem is that Sheldon won’t sell for under $5b. Daiichi will likely budge with so many interested partners....
Votes:
2
0
Yahoo Finance Community
12/27
Comment
Keesha has concluded her interview with Greta Pinderschloss and is favorably disposed toward appointing her as the new chief medical officer. She was impressed that Greta held a real doctorate in speech therapy and thought this would be a great asset to the company. Her knowledge of all things NASCAR will also definitely be a plus and they have a shared disdain for Sheldon so this formed an immediate bond. The only sticking point is that Greta believes she too should have a company jet and Keesha thinks this might be a hard sell to the board....
Yahoo Finance Community
12/27
Comment
Up a dime on a short week I’ll take it! I received some great news to share my new financial bro vest is catching attention. Sheldon just reached out to see if I would be part of the lipid Lurker campaign reboot 2.0 for 2025, hang onto your seats in 2025 will be a wild ride....
Votes:
3
0
Yahoo Finance Community
12/28
Comment
The other board is reflecting on the year that was. One thoughtful commenter states that if someone had told him of all the wonderful things that would transpire for Esperion during they year and then told him the share price would end in the $2'a, he would have been in disbelief. He then concludes by saying it must be the complete lack of sales. Do you think?...
Yahoo Finance Community
12/28
Comment
When ESPR receives a buyout offer, I wonder if shorts will congratulate longs? I suspect most will disappear and change their aliases . Please don’t tell me a Jimmy will start posting on the acquiring company’s board , saying how sad it was that ESPR was purchased for $6b. Or Blurt telling us how much money he made on the purchase. That will be kind of sad....
Votes:
2
0
Quantexa News
12/29
State Street Corp Buys 99,802 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)
State Street Corp lifted its holdings in Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) by 2.7% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 3,854,314 shares of the bioph...
Yahoo Finance Community
12/29
Comment
I think Daiichi royalties pay off the OMER loan in 3 years. OMERS is an extremely sophisticated fund with true professionals. I also suspect they will be involved in another transaction with ESPR. Like Daiichi and Otsuka, OMERS sees the value. The problem is big pharma gets it and are starting to inquire. It’s only a matter of when....
Votes:
2
0
Yahoo Finance Community
12/29
Comment
I believe that the 145m of cash on hand, $40m cash from recent debt restructuring transaction, Israel milestone to be paid within 30 days, Otsuka filing milestone to be paid likely in 30 or so days, Japan sales starting, breakeven due to continued strong ramp of sales, likely Canada deal and cash payments, means that ESPR has clear sailing to $20 per share. It really is inevitable as seen with Friday script data for the last several months. I am nervous for shorts who just don’t want to see the obvious. It’s getting scary now....
Votes:
4
1
Quantexa News
12/30
Esperion Therapeutics Inc (NASDAQ: ESPR) Could Have Exceptional Returns?
In the last trading session, 3.07 million shares of the Esperion Therapeutics Inc (NASDAQ:ESPR) were traded, and its beta was 1.01. Most recently the company's share price was $2.28, and it changed ar...
Yahoo Finance Community
12/30
Comment
Steep decline in the market and XBI. ESPR holding nicely as expected, as the future is so bright for a company soon to be profitable (sooner than you think per ceo and cfo), with so many positives. Just need to be patient as even Sheldon and team can get this in the end zone....
Votes:
5
0
Yahoo Finance Community
12/30
Comment
I write this to longs who might be frustrated. As news piles up the inevitable will occur even if the XBI is still negative. Big pharma need blockbusters. ESPR is close to profitability, which will automatically change ESPR’s leverage when negotiating with big pharma. I expect Japan to really explode once launched, Europe to continue to exponentially grow into triple pill combo launch, and US plan to be finally announced, whether through sales build out, big pharma partner, or most likely, sale to a big partner. 2025 will be a transformative year! Hold strong and don’t be caught on the wrong side of the trade....
Votes:
3
0
Yahoo Finance Community
12/31
Comment
Today the year to date loss and the one year loss are the same. Both are 26.92%! This was the best performance for Esperion in five years! Usually it loses more than 50% per year. This is why people holding for five years have lost 99.23% of their value when the 90% dilution is factored in....
Yahoo Finance Community
12/31
Comment
What a looser muted user! It came with a rhyme lol. He posts over and over on Xmas, NYE, sundays etc so much hate against this company my God, only a sad person with no family or friends to take care (or wrong family and friends who don’t care) would behave like this...
Votes:
5
0
Yahoo Finance Community
12/31
Comment
A profitable ESPR with European sales booming, US ramping and ready to be fully expanded by a big investment or partner, milestones rolling in, and expanding territories including Japan, Canada, Israel, etc, puts ESPR in a new class. Small bio diluting to survive will no longer be ESPR, and an explosion of investments are expected. Ultimately ESPR must sell to a big pharma or expand significantly, but I think a buyout makes the most sense to take advantage of patents and trial results now, while investing in triple pill combo and new molecules/applications. My guess is once new molecules/applications are announced after patent protections are in place, it’s boom time. We’ll see in 2025....
Votes:
5
0
Yahoo Finance News
01/02
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference Esperion Therapeutics, Inc. Thu, Jan 2, 2025, 8:00 AM 1 min read In This Article: ESPR -0.42% Esperion Therapeutics, I...
Yahoo Finance Community
01/02
Comment
Another thought supporting bio in general is that crypto currency will eventually come back to earth. Bio is typically seen as the high risk /reward sector, but with inflation knocking and more regulation threatened, this has been a depressed sector. I suspect with markets heating up everywhere, money will flow into bio, especially if inflation decreases and/or bio M&A starts up with patent cliffs impacting the big pharma. Regardless, undervalued cash flow positive bio will be rewarded. Hello ESPR....
Votes:
4
0
Yahoo Finance Community
01/02
Comment
I am happy that the share price is increasing today but I fear it will be short lived. When the market sees sales stagnated when the Q4 loss report is revealed, it will be devastating. Also, i think further dilution needs to be factored in to the share price....
Votes:
1
2
Yahoo Finance Community
01/02
Comment
It feels like ESPR just wants to explode upward in the coming weeks. You can feel the pressure building. All it takes is a spark. Will it be Canada, new molecules announced at the upcoming conference, milestone payment, other partner?…….it could be almost anything. All the while the sales continue to build....
Votes:
5
0
Quantexa News
01/03
Barclays PLC Buys 154,509 Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Barclays PLC raised its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 99.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exc...
Yahoo Finance Community
01/03
Comment
People on the other board are pondering on why Esperion fails to grow market cap, comparing it to successful pharma companies who trade at many multiples to Esperion. I would like to help everyone understand the basic reasons for market skepticism, because it really is very simple. The reasons:five years of FDA approval and one year of expanded label coverage coming up. Despite spending a billion on sales and marketing over this period, US sales have grown to only $120 million per year and some analysts think this is peak sales.Toxic agreements to raise cash that will impede the company forever.Management that shows no interest in holding shares in the company. They are given millions of shares as part of their compensation and sell them the minute they can.Negative cash flow to the tune of $1 million per operating day. Dilution is the only certainty, if they can get it …...
Yahoo Finance Community
01/03
Comment
Shorts never explain why big pharma Daiichi is raking in the dough with BA. Daichii doesn’t know what to do with all the money they are making and will make. They agreed to take on all manufacturing and distribution worth over $100m per year for almost two decades (out beyond 2040), agreed to pay for the triple combo costs, and they have Omers agreeing to give ESPR $305m upfront to be paid in 3 years, where royalties go right back to ESPR for over 2 decades. Who cares about US. That will be partnered soon enough. Europe rights alone are worth $5b now. Just need everyone to catch up. Sort of like when Apple came out with the iPhone. It takes time for the herd to change direction....
Votes:
7
0
Yahoo Finance Community
01/03
Comment
Explain how they will be profitable with stagnant sales? Each month is a huge burn. They do not have money to burn.Peak sales is looking pretty accurate first half of 25.No one wants this. Where is the sales inflection?This is almost non exit growth when you take into account inflation. Generics are coming...
Yahoo Finance Community
01/03
Comment
Oh no, the shorts are coming out crying again. The worst are shorts who pretend to be neutral or long. Can’t we all just agree that all one has to do is look at Europe and understand the intrinsic value of ESPR? Japan, US, Canada,Taiwan, China, etc, will all be moving soon enough....
Votes:
1
0
Yahoo Finance Community
01/05
Comment
Daiichi invested billions in BA, agreed to take over all manufacturing and distribution costs worth $100m per year, and agreed to develop triple pill combo to extend patent out to 2040+. I doubt they would allow another big pharma come in and buy ESPR and take all these benefits. A buyout would also give golden goose us rights, tax write offs, 30% royalties for Japan, milestones for Japan and Israel, and new molecules. $6b and it is all yours Daiichi. I think sheldon is playing hard ball and insisting on $8b. Makes sense as inclisiran was $9.7b and considered a failure by most....
Votes:
4
0
Quantexa News
01/06
Esperion (ESPR) Gets a Sell from Bank of America Securities
Bank of America Securities analyst Jason Zemansky maintained a Sell rating on Esperion ( ESPR – Research Report ) today and set a price target of $2.05. The company's shares closed last Friday at $2.1...
Quantexa News
01/06
Esperion Therapeutics Inc (ESPR) Stock: A Study of the Market Performance
The stock of Esperion Therapeutics Inc (ESPR) has seen a -1.43% decrease in the past week, with a -38.60% drop in the past month, and a 4.05% flourish in the past quarter. The volatility ratio for the...
Quantexa News
01/07
Fortude partners with Ettos to enhance sustainability across fashion supply chains
With the EU's new Eco-design for Sustainable Products Regulation (ESPR) set to come into full force this year, businesses across the fashion industry must prioritise sustainability and compliance. The...
Quantexa News
01/07
Fortude partners with Ettos to enhance sustainability across fashion supply chains
‹ › With the EU's new Eco-design for Sustainable Products Regulation (ESPR) set to come into full force this year, businesses across the fashion industry must prioritise sustainability and complianc...
Quantexa News
01/07
Fortude partners with Ettos to enhance sustainability across fashion supply chains
With the EU's new Eco-design for Sustainable Products Regulation (ESPR) set to come into full force this year, businesses across the fashion industry must prioritise sustainability and compliance. The...
Quantexa News
01/07
Fortude Partners With Ettos To Enhance Sustainability Across Fashion Supply Chains
MENAFN - GlobeNewsWire - Nasdaq) With the EU's new Eco-design for Sustainable Products Regulation (ESPR) set to come into full force this year, businesses across the fashion industry must prioritise s...
Yahoo Finance Community
01/10
Comment
So now big pharma can buy ESPR and not only get BA, a blockbuster drug for ldl lowering, but possibly next gen aclyi drugs that will treat metabolic diseases such as type 2 diabetes and fatty liver disease?Add a few more billion a year in sales with patents out to forever. Is that the phone ringing again? Please tell Daiichi they got the wrong number. Merck is on the phone talking with Sheldon and Amgen and PFE are on hold....
Votes:
6
0
Yahoo Finance Community
01/10
Comment
It seems like investors have moved on from bempedoic acid as a cardiac risk reduction treatment. I understand this as it never really caught on. Even so, I am surprised they are so keen to wait another five years for other FDA approvals. Especially since such projects will require billions in new capital. Scary....
Quantexa News
01/10
Esperion Therapeutics' (ESPR) “Buy” Rating Reiterated at HC Wainwright
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Friday, Benzinga reports. A number of other...
Quantexa News
01/10
HC Wainwright Reaffirms “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)
‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Friday, Benzinga reports. Several other equities research analysts also recently issued reports...
Quantexa News
01/10
Esperion's Strategic International Expansion and Revenue Growth Justify Buy Rating
Joseph Pantginis , an analyst from H.C. Wainwright, maintained the Buy rating on Esperion ( ESPR – Research Report ). The associated price target remains the same with $16.00. Stay Ahead of the Marke...
Yahoo Finance Community
01/10
Comment
Just the fact ESPR touched green today is triggering shorts? Why did this happen? How could this happen? Longs know. ESPR is so depressed that it has nowhere to go but up. Big firms are buying while small retail sells. Profitability in near term, Japan starting up with milestones, US payors getting in line with DOD starting at end of month, Europe crushing it, new territories in Israel, Canada, Australia coming on board, debt addressed to 2030, Daiichi taking over manufacturing, triple pill combo being developed by Daiichi, triple pill combo for US and other territories just needing a partner, new molecules that can be game changing are being announced and patent protected, potential buyers are lining up-OMERS, Daiichi, Otsuka, MRK, Amgen, sanofi, Bayer, J&J, PFE… Oh my....
Votes:
8
1
Yahoo Finance Community
01/10
Comment
I am happy that this is up on a Friday. It's such a rare event. It scares me though to think that sales are stagnating while the company is still burning though a million dollars per day. Hopefully, some of their stage 1 drugs will show some promise and actually finds a market if they are eventually approved....
Quantexa News
01/10
Esperion Therapeutics Inc (NASDAQ:ESPR) jumps 85.06% In 2025; How Attractive Is It At $2.18?
In recent trading session, Esperion Therapeutics Inc (NASDAQ:ESPR) saw 1.11 million shares changing hands at last check today with its beta currently measuring 1.03. Company's recent per share price l...
Yahoo Finance Community
01/10
Comment
@marc, retired physician. What do you make of the ESPR price action today? My take is that it is being accumulated wisely on a terrible stock market day with the Russell down 2.2% as I write. Or, it could be some great news is on the way and there has been a news leak....
Votes:
8
0
Yahoo Finance Community
01/10
Comment
I guess longs are getting used to moves like this on Friday’s after script data is released, but i suspect we’ll see many more Green Days as the herd mentality starts to shift and focus on soon to be profitable bio tech. Having primary prevention products in the biggest TAM on earth should speak for itself, but it is Wall Street we are talking about here....
Votes:
4
0
Yahoo Finance Community
01/10
Comment
James is the poster who this morning posted: " I have a bad feeling about Esperion's share price today. There is a lot of sell side demand left over from the holiday lull."Actually stock was up .17 (2.80%), in a terrible market...with above average volume...This poster will totally disappear when it covers its short position. (or is the poster a short shill?)....all of it's posts are absolutely worthless....Influence anyone? Only a FOOL would even read it's posts, never mind act on them....
Votes:
6
0
Quantexa News
01/12
HC Wainwright Reiterates “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Friday,Benzinga reports. Get Esperion Therape...
Quantexa News
01/12
HC Wainwright Reaffirms “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Friday, Benzinga reports. A number of...
Quantexa News
01/12
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of “Hold” from Brokerages
Shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) have received an average rating of “Hold” from the five research firms that are covering the firm, Marketbeat Ratings reports. O...
Quantexa News
01/12
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of “Hold” from Brokerages
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) has earned an average recommendation of “Hold” from the five brokerages that are covering the firm, Marketbeat.com reports. One research ana...
Yahoo Finance Community
01/12
Comment
The stars are aligning for the next dilution round. They've pumped up the share price with hints of good news and they've got themselves in on an investor conference. They'll likely announce the next 100 million shares immediately following. At any rate, they need to get it done before the Q4 loss report because the lack of sales will drive the share price down significantly....
Yahoo Finance Community
01/12
Comment
I heard that seats next to Sheldon at the jpm conference are hard to come by. Daiichi, MRK, Amgen, PFE, LLY, and other top executives are trying to get Sheldon’s ear to talk about possible partnerships or a buyout. Can you blame any of them, as all have patent expirations they need to address or synergistic drugs that would work wonders with BA and others being developed by ESPR. This is all very exciting....
Votes:
5
0
Yahoo Finance Community
01/12
Comment
With profitability this quarter or next, milestones from Otsuka and Daiichi rolling in 2025, with $185m cash on hand, ESPR may start a share buyback program to further create value for shareholders. Remember, a new partnership for other territories is likely, and even a bigger one for US benefits (think sharing of revenue for use of huge sales force and distribution network, for a few billion upfront). That’s if a big pharma does not make a bid to buyout ESPR outright ($5 to $8b?). ESPR’s future is very exciting....
Votes:
5
0
Yahoo Finance Community
01/12
Comment
I suspect that Daiichi buys ESPR in 2025. Reason is the triple pill combo rolls out in 2026. Sales are accelerating and they take over manufacturing in 2025 that will cost $100m annually. Dachii owes ESPR milestone payments and 25% royalties indefinitely. Triple pill combo is projected to bring in billions per year for Europe alone out to 2040+. With Japan ramping, US that will be partnered or bought out by another big pharma, new molecules being introduced, Daiichi won’t allow ESPR to be bought out by a competitor....
Votes:
6
0
Yahoo Finance Community
01/12
Comment
Analysts are forecasting 5% sales growth for Esperion. Except for the BofA analyst who believes sales have peaked and will now begin to decline. I think this is why the company has slashed the price of the pills by 60%. The real issue is their pipeline of mew drugs is all phase 1....
Yahoo Finance Community
01/12
Comment
With more than 200billion of revenue at risk for patent cliffs to 2030 for big pharma, you can understand why big pharma are lining up for ESPR and $10b might be the paid price. You have a proven blockbuster, fully derisked, with fundamentally flawed competition still years off. Not everyone likes how ESPR management has gotten to this stage, but there is still time to make everyone very happy (except shorts of course). 2025 will be a great year for ESPR....
Votes:
6
0
Quantexa News
01/13
Esperion Therapeutics’ (ESPR) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright restated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a report released on Friday,Benzinga reports. Other equities analysts have also issued resear...
Quantexa News
01/13
Digital Product Passports: Transforming Brand Engagement in 2027 and Beyond
The EU's new Ecodesign for Sustainable Products Regulation (ESPR) is set to revolutionise how brands connect with consumers. As digital marketing experts, we're excited about the creative opportunitie...
Quantexa News
01/13
Digital Product Passports: Transforming Brand Engagement in 2027 and Beyond
The EU's new Ecodesign for Sustainable Products Regulation (ESPR) is set to revolutionise how brands connect with consumers. As digital marketing experts, we're excited about the creative opportunitie...
Yahoo Finance Community
01/13
Comment
I’d like to reiterate that ESPR has laid all the necessary groundwork to make its approved medication available worldwide to help patients with heart disease. The company has positioned itself to capture a share of the multi-billion-dollar market. At the current price, this stock is truly a gift for investors....
Votes:
3
0
Yahoo Finance Community
01/13
Comment
I was just looking at one of my successful trades, that has gone up by 284% over the last three years. I noted that significant amount of insider ownership and then made the comparison to Esperion. Like my Mom always says, if management and the board refuse to hold the shares, that tells you everything you need to know about the prospects of a company....
Yahoo Finance Community
01/13
Comment
Critical week heading into next weeks anniversary of major dilution/stock issuance which broke everyone’s heart when all had looked so bright from a stock performance perspective . That was a $1.50 issuance/haircut. I’ve been calling for similar dilution this year based on revenue, royalties and expenses. Of course this could be wrong, and who knows the timing (legally anyway). This has been behaving like dilution is a given. I’m not talking today, day to day moves, general outflow pattern. It actually has behaved well during the recent market sell off. Be careful out there....
Votes:
2
2
Quantexa News
01/13
Esperion Therapeutics Inc (ESPR) Shares Down Despite Recent Market Volatility
The stock of Esperion Therapeutics Inc (NASDAQ: ESPR) has decreased by -6.62 when compared to last closing price of 2.34. Despite this, the company has experienced a -0.23% fall in its stock price ove...
Yahoo Finance Community
01/13
Comment
The other board is having a far reaching discussion about insurance coverage for Nexlizet. It's not very inspiring. Here is what one on the posters says: ok got thru to anthem blue cross of ohio. They are calling nexlizet a tier 4 drug now co pay $425 for 3 months. Crazy. Should have switch insurance in Dec. Going back to statins for the year....
Quantexa News
01/13
Recent developments with Esperion Therapeutics Inc (ESPR) have led to the company's beta value being reach 1.03 cents.
Esperion Therapeutics Inc (NASDAQ: ESPR) on Friday, soared 7.83% from the previous trading day, before settling in for the closing price of $2.17. Within the past 52 weeks, ESPR's price has moved betw...
Yahoo Finance Community
01/13
Comment
I think the market is beginning to think about the Q4 loss report that will be announced in February. If Esperion clocks in with a 5% quarter over quarter increase in sales (that's $1.5 million increase), then I think we all know the share price will be annihilated. That's why it's so important to get the next dilution round done this month while the share price is inflated....
Quantexa News
01/15
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $7.30 Consensus Target Price from Analysts
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) has earned a consensus rating of “Hold” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. One equi...
Yahoo Finance Community
01/15
Comment
Some people repeatedly state that this is headed toward $20. I just don't see the catalyst. After five years and billions spent on sales and marketing, the drugs have only achieved $30 million per quarter in the US. Also, the only significant royalty stream has been sold off for the next five to ten years. Bank of America says US sales have peaked, so that's not good. Also, the cash burn of $1 million per operating day will require multiple rounds of equity funding. It's really scary....
Yahoo Finance Community
01/15
Comment
Look for the comments at today's conference to be highly focused on the early development stage pipeline. I think management has realized the limited market for BA and will therefore focus on the distant future. This will help them to raise the equity they'll need to fund themselves over the next five years. No investor, however, will want to buy into the debacle of a balance sheet now held by Esperion. It is likely that if they can raise capital, a subsidiary company will need to be formed and the early-stage assets transferred to that company. New investors will likely take a 90% stake in the new company with Esperion having a 10% interest....
Yahoo Finance Community
01/15
Comment
ESPR is like Apple before the iPhone or Amazon when selling and losing money with a bigger scheme in mind. Since ESPR is near profitability, and now new applications are being introduced to roll patents out to 2040 + (as done with triple pill combo in Europe), the run ton$20 is inevitable. So exciting to see the transition of this little caterpillar into a beautiful butterfly and we all have front row seats....
Votes:
2
0
Yahoo Finance Community
01/15
Comment
With a one-year return of -28%, and a five-year unadjusted return of -96%, and a five-year dilution adjusted return of -99.53%, it is just natural to feel a sense of sadness as an Esperion investor. Watching the rest of the market soar is just like pouring salt into the wound....
Yahoo Finance Community
01/15
Comment
We know shorts are desperate when they post gifs. All we need are some troops going up a hill, or a bomber, and you can be assured of a green finish. It’s very reassuring when shorts come out of the woodwork. It’s very exciting to see them jump up and down , with the short term noise distracting them from the inevitable that is nearly here....
Votes:
1
0
Quantexa News
01/15
Why Esperion Therapeutics Inc (ESPR) Stock Could See Much Higher Prices Ahead
Esperion Therapeutics Inc (NASDAQ: ESPR) is 1.82% higher on its value in year-to-date trading and has touched a low of $1.58 and a high of $3.94 in the current 52-week trading range. The question beco...
Yahoo Finance Community
01/15
Comment
Remember longs that even with a few Pennies decrease today, the shorts insatiable urges to gamble are strong. Unfortunately they will continue to gamble and not understand what can and will happen. I think we should all try to help them out, but keep reasonable expectations as it really is a tough habit to break....
Votes:
3
0
Yahoo Finance Community
01/15
Comment
Wow. I just listened to ESPR’s presentation and I have never felt more confident. I expect sales to really start to inflect, as the number of prescribers continue to rise by double digits along with scripts. Remember, this is an avalanche of demand, meaning there is zero competition until 2027 for CETP inhibitors (which 4 others failed and I have serious reservations about NAMS) and pcsk9 oral from Merck in 2029 (which has same issue of injectable PCSK9s with limited inflammation reduction. Once taking BA there is no going to an alternative. I don’t expect shorts to grasp the details, but longs should....
Votes:
4
0
Yahoo Finance Community
01/15
Comment
Just think of this fact, neither CETP inhibitor or PCSK9 oral will even compete with the primary treatment indication of BA! That’s 10m tam vs 70m tam for BA, and in 2027 and 2029. Triple pill combo in Europe is patent out to 2040+ and starts in 2026/7. US is next with outcomes study and big pharma partner to extend patents out to 2040+. If you don’t see this coming, blame yourself. ESPR management may be sandbagging and diluting too much, but this is pocket aces going up against Kurt’s 7-2 off suit. Don’t worry about dilution when this will be making billions per year and buying as many shares as are currently outstanding (per year). Of course, ESPR will long be bought out but for much more than the $6-8b I was projecting....
Votes:
5
1
Yahoo Finance Community
01/16
Comment
Picture has never looked better for longs. Profitability near, sales ramping, new molecules with big Tams and un met needs, partnerships for new territories, likely new partnerships with existing partners, clarification on competition which is essentially non existent, $130m milestones to be received in 2025, prescribers added at double digit rates, new large contracts-DOD, triple pill combo out to 2040+, etc. sure I wish management was better, but there is intrinsic value that will be appreciated. A buyout is still likely but the value will be increasing though out 2025....
Yahoo Finance Community
01/16
Comment
ESPR may want to go it alone, but I’m afraid it is just a matter of time before big pharma takes over. Daiichi’s sales vs US tell you everything you need to know. Sure, US is still starting out but does ESPR really want to build out sales and manufacturing needed to get to blockbuster status ? Big pharma does this and they need blockbusters. With new molecules it becomes even more enticing. Look for big partnership news that leads to closer bond and then buyout….maybe with current partner or any number of big pharma. Writing is on the wall. Too bad some shorts can’t read....
Votes:
6
0
Yahoo Finance Community
01/16
Comment
There is a lot of criticism of Sheldon on the other board. I don't think this is fair. He never misled anyone. If he had, he would have forecast sales. He did not, and in this they should have understood that sales are gloomy. He sold all of the shares he was ever given, as soon as he was allowed to sell them. He could not have given a clearer signal that there was no value here. Short of coming to the investor conference and saying it all looks terrible, what more could he have done....
Yahoo Finance Community
01/16
Comment
Once digested, I would not be surprised if ESPR ends up green today. ESPR’s execution is the only thing that can be questioned, as the drug is proven, as up to 2040+ if patent protection, has no competition for a decade, and new molecules can create even more value. Cash will not be a problem moving forward. So if execution falters, you literally have dozens of big pharma who would want to partner or buy ESPR. Works however you slice it....
Votes:
5
0
Quantexa News
01/16
Esperion stock falls on higher operating expense forecast
Investing.com -- Shares of Esperion (NASDAQ: ESPR ) Therapeutics (NASDAQ: ESPR) fell 5.8% after the company provided an update on its expected operating expenses for the fiscal year ending December 31...
Yahoo Finance Community
01/16
Comment
No surprise here for me. ESPR has never been in a better position. When you have a clear road to profitability, no more dilution, proven blockbuster, new molecules with huge potential, huge partnerships with big pharma and investment fund, no competition for a decade, with fda and Ema approvals in the biggest TAM in the world,it’s time to buy...
Votes:
4
1
Quantexa News
01/16
Esperion stock falls on higher operating expense forecast
Investing.com -- Shares of Esperion (NASDAQ: ESPR ) Therapeutics (NASDAQ: ESPR) fell 5.8% after the company provided an update on its expected operating expenses for the fiscal year ending December 31...
Yahoo Finance Community
01/16
Comment
And to be clear, it is only US execution-sales, which I believe was intentionally set up as a placeholder. Are you telling me that a big pharma would not partner with ESPR to support US roll out? Otsuka, OMERS, or Daiich, MRK, Amgen, PFE, Lly, etc would jump on in a heart beat. ESPR purposely kept US unencumbered so a sale or big partnership would be clean. Sales/marketing can be relaunched in a month. Come on, it’s too easy to see. Unless you are Kurt....
Votes:
1
0
Quantexa News
01/16
Esperion stock falls on higher operating expense forecast
Investing.com -- Shares of Esperion (NASDAQ: ESPR ) Therapeutics ( NASDAQ : ESPR) fell 5.8% after the company provided an update on its expected operating expenses for the fiscal year ending December...
Yahoo Finance Community
01/16
Comment
Ahhhhhh. There’s the green. Like there was any doubt. But who really cares when the writing is on the wall for all to see. If you can’t read, don’t blame patient longs. Unless you need to sell in the short term, relax, pour yourself a tall glass,kick your feet up next to the fireplace, and giggle at the theatrics. I get we want returns yesterday, but you have the opportunity to set yourself for the inevitable future. That’s what I have already done....
Votes:
4
1
Quantexa News
01/16
Esperion stock falls on higher operating expense forecast
Investing.com -- Shares of Esperion (NASDAQ: ESPR ) Therapeutics (NASDAQ: ESPR) fell 5.8% after the company provided an update on its expected operating expenses for the fiscal year ending December 31...
Quantexa News
01/16
Bank of America Securities Reaffirms Their Sell Rating on Esperion (ESPR)
In a report released today, Jason Zemansky from Bank of America Securities maintained a Sell rating on Esperion ( ESPR – Research Report ), with a price target of . The company's shares closed yesterd...
Yahoo Finance Community
01/16
Comment
So appropriate!!!! Up a nickel for our friend Kurt. Poor kid still doesn’t get it. But he’ll plug away and try again another rainy day when ESPR is down a few cents. All looking past the pile of gold that awaits long shareholders. One can only giggle with feet warming next to the fireplace drinking a nice drink of choice as the hysterics start up again....
Votes:
3
0
Yahoo Finance Community
01/16
Comment
Don’t look now, but the big boys are putting two and two together. Triple pill combo out to 2040+ . Daiichi begged for rights for Europe and they only had to agree to pay for all trial and filing costs, give 20-25% back to ESPR in royalties and pay all manufacturing costs indefinitely. Guess who has the patent in US for triple pill combo? Once espr finds the right partner, a few billion upfront , trial costs, royalties, and you got it….a big pharma partner will be onboard. Or ESPR is bought out. Either way, start counting the billions. I lost count after 10....
Votes:
3
0
Yahoo Finance Community
01/17
Comment
Losing 1.5487% of its value is just a regular day for Esperion. Even so, all of the indices making so many gains over the past week, it must bring a sense of regret to long term Esperion shareholders. The moment where they realize how much opportunity has been lost while watching Esperion decrease in value day after day after day. So sad....
Votes:
1
2
Yahoo Finance Community
01/17
Comment
So here is the strategy. There is 0 competition for a decade or more for BA. ESPR owns the patent for triple pill combo. Daiichi agreed to run trials and incur all costs in Europe (including manufacturing) while giving pure profit of 20-25% in perpetuity to 2040+. Same exact thing will be done in US, but with even more favorable terms as BA is completely derisked with fda approval for primary treatment and Daiichi sales proof. ESPR does not want to run another trial and incur costs to avoid short term expenses and knock on balance sheet/debt, but rather partner like done with Daiichi. This is a winning strategy and a buyout is still likely. Shorts have no rebuttal. It’s like that one friend who always has the blank stare in every conversation. That would be Kurt, aka, Bubba....
Votes:
4
1
Yahoo Finance Community
01/17
Comment
Shorts are working hard to push their narrative, but the facts remain: ESPR is a truly unique medical company with life-saving medicines. Esperion’s treatment represents a new class of heart disease therapy poised to challenge outdated options. The market potential is enormous, and even capturing just 20% could deliver significant returns for long-term investors. Stay patient—good things are coming....
Votes:
5
0
Yahoo Finance Community
01/18
Comment
Hey Gregg, good info posted. How long will it take for the herd to figure out that big pharmas next step is to buy ESPR out for any price to protect and enhance its weight loss drug portfolio (on top of everything else!): Combining an inhibitor of liver ACLY, bempedoic acid, and the GLP-1R agonist. $20 was appears way too low of a target price....
Votes:
4
0
Quantexa News
01/18
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Update
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 32,350,000 shares,...
Quantexa News
01/18
Short Interest in Esperion Therapeutics, Inc. (NASDAQ:ESPR) Rises By 27.0%
NASDAQ:ESPR – Get Free Report ) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totalling 32,350,000 shares, an increase of 27.0%...
Quantexa News
01/19
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $7.30 Average Price Target from Analysts
Shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) have been assigned an average rating of “Hold” from the five brokerages that are presently covering the stock, MarketBeat.com re...
Quantexa News
01/19
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $7.30 Consensus Price Target from Analysts
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) has been given an average recommendation of “Hold” by the five research firms that are presently covering the stock, MarketBeat Ratings re...
Yahoo Finance Community
01/19
Comment
When ESPR is bought out, it will be very exciting. Sheldon already implied a price similar to inclisiran ($10b). My top guesses are MRK ( they already invested billions in oral PCSK9 which is limited and not out to 2029), LLY ( they bought inclisiran for $9.7b which is injectable and not well received), Amgen (injectable PCSK9) Regeneron or Sanofi( injectable PCSK9) ,AZN which is in cardio field, and NVS which has strong cardio metabolic portfolio. Big pharma needs blockbusters and our little ESPR has them and others in development-triple pill combo, aclyi metabolic, etc. PCSK9s are ducks in the water and ESPR has its sights on their patients. Using logic. It is only a matter of when, not if, a buyout occurs....
Votes:
7
0
Quantexa News
01/20
Key steps for tech entrepreneurs looking to thrive amidst the ESPR’s DPP mandate
Tech entrepreneurs, SMEs, and businesses across Europe may already be aware of the Ecodesign for Sustainability Products Regulation (ESPR), a legislation focused on creating sustainable products that...
Yahoo Finance Community
01/20
Comment
My dad got invited to the inaugural ball tonight sponsored by the pharmaceutical lobby. Guess what, Esperion is sponsoring the swag bags. It will include a Fendi handbag emblazoned with the Esperion logo, a Swarovski statue of the Lipid Lurker, and many pet grooming and house cleaning products enhanced with bempedoic acid. The value is stated at $2,000 per bag. With 1500 attending the ball, Sheldon is really pushing the boat out. Sheldon can't attend himself because he is in West Palm with his mother. Keesha will represent Esperion....
Votes:
1
0
Yahoo Finance Community
01/20
Comment
Andrea is on to something. Big institutions adding shares is just another sign that the herd is slowly noticing ESPR. I guess it is inevitable, as they want to own as many shares at these super depressed prices before the run up and buyout. How else can these firms make so much money? Just think, current patent is out to 2031 for US, with zero competition until 2027/2029, and they are inferior and have issues and will not address primary prevention. Triple pill combo in Europe extends out to 2040+ and US will follow. Too easy....
Votes:
5
0
Yahoo Finance Community
01/20
Comment
I have a feeling this will be a very bad trading week for poor Esperion. With the holiday today, there will be a lot of pent-up demand to sell shares going into the opening tomorrow. I think the lack of sales and dwindling cash is really starting to impact the share price. If only they could make some sales....
Yahoo Finance Community
01/21
Comment
Understandably, the other board seems to he hyper focus on the studies that could extend the life of the patents beyond 2030. It would make sense for Esperion to stop shoveling cash into the furnace trying to sell the drug as it is since no one seems to want it. They could cease further sales efforts, layoff the sales force and spend the remaining little cash on R&D. In three years they could have a salable product....
Yahoo Finance Community
01/21
Comment
One might ask, rightly, how this drug that was supposed to be a blockbuster, arrived in Q1 of 2025 selling only $30 million per quarter with sales growth now peaked. I think the answer is that the target addressable market was always over estimated. Management likes to put this figure at 70 million in the US, but in reality, it is only a tiny sliver of that. It seems 99% plus are happily taking their statins at $14 per month. Why pay nearly 20 X that amount for a pill that has delivers only a moderate reduction in LDLC....
Yahoo Finance Community
01/21
Comment
You can understand why big pharma are so interested in ESPR. Only drug with primary treatment. Other drugs in development for late 2027 and 2029 aren’t even pursing a majority of the market (primary treatment), limiting competition to 15% of the market and also having significant deficiencies , ie, no inflammation reduction, side effects, etc....
Votes:
4
0
Yahoo Finance Community
01/21
Comment
I am sad, but not surprised, that Esperion is opening the week down, again. With so much optimism about the nation's financial future under a new administration, people are latching on to companies that have a bright future. This draws capital away from risky and unproven enterprises....
Yahoo Finance Community
01/21
Comment
I am worried that when Esperion announces a $3 million quarter over quarter growth in sales, that the share price may hit all time lows, again. After so much talk of blockbuster, it would be inconceivable to think that after spending $25 million on sales and marketing, they would only achieve $#3 million in sales growth, but that seems to be the case. No wonder management delays the earnings release until the very last minute....
Yahoo Finance Community
01/21
Comment
It is officially the single most dangerous 2 week period of the year for ESPR. Given past history of stock issuance/dilutions during this time, and fiscal advantages of doing so in January, hold ESPR at your own risk. $1.50 last year at this time due to massive dilution, expect a bit less but similar concept very soon....
Quantexa News
01/21
How The Digital Product Passport Will Reshape Fashion Supply Chains
By Barbara Oswald T he textile and apparel industry is on the cusp of transformation. The EU Green Deal targets carbon neutrality by 2050, reinforced by regulations such as the Green Claims Directive...
Yahoo Finance Community
01/22
Comment
Knowing that there are no other molecules even seeking primary prevention approval, meaning for the next decade it will be statins and BA, is quite comforting. More comforting than that warm blanket and hot cocoa next to the fireplace in your most comfortable reclining chair....
Votes:
3
0
Quantexa News
01/22
Esperion Therapeutics Inc (ESPR) Stock: Assessing the Risk and Reward
The stock of Esperion Therapeutics Inc (ESPR) has gone down by -5.70% for the week, with a -12.60% drop in the past month and a 1.90% rise in the past quarter. The volatility ratio for the week is 8.1...
Yahoo Finance Community
01/22
Comment
It maybe the case that today's promotional activity causes an afternoon rise in the share price as unsophisticated penny stock investors hang on every forward looking statement. When this occurs, we typically see a significant drop in price the following day when more sophisticated investors realizes it is simply rehashing data from a five year old study. It is sad but predictable....
Yahoo Finance Community
01/22
Comment
I feel so good about this upcoming conference they are speaking at today. Sitting in my lazy chair by the fire with good things around the corner knowing that the stock is going to increase in price any day now when sales hit their inflection point lol...
Votes:
4
0
Yahoo Finance Community
01/22
Comment
Once again, I’d emphasize that the shorts are working hard to push their narrative. However, the facts remain clear: ESPR is a truly unique medical company delivering life-saving treatments. Esperion’s innovative therapy represents a new class of heart disease treatment poised to disrupt outdated options. With enormous market potential, even capturing just 20% could yield substantial returns for long-term investors. Stay patient—good things are on the horizon....
Votes:
4
0
Yahoo Finance Community
01/22
Comment
Low volume walk downs are the best. Longs who are patient are fine with a lower price to buy. That’s what I never quite understand with investor attitudes. If you are confident of the end result, and you factored in the time frame for your return, sit back and relax. Buy more on dips. Watch the shorts scramble to put food on the table and enjoy the show....
Votes:
2
0
Yahoo Finance Community
01/22
Comment
Buying will come today before the market closes or right after closing from the big holders. More approvals from other countries coming. They are studying and using the product at USF research dept and TGH. The big news will come if they don't need the other 2 markers for the doctors to add this to the daily regime....
Votes:
4
0
Yahoo Finance Community
01/22
Comment
The big take away on the SW board is the fact that the other doctor says that BA is prescribed so little by physicians because they are simply not aware it exists. This is angering the long-term investors because for years Sheldon has been trumpeting the benefits of their digital marketing campaigns and NASCAR sponsorship in raising awareness.The naive investors believe that an advertising campaign would be the best approach. They fail to realize that a meaningful campaign using television or relevant social media would likely cost a$100 million or better. For a niche drug, this type of spend is not on the cards. Very sad....
Votes:
2
1
Yahoo Finance Community
01/22
Comment
I think big pharma will look at what Daiichi is selling in Europe, plans for sales out to 2040+, no competition for many years, and decide they want ESPR. From a competitive standpoint, many would be interested in ESPR to reduce competition or damage competing big pharma (think PFE collecting royalties from Daiichi for 15 years on billions of sales per year). Just common sense....
Votes:
4
0
Yahoo Finance Community
01/22
Comment
I have returned from school now and I am watching the presentation. I am ten minutes in and it seems to be a review of the Clear Outcomes trial that were released 3 years ago when I was just twelve. Now I am 15 and have been seeing the same slides drug out over and over again. Yet no one seems to want these pills....
Yahoo Finance Community
01/22
Comment
I listened to the KOL presentation. All anyone needs to know is patients enjoyed a 43% cv death risk reduction with bempedoic acid. Primary prevention results are unbelievable. No wonder why Daiichi, Amgen, Sanofi, Merck, and dozens of other big pharma’s are calling Sheldon. Along with james’ calls, you’re talking hundreds per day. James, please stop calling Sheldon and let him take the calls from big pharma ceos! There are millions of lives at stake....
Votes:
6
0
Quantexa News
01/23
Buy Rating for Esperion Based on Strong Clinical Data and Market Adoption of NEXLETOL and NEXLIZET
JMP Securities analyst Jason Butler reiterated a Buy rating on Esperion ( ESPR – Research Report ) today and set a price target of $7.00. Invest with Confidence: Follow TipRanks' Top Wall Street An...
Yahoo Finance Community
01/23
Comment
I was disappointed when the Dr. qas asked why the number of BA prescription was so low. He said no one has ever heard of these drugs. He said he had to inform one of the cardiologists at his hospital that they existed, just yesterday. He said ot could take many years to raise awareness, well beyond patent expiration in a few years....
Yahoo Finance Community
01/23
Comment
Biogen has made an offer to acquire Sage at a 30% premium to the share value at offer. Analysts view this as the new trend, no more pie in the sky money for unproven pills. A similar offer would value Esperion shares at about $2.61 but then Sage didn't have the disaster balance sheet, lack of sales after five years, and the closet full of toxic agreements that Esperion holds. So it likely couldn't fetch that kind of premium....
Quantexa News
01/23
HC Wainwright Reiterates “Buy” Rating for Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They cur...
Yahoo Finance Community
01/23
Comment
The other board seems to be increasingly despairing. They too were shocked to hear from the expert doctor that no one in the CV community was aware of these drugs. The other board wants to do a mass email campaign to investor relations requesting that the board allocate $20 million for television marketing. While this seems like a good idea, it would only add to the $200 million + cash burn scheduled for this year and currently unfunded. Perhaps when they do the next equity round they could do another 20 million shares to fund the advertising....
Quantexa News
01/23
JMP Securities Reiterates Market Outperform Rating on Esperion Therapeutics (ESPR)
January 23, 2025 7:07 AM EST JMP Securities analyst Jason N. Butler reiterated a Market Outperform rating and $7.00 price target on Esperion Therapeutics (NASDAQ: ESPR).The ... This is a premium onl...
Yahoo Finance Community
01/23
Comment
I think the real breaking point on this stock will be the Q4 loss release. After five years on the market, it will be hard for management to report a $3 million increase in US sales after spending their usual $20 million on sales and marketing for the quarter. At the current growth rate, each sales rep is bringing in .5 new prescriptions per month. Many of these are on the free pills program offered by Esperion when the insurers refuse to pay....
Yahoo Finance Community
01/23
Comment
As shorts become desperate, their post becomes more frequent. Let’s hope we see a lot more nonsensical posts trying to convince you that ESPR does not have a blockbuster, Otsuka, Daiichi and OMERS are both partners who invested billions in ESPR and continue to invest to beyond 2040, that BA is the only drug approved for primary treatment besides statins, competition coming in won’t be for years and not address primary treatment, and milestones alone will support ESPR until profitable. Very sad....
Votes:
3
0
Quantexa News
01/23
JMP Securities Reiterates Market Outperform on Esperion Therapeutics, Maintains $7 Price Target JMP Securities analyst Roy Buchanan reiterates Esperion Therapeutics (NASDAQ:ESPR) with a Market Outperform and maintains $7 price target.
JMP Securities Reiterates Market Outperform on Esperion Therapeutics, Maintains $7 Price Target JMP Securities analyst Roy Buchanan reiterates Esperion Therapeutics with a Market Outperform and mainta...
Quantexa News
01/23
Promising Potential of Esperion's Non-Statin Drugs in Cardiovascular Disease Management
Esperion ( ESPR – Research Report ), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on the stock and...
Quantexa News
01/23
Esperion Therapeutics' (ESPR) “Market Outperform” Rating Reiterated at JMP Securities
‘s stock had its “market outperform” rating reaffirmed by JMP Securities in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $7.00 target price on...
Quantexa News
01/23
Positive Market Reception and Promising CVOT Data Drive Buy Rating for Esperion
BTIG analyst Thomas Shrader maintained a Buy rating on Esperion ( ESPR – Research Report ) yesterday and set a price target of $9.00. Invest with Confidence: Follow TipRanks' Top Wall Street Analys...
Yahoo Finance Community
01/23
Comment
People on here often point to the marginal success of BA in Europe as a pointer toward the promised success of BA in the United States. What they fail to recognize is that in Europe you have a central buyer and in the US you have a free market. For instance, in the UK, you have the National Institute of Clinical Excellence (NICE). Nice decides whether or not a drug will be used based not only on safety and efficacy but also based on price. Once all three have been established as working, the drug is accepted. NICE then issues prescription guidance to physicians and provides ongoing training as to when drugs are to be prescribed v. alternative. In the US, you have studies, physicians either read these or they don't and then you have sales and marketing to raise the profile and steer physicians into awareness. Unfortunately, Esperion's efforts …...
Yahoo Finance Community
01/23
Comment
So basically shorts argument no one wants these pills because sales don't grow as they should, yesterday the expert called out managment saying basically no one KNOWS these pills so the major issue is not that no one WANTS is that no one KNOWS so thats mgmt issue and not the product itself, conclusion great product in wrong hands...
Votes:
3
0
Yahoo Finance Community
01/23
Comment
I have been steadfast in saying short all you can. I said every pop is a short.Sheldon said sales would inflect. I said never.I said they would dikute and they did. I said problem with milestones before announced. No one wants this drug. Only desperate longs....
Yahoo Finance Community
01/23
Comment
Ok, be honest! Who bought below 2.05? I’m so happy I can burst. And hope to have more fund S soon of small day traders try knocking this down a few more nickels. You have to love the inefficient marketplace. How else did Warren Buffett make so much money? It’s almost too easy if you are patient....
Votes:
4
0
Yahoo Finance Community
01/23
Comment
Primary prevention won’t be touched by any competing non statin…..maybe forever! That is quite unbelievable. PCSK9s and CETP inhibitors can never compete. Don’t get me wrong, like inclisiran, they’ll find a niche, but they can’t compete against BA. The science has spoken and soon the herd will get it....
Votes:
2
1
Quantexa News
01/23
A Quick Glance At Esperion Therapeutics Inc (NASDAQ: ESPR) Stock: It Is up 25.12% From Its 52-Week Low; YTD, It Is Down -4.28 Percent
During the recent session, Esperion Therapeutics Inc (NASDAQ:ESPR)'s traded shares were 1.56 million, with the beta value of the company hitting 1.03. At the last check today, the stock's price was $2...
Quantexa News
01/23
Cautious Outlook on Esperion: Sell Rating Amid Market Challenges for Bempedoic Acid
Analyst Jason Zemansky from Bank of America Securities maintained a Sell rating on Esperion ( ESPR – Research Report ) and keeping the price target at $2.05. Invest with Confidence: Follow TipRanks...
Yahoo Finance Community
01/23
Comment
Thinking about this, MRK might buy ESPR. Ties to Sheldon. They have an inferior PCSK9 they are developing that won’t be ready for years and will not be for primary treatment, and they want to block a competing big pharma from buying and driving sales/capturing market. Very logical....
Votes:
6
0
Quantexa News
01/24
Esperion Therapeutics’ (ESPR) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reissued their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a report published on Thursday,Benzinga reports. They currently have a $16.00 target price on...
Quantexa News
01/24
Esperion Therapeutics (NASDAQ:ESPR) Given Market Outperform Rating at JMP Securities
JMP Securities reiterated their market outperform rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a report released on Thursday, Benzinga reports. They currently have a $7.00...
Quantexa News
01/24
Esperion Therapeutics' (ESPR) Market Outperform Rating Reiterated at JMP Securities
JMP Securities reaffirmed their market outperform rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a research report report published on Thursday morning, Benzinga reports. The...
Yahoo Finance Community
01/24
Comment
Oh my, the other board is awash with stock manipulation theories after yesterday's loss. It never occurred to them that the loss came on the heals of a well respected doctor stating that no one was buying the pills because doctors have never heard of them. These doctors must not he following NASCAR....
Yahoo Finance Community
01/24
Comment
So someone like BoA downgrades and people say they did it to buy shares lower price. However when espr gets a price target higher than current stock price, why do not these same people say they did it to sell their shares at a higher price.ESPR got positive analysts news yesterday and stock tanked. Id argue it was done to sell all shares. Stock got pummeled after. You cant be a hypocrite folks. Accept the stock is finished. Sales are a joke and they are doing nothing to change it. Someone should ask of what was spent on NASCAR over years, how many sales people could have been added?...
Yahoo Finance Community
01/24
Comment
ESPR took all the risk, paid for a $600m trial and studies, has agreements with big pharma and investment fund, and has a proven blockbuster. Competition is so far away and is for only secondary market, 15% of the demand. It’s like roulette, the wheel has spun, and your number hit. Now you just collect (I figured Kurt can understand this analogy)...
Votes:
6
0
Yahoo Finance Community
01/24
Comment
Someone on the other board said there are now 500K Europeans taking BA. If we do the math, this is generating $10 million per quarter in royalties (less than the cost of supplying the pills). This works out to $80 per patient per year in royalties. If sales grow to cover 3 million patients then Esperion would receive $240 million in royalties. Of course, this is many years away and the first $400 million will go to cover the payments due under the toxic Omers agreement....
Yahoo Finance Community
01/24
Comment
It’s almost too easy for the longs printing money here every week. Just remember everybody that all the shorts that we were going on a business at $.75 and to short it zero also Don’t forget that me and Anthony were telling everybody to buy in the high 20s...
Votes:
3
0
Yahoo Finance Community
01/24
Comment
Cha Ching. Another green day longs even though bio market was down. Like there was any doubt? Wait until the news is released that Daiichi is investing in ESPR and buying stock. Or MRK is partnering in Canada. Or Otsuka is funding development of new aclyi molecule. The news can really result in dramatic share price increases, and ESPR may never see below $10 a share again. I guess what I’m saying is be ready to help our weeping shorts as this can get ugly pretty quickly....
Votes:
3
0
Quantexa News
01/25
Esperion Therapeutics (NASDAQ:ESPR) Earns Market Outperform Rating from JMP Securities
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “market outperform” rating reissued by equities researchers at JMP Securities in a report issued on Thursday, Benzinga reports. T...
Quantexa News
01/25
Esperion Therapeutics (NASDAQ:ESPR) Earns “Buy” Rating from HC Wainwright
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They currently ha...
Quantexa News
01/25
SJS Investment Consulting Inc. Makes New Investment in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
NASDAQ:ESPR – Free Report ) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 25,000 shar...
Yahoo Finance Community
01/25
Comment
“Hello, this is Sheldon. Sure I’ll listen to your offer. Yes, you are not the first to call, but out of the dozens of companies, I think you have a shot” Big pharmaceutical companies, including industry stalwarts like Bristol Myers Squibb, Merck, and Johnson & Johnson, are bracing themselves for a significant challenge – the looming patent cliff. Between 2024 and 2030, blockbuster drugs are set to fall off patent, putting tens of billions of dollars in sales at risk....
Votes:
4
0
Quantexa News
01/26
Esperion Therapeutics' (ESPR) Market Outperform Rating Reiterated at JMP Securities
JMP Securities reissued their market outperform rating on shares of Esperion Therapeutics ( – in a report published on Thursday, reports. JMP Securities currently has a $7.00 target price on the bioph...
Quantexa News
01/26
Esperion Therapeutics' (ESPR) “Market Outperform” Rating Reiterated at JMP Securities
JMP Securities restated their market outperform rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a report issued on Thursday morning, Benzinga reports. They currently have a $7...
Yahoo Finance Community
01/26
Comment
I have been following Esperion for five years. Usually the average of analyst estimate for one year out is 10x the current share price. This figure is now out of whack with an average of $7.11. This means the share price should be at about $.70 which would seem more appropriate for a firm with the number of risks and challenges Esperion faces....
Yahoo Finance Community
01/26
Comment
“Sheldon, this is Daiichi. We know you are talking to Merck, PFE, LLY, Amgen , Otsuka, Sanofi, J&J, Bayer, Regeneron, and many others. But we think our $7b offer is fair. If you agree, we’ll put out a press release stating we are buying shares and pursing a US or global agreement. What do you say , buddy”...
Votes:
2
0
Yahoo Finance Community
01/26
Comment
So we should expect a Canada deal announcement soon . Perhaps an Australia deal as well. We’ll hear about new molecules, patents, applications and likely partnerships for the new molecules as well. The big one is what will be done with the golden goose market-US. Does ESPR partner with a big pharma with a much more favorable royalty and cash up front deal when compared to Otsuka or Daiichi ( trials are done and fda primary treatment approval in place, so completely derisked). Partner can fund triple pill combo effort and market quickly. Or does Sheldon slow walk and continue with 150 sales agents? Even Sheldon knows this has to change. So partner US right or sell the company. Either way longs win but this should be done in 2025....
Votes:
3
0
Yahoo Finance Community
01/26
Comment
I’m starting to think the strategy now is partner US and global rights, get boat loads of cash up front, place lucrative royalty deal, possibly milestones, and then look to build our new molecules with/without buying complimentary molecules (explains Sheldon’s comments on acquisition and maintaining 150 sales reps). Partnership on development of next gen molecules (think Otsuka with J.P. Morgan comments, OMERS, Daiichi, or new US partner). This is very logical....
Votes:
2
0
Yahoo Finance Community
01/27
Comment
I am worried that when people see the Q4 US sales numbers are stagnant and then they see the amount of cash that has been burned through in just one quarter, that we'll be sub-$1.00 again. Also, I believe that there will be a huge accounting loss related to the toxic agreements exited and entered into during the fourth quarter. This company just needs one piece of really good news that is not related to NASCAR sponsorship....
Yahoo Finance Community
01/27
Comment
I can see a hostile bid to take out ESPR by an astute big pharma. Really makes sense if you think about it. If they come in too low, they may bring in other bidders. So think of a fair bid that is multiples above current market cap but well below long term value potential of ESPR. It’s a very logical approach....
Votes:
5
0
Yahoo Finance Community
01/27
Comment
Big market sell off today. Mostly related to Chinese DeepSeek AI implications. DeepSeek would be useful for any of the long pumpers here. Because it’s a deep seek up where the sun don’t shine to pull your head out. Hope no one’s lost money believing the pumps....
Votes:
1
0
Yahoo Finance Community
01/27
Comment
On December 9, ESPR was at $3.94 today on January 27. We are at $2.00 there has been nothing that’s happened that we should’ve lost 50% of our value that’s why I will continue to buy. Back up to 97,000 shares Strong, including options of course June’s....
Votes:
5
1
Quantexa News
01/28
Equities Analysts Offer Predictions for ESPR FY2028 Earnings
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) – Investment analysts at HC Wainwright lowered their FY2028 earnings per share estimates for shares of Esperion Therapeutics in a note issued...
Yahoo Finance Community
01/28
Comment
Longs need to forgive the desperation of some shorts on this board. They have not factored in the reduction of $80m annually for Daiichi taking over manufacturing. Also, $130m milestones are due. On top of other markets starting up, including the enormous Japan shortly, you can see why longs are happy and shorts are so sad....
Votes:
4
0
Yahoo Finance Community
01/28
Comment
The other board seems to have lost all hope. One thinking poster writes that Esperion is promoting their "five years out" indications in a desperate attempt to raise more equity capital. This make sense since it is unlikely that equity investors would fund stagnant BA sales and $1 million per day in cash burn....
Votes:
2
1
Yahoo Finance Community
01/28
Comment
Snuggled up in my comfy warm chair next to the fire watching the opportunities grow on Wall Street. None compare to our little ESPR which warms my toes more than the roaring fire. I’ll start with warm cocoa and end with a nice red wine in the evening. ESPR’s day will be soon enough. Leave the hysterics to shorts trying to put food on the table....
Votes:
2
0
Yahoo Finance Community
01/28
Comment
I don’t know if everyone remembers Kurt/ bubba, but he was pushing nktr at about $1.30. Look at it now. This is common with all small bio. Astute investors see the market influences on their stocks and understand the fundamentals of the companies they own. If they don’t, they just end up like Kurt, buying high, selling low, and repeating the money losing effort....
Votes:
1
0
Yahoo Finance Community
01/28
Comment
I am worried that when Esperion announces a $3 million growth in US sales for the quarter, after having spent $25 million in sales expense, the market will react very negatively. After, 5 new prescriptions per week generated by 150 sales people, is not very encouraging. It kind of validates BofA's assertion that sales have peaked....
Yahoo Finance Community
01/28
Comment
As you know, I try to be diligent in my research. In looking at the other board, I thought one poster summed up the sentiment that seems to be driving investors when it comes to Esperion. He said:"I’m all out. Can’t afford to go negative. This is just going down the toilet everyday while most of the market is going sky high. Too much opportunity cost. Thanks to all the bulls for all the good info and data. Hope it all works out for you guys in the end. But this is like climbing a steep mountain without any hiking gear."I thought it was really touching and that everyone here would benefit from it....
Votes:
1
2
Yahoo Finance Community
01/28
Comment
The current price is so arbitrary with massive debt and min sales growth, and negative earnings almost all preset royalties. The market and insiders know this. Fair value is way under $1, either way reverse split inevitable sooner than later. But new shares issuance is imminent and leaked....
Votes:
1
5
Yahoo Finance Community
01/28
Comment
ESPR is a long term play and short term fluctuations are of no concern. The science and product performance in lowering LDL is proven ;it's a matter of time it gets the full recognition in Medical community and the sales ramp up. The current SP is undervalued and a good buy at this level....
Votes:
5
0
Yahoo Finance Community
01/28
Comment
DOD contract goes into effect, demand increases dramatically, and everyone acts so surprised when ESPR is profitable. Yup, so predictable and so glad the market keeps insisting on giving me cheap shares. I really have to figure out who to thank....
Votes:
4
0
Yahoo Finance Community
01/28
Comment
I can see Sheldon going in one of two directions-stay with ESPR forever so partner US in a Daiichi like cash up front and royalty deal OR sell the company outright. Either way, longs win and my island is quite large. Thanks, shorts, for stuffing my pockets with so many shares....
Votes:
4
1
Quantexa News
01/29
HC Wainwright Brokers Decrease Earnings Estimates for ESPR
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) – Stock analysts at HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a report issu...
Quantexa News
01/29
What is HC Wainwright’s Estimate for ESPR FY2028 Earnings?
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Investment analysts at HC Wainwright lowered their FY2028 earnings estimates for shares of Esperion Therapeutics in a research note issued on...
Yahoo Finance Community
01/29
Comment
I am sad, but not surprised, that Esperion is down again. I think the investment community is coming to terms with the quarterly process of hype, hype, hype followed by a set of numbers that does not quite agree with the promise of "blockbuster status". It is very predictable at this point, along with the cash dwindling to dangerously low levels again....
Yahoo Finance Community
01/29
Comment
Historically, investment analysts have had a one-year target estimate on Esperion that is about 10X the current share price. For months now, this has been out of range. The average target one year price is now $7. I believe that we will see a share price correction to about $.70 to correct this ratio....
Yahoo Finance Community
01/29
Comment
Why, pray tell, is Sheldon still in charge at ESPR? There is no excuse to keep him on and pay him for this company's dismal performance since he was hired. Shareholders, stakeholders, BOD members are you all blind? Give him and his cohorts the boot and sell what's left here to the best bidder. This circus is a total waste of time and resources....
Votes:
4
0
Yahoo Finance Community
01/29
Comment
Maybe the quarterly loss call, to be scheduled sometime in February, will provide some meaningful updates. If it follows tradition, we will learn:Heart disease is the number one killer and bempedoic acid meets an unmet need in treatmentthe management team will review their key accomplishments during 2024 including the refinancing of toxic debt agreements with even more toxic debt agreementsthey will tout their digital marketing prowessthey are really pleased with their progressthey will not mention the DSE manufacturing takeover because DSE has informed them they won't take it over until 2027 when Sheldon had stated in would be late 2024.they won't address concerns that after five years on the market, the drug is facing stagnating sales in the USthey will reiterate spending guidance at $240- 250 million for the year unless they need to defend more lawsuits....
Yahoo Finance Community
01/29
Comment
High interest rates and drug price control is killing small bio. Unfortunately, ESPR is lumped into this group. Since I don’t have to sell for decades, I can roll With the punches, pick up cheap shares, and am confident that BA will succeed and shareholders will be rewarded soon. Profitability cures all and ESPR has a lot of pathways to make it real big....
Votes:
5
0
Yahoo Finance Community
01/29
Comment
Listen, if shorts are going to post nonsense about dilution, RS, and the likes, we might as wall discuss more likely scenarios such as buyout at $6b, or partnership of US rights for $3b, etc. ESPR has $150m cash, has $130m cash slated to arrive from Otsuka in 2025, and will be profitable soon. All else is nonsense and market driven. I say buy more when you can....
Votes:
6
0
Yahoo Finance Community
01/30
Comment
I wonder what deal will be announced first-Canada/Australia, China, US, new molecule partnership or buyout? Any one of them will be great. And Friday is coming here soon so we’ll have the day traders covering due to strong sales. It seems like a snow ball effect will occur with a quick share price recovery, as we have seen many times in the past. But one of these times we’ll be at $10, moving to $20, and everyone will be happy....
Votes:
4
0
Yahoo Finance Community
01/30
Comment
At least tomorrow is Friday. We typically see a 10% uptick even when the bio market is down. Double digit script growth week over week over week will do that. Wait until all these new doctors start prescribing to new patients and the DOD contract is effective. You can understand why shorts are so nervous....
Votes:
5
0
Yahoo Finance Community
01/30
Comment
It just feels like espr wants to bounce quickly to $4. It almost made it a few weeks ago, and with a little news, $5 should be breached . Then we are double digits and $20 is a few good Friday script reports away. When you think logically it’s amazing we have the opportunity to buy ESPR under $20....
Votes:
3
0
Yahoo Finance Community
01/30
Comment
I heard Kurt was hit hard by SMCI and lost his shirt. Even his own made up group-the syndicate-kicked him out. Poor kid. I hope he is alright. I miss his bomber posts and him telling everyone how much money he made on every other stock but ESPR. If he only invested long in ESPR he could ride it up to $20 as all of us longs will do....
Votes:
3
0
Yahoo Finance Community
01/30
Comment
Listen, shorts crying ESPR is going lower is fine with me. I’ll buy more before it inevitably recovers. And if you cry dilution, fine, more shares that will be bought when ESPR is rolling in billions of revenue per year. If you want to scare longs, tell them that daiichi or a hedge fund will buy ESPR for $4b. Now that my friend, makes me shiver even when I’m drinking my hot cocoa next to the fire place. Brrrrrr!...
Votes:
4
1
Yahoo Finance Community
01/30
Comment
We already know the future. The science has spoken and unless a new study comes out to rebut the hundreds out on BA about its safety and efficacy, all else is hysterics. Bio is down. But small bio soon to be big bio with big revenue are few and far between. ESPR made it so if it gets pushed down, buy more. Make it proportional so if it goes down more, more is bought. So when it is inevitably $20, shorts simply helped longs’ bank accounts. I can live with that....
Votes:
4
2
Yahoo Finance Community
01/31
Comment
Hey Jimmyboy!!! Read DSE sales? Will you post some smoke now that in Europe they have green blood and the US it’s on some other planet??? Esperion is a company with a blockbuster so get used to it.For those who really care 242MM is DSE projections for 2024 revenues, at this 15% pace OMERS will be paid in 3 years aprox. Esperion needs a partnership to market this drug right in the US and voila… you will have a billion dollar in sales drug by 2027....
Votes:
2
0
Yahoo Finance Community
01/31
Comment
Yes , looks like inflection of sales is starting . It was very clear to everyone this would happen. A few funds might try to keep ESPR down before they cover but now it is only a matter of time before the ramp in share price begins. Just remember longs, shorts have made this opportunity to buy at such depressed share prices, so they are to thank for our inevitable riches....
Votes:
3
0
Yahoo Finance Community
01/31
Comment
Again, a longs biggest concern should only be regarding a cheap buyout of $4 to $5b. Other than that, it’s sit by the fire and pick up more shares at these low prices. I suspect Amgen, sanofi, Regeneron, Daiichi, Otsuka, OMERS, PE firms, MRK are the likely buyers and then there are all others like J&J, PFE, Bayer, etc. ESPR has not built out the infrastructure to sell BA (or other developing drugs) in scale, and a partnership or sale is the only way. Tick tick boom....
Votes:
5
0
Yahoo Finance Community
01/31
Comment
I thought there would have been an opening pop because retail investors seem to spin any news into good news. I see that they are becoming more discerning so there was no buying frenzy from their side even as the institutions continue their exit. Hopefully not another 10% down day which has become some common on this march to 0....
Yahoo Finance Community
01/31
Comment
Early this morning, someone on this board called Alberto, told me that news out of DSE on European sales was fantastic and indicated a blockbuster drug. I was so excited, and I believe the share price would soar today on the news. Now I see it is down again, and I feel like I've been misled by this poster. A little betrayed and a little sad about it....
Yahoo Finance Community
01/31
Comment
Relative to the US, DSE had pretty good growth in Europe over the last quarter. Clearly, from the share price action, not as good as investors would have hoped. My fear is that when Sheldon announces $3 million in US sales growth for Q4, after having spent $25 million in sales and marketing expense during the quarter, that this thing will be back at $.70. After all, $25,000 spent per new prescription is a pretty horrendous outcome that validates BofA's theory that sales have peaked. Scary times....
Yahoo Finance Community
01/31
Comment
Please explain me why would they dilute? 140MM cash by 9/30 then 45MM from debt restructuring plus 10MM from Otsuka and 33MM from sales, that’s 235MM aprox 12/31, expenses will likely be 65MM. That leaves a 170MM in cash plus sales in the US that will cover until next Otsuka milestone....
Votes:
3
0
Yahoo Finance Community
01/31
Comment
New lows being made daily. Sales are not increasing enough for this to survive. Markets pricing in BK. No manipulation. Our short has paid off so much.I have to sayLongs are losers!!!!! A loser cant accept when they lost. Last bagholder, turn off the lights....
Votes:
1
0
Yahoo Finance Community
01/31
Comment
Who gave up? Who is close to giving up?Sales are showing minimal growth at best. Peak sales are weeks away. Stock is screaming it.We do not feel sorry for any of you. We and James have been screaming for years to short this.PTLA. Sheldon does not want to increase sales. Wants to have this taken private at 1.25! A share....
Votes:
1
0
Yahoo Finance Community
02/01
Comment
Name the biggest clowns now that failure has arrived. Who pumped this the most?Folks its over. This has been over.There are winners, there are non winners and then people like anthony, gary, RS, charles. To be in a stock for five years and to never bank a profit. It’s impossible. It really is. You all are down so much. You will never even get to where you are down only 70% of investment. Getting even is like one of you going to the moon. Impossible.Sales were so bad this week by the way. Next week is 1.6s...
Yahoo Finance Community
02/01
Comment
In 2020, Sheldon stated he was thinking of retiring but decided to take position at ESPR. This can explain the strategy in US. Create value by getting fda and. Ema approval, prove market by partnering Europe and Japan, leaving the golden goose unencumbered and ready for partnership but more likely sale. Each step is very predictable so sale would be anticipated soon based on stages of company to date. Could even time partnership/sale to development of new molecules....
Votes:
5
0
Yahoo Finance Community
02/01
Comment
nice study issued on triple combo >> Rapid reduction of low-density lipoprotein cholesterol to target levels immediately following acute coronary syndrome event is critical to prevent future events. High dose statins alone often fail to achieve ldlc goals. pcsk9 combined with high-dose statins improves ldlc goal attainment...
Votes:
5
0
Yahoo Finance Community
02/01
Comment
You have to expect with Canada deal (perhaps other territories) announcement we’ll see an uptick. Very interesting action with the shorts. Imagine a big pharma North America deal with US? We would literally be $10 to $20 overnight depending on the details....
Votes:
4
0
Yahoo Finance Community
02/02
Comment
If I were a short I would be nervous about a Canada and/or larger partnership being announced and resulting in a big jump in the share price. It can even be a partnership for development of triple pill combo in US or a new molecule development (think Otsuka and new acyl molecule). Once the covering starts, it may not end until $20. Wow, now that is scary....
Votes:
2
0
Quantexa News
02/03
Esperion Therapeutics Inc (NASDAQ: ESPR) Prices Could Soar To Much Higher Levels In Coming Months
In the latest trading session, 0.81 million Esperion Therapeutics Inc (NASDAQ:ESPR) shares changed hands as the company's beta touched 1.01. With the company's most recent per share price at $1.79 cha...
Quantexa News
02/04
41,779 Shares in Esperion Therapeutics, Inc. (NASDAQ:ESPR) Purchased by China Universal Asset Management Co. Ltd.
China Universal Asset Management Co. Ltd. bought a new position in shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) during the 4th quarter, according to the company in its most rece...
Quantexa News
02/04
Esperion (ESPR) Receives a Sell from Bank of America Securities
In a report released today, Jason Zemansky from Bank of America Securities maintained a Sell rating on Esperion ( ESPR – Research Report ), with a price target of . The company's shares closed yesterd...
Yahoo Finance Community
02/04
Comment
The premarket seems to be pointing to a down day for poor Esperion. I think they delay in the quarterly/2024 loss report is sending negative signals to the market. Investors are not expecting much, we know that US sales growth is very poor, but there must be other bad news lurking that management is not keen to disclose. Part of it is the rapidly dwindling cash position. There may also be a major accounting loss that occurred as the transitioned out of their toxic revenue sharing agreement into a new toxic agreement. Also, they have gone very quiet about the Japanese milestones, so perhaps these have been denied like DSE denied the European milestone payment. So much risk. Very sad....
Yahoo Finance Community
02/04
Comment
The market cap for Esperion is currently $347 million. Ironically, the deferred tax credits for Esperion, as a result of the many billions they have lost, is far greater than the market cap. If Esperion would stop selling the pills, lay off all the employees and sell the company as a tax shell, it would be a much better scenario for the shareholders than the one that is playing out. It is very sad....
Yahoo Finance Community
02/04
Comment
So when OMERS is paid off in 2028 or so, Daiichi will be paying ESPR hundreds of millions of dollars per year in royalties. Add that to Otsuka’s and the North American deal being set up, you can see why many are bullish. Don’t forget the new molecules, patent out to 2040+ for triple pill combo, and you can understand why Sheldon thinks ESPR is worth as much as inclisiran....
Votes:
5
0
Yahoo Finance Community
02/04
Comment
The other board seems very down again today. As I always knew would be the case, the focus of their anger seems to be poor Sheldon. Sheldon should have done TV commercials, Sheldon doesn't know how to sell, etc. etc. You must remember, to sell something - it generally has to be a desirable product. This has always been the problem....
Yahoo Finance Community
02/04
Comment
What makes ESPR move: New molecules, nope. Awarded Primary treatment, nope. Dod contract, nope. Japan start up, nope. Triple pill combo in Europe, nope. Soon to be profitable, nope. $130m milestones confirmed for 2025, nope. Soon to be announced Canada /Australia deal, nope. Talks with Amgen, nope. Kurt showed up as mo money, yup. Best indicator of future success for ESPR....
Votes:
2
0
Yahoo Finance Community
02/04
Comment
I am happy that retail investors were able to push this up by $.07 per share today on very low volume trading. These small gains will serve as a buttress against the devastating crash that will occur when losses are reported, and institutions continue their selloff....
Yahoo Finance Community
02/04
Comment
It’s really about the market cap and future potential. With triple pill combo out to 2040+, and Daiichi projecting billions of sales per year, and ESPR receiving 25% of those sales at no cost to ESPR, you can see why shorts are nervous. Japan is the third largest market and is ramping to start soon. ESPR can do the same agreement in US/Canada/globally, at any time. Triple pill combo would stomp out all other competitors. Then you add in other molecules , you can understand why Sheldon is thinking ESPR should have a $10b market cap in short order....
Votes:
3
0
Quantexa News
02/05
SG Americas Securities LLC Increases Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
SG Americas Securities LLC lifted its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) by 96.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities...
Quantexa News
02/06
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) has been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the stock, MarketBeat Ratings rep...
Quantexa News
02/06
Esperion Therapeutics Inc (ESPR) Moves 0.53% Higher: These Numbers are Too Good to be True
Esperion Therapeutics Inc (NASDAQ: ESPR) open the trading on Wednesday, with great promise as it jumped 0.53% to $1.89, before settling in for the price of $1.88 at the close. Taking a more long-term...
Yahoo Finance Community
02/09
Comment
Will this ever get over 2 again? How will they ever obtain blockbuster status unless you all referenced the chain blockbuster that went out of business?How will they get billions in revenues when they are growing 2 million a QTR and are currently 32 million?What will US revenues be after generics come to markets?How many outstanding shares will there be when generics come to market?Will there ever be an CC where sheldon answers 50% of questions? This dude knows nothing of this company. COHR CEO on his calls answers all questions becuase he is a legit CEO. Sheldon is a clown. He just binges netflix all day watching the big short. He destroyed this stock forever. Look at that chart. Look at how the stock is lifeless on the side of the road.When will longs ever male any money?...
Yahoo Finance Community
02/09
Comment
A lady called Janine called me. She was very upset. She said she was Charles' personal care assistant. She went to his apartment today and Charles was gone. She thought there might ne dowl play because she checked his bank and brokerage balances and they were both near $0. I explained that Charles lost all his money on Esperion. She was so relieved but also sad....
Yahoo Finance Community
02/09
Comment
Hahahah. It is all time low. And obsessed gambling m0r0ns like tony are still red faced crying every day in hope to return their lost 97% of value XDDDD Pathetic. It is so sad. You really made this board of a trash stock INTO YOUR LIVING SPACE. Your life must be ruined by your failed gambles XD While my 2024 saw 144% increase you are at all time low clinging to a dead company XDDD...
Yahoo Finance Community
02/10
Comment
One insightful poster here said Esperion may be delaying the Q4 loss report call as long as possible because their auditor is going to include a going concern statement in the audit letter. This would make sense since cash is dwindling rapidly and failing another equity round, it is unlikely that Esperion can survive through the summer. If only sales would increase just a little bit, it would give people some hope....
Yahoo Finance Community
02/10
Comment
I feel sad but not surprised that Esperion is down in opening trading today. Investor fears over the delayed announcement of Q4 losses, the pressing negative cash flow issues and the failure to grow sales in the key US market, are all weighing heavily on the share price. Add to this, the failure to secure either Canadian or Australian partnerships indicates a lack of interest in this drug not only in the US but also abroad....
Yahoo Finance Community
02/10
Comment
The other board is in a state of collective grief and anger today. They are blaming Esperion management and the BoD for this dreadful ending. In reality, they all wanted to keep their jobs. Standing up and stating that the drugs they produced after 10 years and billions in spend really only suited a very small patient population would have put them all out of work. So, you have to consider everyone's interest. Unfortunately, for the shareholders, they were slightly misled, but then many of them wanted to be....
Yahoo Finance Community
02/10
Comment
We know a Canada deal is pending. Australia as well. US as a greater deal may be in the works. Based on money upfront and stage for Europe and Japan, we are talking billions up front for US and royalties with milestones. All the rest is noise as clearly the plan is to partner or sell the company outright, and based on royalty deals in place, you are talking Npv of billions for just Europe and Japan alone. Then you have new molecules. I talk about short squeeze’s seriously, as just with Apple, things can change very quickly and I don’t want to see anyone hurt....
Votes:
4
0
Yahoo Finance Community
02/10
Comment
I think shorts are in trouble. Sheldon is catching on to the fact that his 150 sales team is inadequate for US sales and the BOD and management are storming his hacienda. Is it time for the inflection to begin? Longs predicted 2025 and it sure looks accurate. US partnership will decimate shorts and leave only longs with $&@“ eating grins....
Votes:
3
0
Quantexa News
02/10
Analysts' Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), Enanta Pharmaceuticals (ENTA) and Esperion (ESPR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY – Research Report), Enanta Pharmaceuticals (ENTA – Research Report) and Esperion (ESPR – Research Report)...
Yahoo Finance Community
02/11
Comment
This AI stuff is amazing. I just asked one of the bots why Esperion share price continues to be so low. It answered very well by citing competitive pressures from better drugs, lack of market awareness of the pills, poor management and, of course, concern over the horrific side effects....
Quantexa News
02/11
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of “Moderate Buy” from Brokerages
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) has been given an average rating of “Moderate Buy” by the six ratings firms that are currently covering the stock, Marketbeat Ratings repo...
Quantexa News
02/11
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Rating of “Moderate Buy” by Analysts
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, Mar...
Quantexa News
02/11
JMP securities lowers Esperion Therapeutics Price Target to $4 (ESPR)
February 11, 2025 4:13 AM EST JMP Securities Jason N. Butler Market Outperform Esperion Therapeutics (NASDAQ: ESPR) price target of $4.00 (from $7.00).The analyst commented, “We ... This is a premiu...
Quantexa News
02/11
Esperion price target lowered to $4 from $7 at JMP Securities
JMP Securities lowered the firm's price target on Esperion ( ESPR ) to $4 from $7 and keeps an Outperform rating on the shares. JMP updated its model ahead of the Q4 earnings report to reflect ongoing...
Quantexa News
02/11
Analysts' Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), Enanta Pharmaceuticals (ENTA) and Esperion (ESPR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte ( INCY – Research Report ), Enanta Pharmaceuticals ( ENTA – Research Report ) and Esperion ( ESPR – Research Re...
Quantexa News
02/11
HC Wainwright Reiterates Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports...
Yahoo Finance Community
02/11
Comment
I think that what you are seeing in this continuous price erosion is the exit of the long-beleaguered retail investor. I think the turning point for all of them was when that Doctor on the Esperion sponsored expert event said no one was taking the pills because most doctors have never heard of them. Since then, I think even the naivest investor realizes it's too little too late for this company....
Yahoo Finance Community
02/11
Comment
Small bio is all getting crushed. I know it stinks if you are fully invested but these are the opportunities that long investors dream of. Stocks are going down indiscriminately and that means opportunities. Doesn’t feel like it now, but that is how to make money....
Yahoo Finance Community
02/11
Comment
ESPR worst performer by 3X on my list of similar small cap biotech. CPIX top again. Unlike what some would have you believe this is 100% company specific. We overshot my 1.75 near term target and the horrific news isn’t official yet. Soon. Now looking at .9s, but quick in and out, doldrums/reverse split will follow....
Quantexa News
02/11
Esperion Therapeutics’ (ESPR) Market Outperform Rating Reaffirmed at JMP Securities
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report)‘s stock had its “market outperform” rating reaffirmed by JMP Securities in a report issued on Tuesday,Benzinga reports. They currently have a $4.0...
Yahoo Finance Community
02/11
Comment
If Daiichi will sell billions per year with triple pill combo out to 2040, what is that worth to ESPR receiving 25% of that indefinitely ? Then you have Otsuka anticipated to sell at least a billion (blockbuster) and ESPR collects 30% of that indefinitely. Then you have global, including US, which will likely be partnered for billions up front with similar milestones and royalty agreements. And then you have new drugs that will soon to be announced . All while ESPR will be profitable soon, has ample cash, will collect $130m in milestones from Otsuka in 2025, and receive partnership up front cash. You can understand why longs are giggling while collecting the free money that is being stuffed into our pockets....
Votes:
1
0
Yahoo Finance Community
02/11
Comment
I implore small investors to not listen to confabulations of longs. Wainwright, Geode Capital, others pump and dump and horrific records. Due diligence, including back review of posts to see buy points. It’s truly scary. This stock was at $100 a few years back, and has had FDA approval for over 4 years. It would be a trade at $.9s, or intraday bottom when new dilution announced....
Yahoo Finance Community
02/11
Comment
It’s interesting shorts always say look at the past, although the present and future dictates the future price of the stock. Similar to my analogy of Apple with the iPhone release, ESPR is not the ESPR of five years ago after clear outcomes trial, proven 40% fatality reduction for primary care, fda and Ema approvals for primary and secondary treatment, Daiichi killing sales in Europe, Japan soon to follow, and US/global to be partnered for billions. Then you have new molecules being announced in a few weeks. All while cash is ample, debt is pushed out to 2030, and sales are ramping. That is why I am loading my pockets as shorts cry....
Votes:
2
0
Yahoo Finance Community
02/11
Comment
My Mom says this is in a death spiral. She says that no one will underwrite the next dilution round because after six years they have no sales. She says their best bet would be to layoff everyone and just try to preserve cash so they can get about $.60 per share from a private equity firm specializing in troubled pharmaceuticals. This makes sense....
Yahoo Finance Community
02/11
Comment
Listen, if we get lucky, the big firms drive this down to .70 where we can all buy more. But unfortunately, I don’t think we’ll be that lucky. Best buy when you can before the inevitable swing in trades and ESPR runs. I like to say it is inevitable but it really is....
Votes:
4
0
Yahoo Finance Community
02/11
Comment
Some say a buyout would be good, but a 3x to 5x multiple would be the low end of long’s expectations from here . That would be a realistic low buyout price. A partnership of US rights is clearly the value play. You’re talking billions which would simply destroy shorts, and eliminate all risk as ESPR would collect royalties to 2040+. Would give Sheldon ample room to cash out and retire or play around with new molecules and make them a blockbuster franchise as well. This is not hard to see. Just a question of when . Longs would be smart collecting as momos cry all day long....
Votes:
2
0
Yahoo Finance Community
02/11
Comment
Any effort to grow in the US market with 150 sales persons from a small bio no one has heard of instead of partnering like Europe or Japan, fully utilizing a big pharmas sales, marketing, distribution and manufacturing capabilities, is something Kurt would do. Even Sheldon’s dim bulb is flickering with the idea of partnering US. Does it happen with Canada and US together, as it makes sense logistically? Is that what Ben and Sheldon meant when they said “ we are closer than most think”. Is that why the announcement in 2024 was delayed? Hmmmm....
Votes:
2
0
Yahoo Finance Community
02/11
Comment
I believed that ESPR held off partnering US as they wanted to prove Europe and Japan sales, and then sell the entire company to a global big pharma. Otsuka or Daiichi would not be the partner in North America, but there are literally dozens of big pharma who would jump at the opportunity. With the market cap at $350m, I think it is time to pivot to “cash cow “ plan, partner US and global territories, kick sales into overdrive, collect billions up front and in royalties per year, and develop new molecules while buying back stock, issuing distributions, etc. Triple pill combo funded by partner. Debt paid off. This isn’t too hard and Sheldon is stirring from his nap. The light bulb is flickering. He is coming to life....
Votes:
2
0
Quantexa News
02/12
Esperion Therapeutics' (ESPR) “Market Outperform” Rating Reaffirmed at JMP Securities
JMP Securities reaffirmed their market outperform rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a research report report published on Tuesday morning, Benzinga reports. They...
Yahoo Finance Community
02/12
Comment
The people on the other board are doing a lot of research trying to find out why Esperion failed with their pills in the US market. One researcher has been looking at the profiles of Esperion sales people and was shocked to find none had any pharma sales experience. There is one who was a waiter and another that came from a tanning salon and another who was a volunteer. They should have done this work two years ago before the company put itself back in a final cash crisis. Too little, too late....
Quantexa News
02/12
The EU Ecodesign Legislation: A Strategic Shift for Smartphone Manufacturers
The European Union’s Ecodesign for Sustainable Products Regulation (ESPR) will come into force on June 20, 2025. It will introduce a new framework to make electronic devices more sustainable. This law...
Yahoo Finance Community
02/12
Comment
It was up 1.8% in the earlier premarket, but it looks like this little gain is vanishing into another loss position out of the gate. I fear once the terrible Q4 losses are reported, this will sink rapidly to under a dollar again. I think the market has waited 6 years for sales in the US and unfortunately, they just never materialized. Sad....
Yahoo Finance Community
02/12
Comment
Tick tockTrend is your friend and that trend is lower. Generics soon. Stagnant sales ate here. Price is going lower.I heard keisha loves her job as VP of marketing. She not qualified at all but she is the right color. How is 2025 working out for you all so far?Anyone making any money or you all still losers that you have demonstrated?...
Yahoo Finance Community
02/12
Comment
I forgot to mention, we should expect some belligerent and belittling posts as well . You have to remember when gamblers start losing, they lash out fiercely. Along with a lot of misinformation and blatant lies, hostility is likely just around the corner....
Votes:
2
0
Yahoo Finance Community
02/12
Comment
I heard there are now rumors of a US or US/Canada partnership. Yes that makes sense given the billions in upfront payments, milestones and not including the 30% royalties in perpetuity, including for triple pill combo development, that would immediately put ESPR on the way to $20 per share....
Votes:
5
0
Yahoo Finance Community
02/12
Comment
Am I good or what: “I forgot to mention, we should expect some belligerent and belittling posts as well . You have to remember when gamblers start losing, they lash out fiercely. Along with a lot of misinformation and blatant lies, hostility is likely just around the corner.”...
Votes:
5
0
Quantexa News
02/13
Esperion Therapeutics (NASDAQ:ESPR) Given Market Outperform Rating at JMP Securities
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “market outperform” rating reaffirmed by analysts at JMP Securities in a report issued on Tuesday, Benzinga reports. They present...
Quantexa News
02/13
Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday,Benzinga reports. They...
Quantexa News
02/13
Esperion Therapeutics (NASDAQ:ESPR) Earns “Market Outperform” Rating from JMP Securities
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “market outperform” rating restated by equities researchers at JMP Securities in a report released on Tuesday, Benzinga reports....
Quantexa News
02/13
Esperion Therapeutics' (ESPR) “Buy” Rating Reaffirmed at HC Wainwright
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They present...
Yahoo Finance Community
02/13
Comment
I have this poster JAMES BLOCKED because of the worthless posts - full of lies and mis information, so I have no idea what it's posting anymore. It uses several ID's on Yahoo, sometimes remarking to itself. Pretty Pathetic. All you have to do is read its posts and make your own conclusion. Take away it's audience...BLOCK THER POSTER JAMES - you will miss nothing, and the forum will be more enjoyable....
Votes:
3
0
Yahoo Finance Community
02/13
Comment
After a little blip yesterday, I am sad but not surprised that Esperion is trending down again today. With so many existential challenges facing it, there is little to be optimistic about. Dwindling sales, little cash, enormous cash burn, poor management and so on. It is difficult to see the value here....
Yahoo Finance Community
02/13
Comment
With Australia-Canada/Us deal pending, you can understand why shorts are nervous this can triple overnight. If Daiichi and Otsuka partnered for smaller and less lucrative Europe and Japan territories for billions, how much is US worth to a big pharma partner? This is starting to get exciting!...
Votes:
4
0
Yahoo Finance Community
02/13
Comment
Everyone knows a US partnership is the only way to go. I believe it has not yet been done as Sheldon wants to retire and sell the entire company to a big pharma. Going the partner route for US may complicate a buyout or at the very least, limit the number of buyers. Even with a partnership, you then introduce funds such as blackrock or OMERS to buy ESPR and collect royalties for decades to come. I call this a win win win scenario for ESPR longs, as we are collecting our returns no matter the decision....
Votes:
4
0
Yahoo Finance Community
02/13
Comment
The other board seems to have turned very somber again. They seem to be resigned to final days. We know that sales stagnated in Q4 and that all European royalties have been sold off for many years in another toxic debt deal. I think everyone realizes that although management pumped a Candada deal, there was none to be had. Finally, as the cash dwindles to nothing, people realize there will be another 80% dilution round. Even worse, if they can't get it done, it's curtains. So sad....
Yahoo Finance Community
02/13
Comment
My guess is J& J is the partner for US and Canada. Do they start with one territory and roll into the other or just agree to a huge deal upfront? That will be interesting. But we all know Foody and Sheldon are best buds, and as global head of pulmonary development for J&J, it’s a matter of time before it is announced....
Votes:
4
0
Yahoo Finance Community
02/13
Comment
It feels like ESPR may hover around here to $2 and then one morning soon, BOOM! $6 and up over $10 from there. I’m nervous for shorts as longs don’t care if ESPR stays here for a bit but a quick jump in share price may really get shorts in a pickle....
Votes:
3
0
Yahoo Finance Community
02/13
Comment
So the question is , when in 2025 is the partnership announced? Makes so much sense . Why would any company try to replicate the sales, marketing, distribution, manufacturing, and take on the pure headache of building out the infrastructure to sell billions per year. The new molecules and patents point to partnership and development of new acly molecules and applications. It would explain why they are not developing a triple pill combo pill plan, even though ESPR has the patent and Daiichi is developing it in Europe. Also explains whey sales force is 150 people. Bingo!...
Votes:
3
0
Yahoo Finance News
02/13
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Esperion Therapeutics, Inc. Thu, Feb 13, 2...
Quantexa News
02/13
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Symbols Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Markets Stocks ETFs Tools Overview News Currencies Int...
Quantexa News
02/13
Esperion Therapeutics Inc (ESPR) plunge -0.53% in a week: will this be a lucky break through?
Esperion Therapeutics Inc (NASDAQ: ESPR) established initial surge of 5.03% at $1.88, before settling in for the price of $1.79 at the close. Taking a more long-term approach, ESPR posted a 52-week ra...
Quantexa News
02/14
Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a report released on Tuesday,Benzinga reports. The brokerage currently has a $16.00 target p...
Quantexa News
02/14
Esperion Therapeutics’ (ESPR) “Market Outperform” Rating Reiterated at JMP Securities
JMP Securities reissued their market outperform rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report sent to investors on Tuesday morning,Benzinga reports. They c...
Quantexa News
02/14
Esperion Therapeutics (NASDAQ:ESPR) Receives “Buy” Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a report issued on Tuesday,Benzinga reports. They currently have a $16.00 price target on th...
Quantexa News
02/14
Esperion Therapeutics (NASDAQ:ESPR) Given Market Outperform Rating at JMP Securities
JMP Securities reissued their market outperform rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a report released on Tuesday, Benzinga reports. The firm currently has a $4.00...
Quantexa News
02/14
YOKE equips all products with Digital Product Passports, as part of ESPR
YOKE equips all products with Digital Product Passports, as part of ESPR YOKE Industrial Corp. has equipped its full range of lifting and rigging products with Digital Product Passports (DPP), suppor...
Yahoo Finance Community
02/14
Comment
My guess is partnership with MRK, J&J, Amgen. Buyout from Daiichi or investment firm a real possibility. When you have a company projected to make billions from royalties alone (Europe with triple pill combo out to 2040+ and Japan), not even considering the golden goose US market, it’s obvious. Sheldon and certainly Ben get that. 2025 is the year so now it’s just when does it happen. It’s all very exciting....
Votes:
5
0
Yahoo Finance Community
02/16
Comment
The other board is still very sad. They used to talk endlessly about sales inflection points but sales never grew. Now they focus on conspiracy theories about the share price being manipulated by institutions. It never occurred to them that the price is being held back by lack of sales and horrific cash burn....
Yahoo Finance Community
02/16
Comment
I equate ESPR as a prospector who hit the mother load and found a gold mine on his property. He can dig up the gold alone or partner with Barrick, Newmont, Rio Tinto or another partner. Either way he is rich, but the timing of the success will change depending on how he decides to extract the gold. Does he dig up nuggets with 150 friends and family, or does he bring in the big firms with huge equipment, connections for processing and selling, while giving them a percentage of the take....
Votes:
5
0
Yahoo Finance Community
02/17
Comment
I equate ESPR with a pan handler who has been recognized as such by the local population. After years of promoting its pills as "blockbuster" it now seems as though this was a scam and there is little market for these pills that were so ineffective as to not qualify for the DSE milestone payment. Now that the population realizes they have been scammed, the panhandler will have to move on to new scams, like new molecules and such....
Yahoo Finance Community
02/17
Comment
The holiday today gives us a chance to contemplate on the bad news that will be embedded in the Q4 loss report. Look for a major accounting loss related to the refinancing of the toxic debt agreements with new toxic debt agreements. This may be in the range of $40-$50 million. Another issue that will not be addressed is the promise that DSE will take over manufacturing costs for Europe. We were promised this would occur in 2024 but DSE has determined they won't do it until 2027 or in the case that ESPR becomes bankrupt. Finally, we will learn that $25 million invested in sales and marketing over the quarter resulted in a sales increase of $3 million giving credence to the Bank of America analyst who stated that sales were peaking....
Yahoo Finance Community
02/17
Comment
Shorts are riding the down wave in small bio, hoping ESPR will follow that same trend. Everyone knows ESPR will turn soon. But gambling is a troublesome disease and the thrill of rolling the dice is strong. I hope no one loses everything like Kurt. That was a sad fall from grace that no one should suffer....
Votes:
5
0
Yahoo Finance Community
02/17
Comment
It’s clear ESPR has kept its sales force to 150 mostly inexperienced persons to eventually partner or sell. Why build out the sales, marketing, distribution and manufacturing when a partnership has that in place? Collect a few billion upfront, 30% royalties, no risk, and work on new molecules. Easy peasy. Of course, if you are short when it is announced, you are toast....
Votes:
4
0
Quantexa News
02/17
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Update
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) was the target of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling...
Quantexa News
02/18
Zacks Research Issues Negative Outlook for ESPR Earnings
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) – Stock analysts at Zacks Research cut their Q3 2025 earnings estimates for shares of Esperion Therapeutics in a research note issued to inves...
Polygon News
02/18
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
Esperion Therapeutics, a commercial-stage biopharmaceutical company, will report its third quarter 2024 financial results on March 4, 2025. The company will host a webcast to discuss the results and p...
Quantexa News
02/18
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025. Foll...
Quantexa News
02/18
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025. Foll...
Quantexa News
02/18
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
February 18, 2025 at 08:00 AM EST ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market ope...
Quantexa News
02/18
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025. Foll...
Quantexa News
02/18
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
February 18, 2025 at 08:00 AM EST ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market ope...
Quantexa News
02/18
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025. Foll...
Quantexa News
02/18
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025. Foll...
Quantexa News
02/18
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 2025. Foll...
Quantexa News
02/18
Esperion To Report Fourth Quarter And Full Year 2024 Financial Results On March 4
- GlobeNewsWire - Nasdaq) ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 MENAFN financial results before the market op...
Quantexa News
02/18
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4 Esperion Therapeutics, Inc. Tue, February 18, 2025 at 2:00 PM GMT+1 1 min read In This Article ESPR Esperi...
Quantexa News
02/18
Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4
ANN ARBOR, Mich., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: NASDAQ: ESPR ) today announced it will report third quarter 2024 financial results before the market opens on Tuesday, March 4, 20...
Yahoo Finance Community
02/18
Comment
So frequently, see an Esperion trading pattern where retail investors bid the stock up in the AM on very low volumes. This is most typically followed by a fairly large downward adjustment in the PM as institutions view the little pop as an opportunity to continue bailing out of their positions. I was also looking on etrade this morning and noted that the three analysts listed there that cover Esperion all have either sell or avoid ratings on the stock. We are nearing the end with this one. Very sad....
Yahoo Finance Community
02/18
Comment
ESPR may have been kept down artificially for a bit, but it also allowed the opportunity to load up on shares. A US partnership just makes too much sense now. It’s too valuable for an industry picking up every stone looking for blockbusters to address patent cliff. The investments in deficient alternatives like CETP inhibitors and oral PCSK9s shows you the desperation of big pharma. They want BA. They need BA!...
Votes:
5
0
Yahoo Finance Community
02/18
Comment
I feel the situation with ESPR is similar to walking on the beach on a warm summer day and running across some gold coins in the sand. When investigating, you find a whole bunch of gold coins. The more you stuff in your pockets, the more you find. People start noticing and some come over and start taking the gold coins as well. There’s enough gold for all but many just walk the other way, thinking it is too good to be true or there are better gold coins somewhere else to be found. So you stuff and stuff the gold in anything you can find, including your blanket and pails, and coolers. Who doesn’t want gold coins? Apparently, many don’t want them....
Votes:
4
0
Yahoo Finance Community
02/18
Comment
I’m being told after March 16th big news is coming.. deal was agreed on last December when Espr had that spike up.. big money partnership/or buyout coming. Espr wants the deal after March 15…after the big drop from 2 years ago March 15th…then trading for the last 2 year from .70-$3.30. Partnership/or buyout for $8.00+ would look good on both sides. Anyone that was buying higher had plenty of time for averaging down…Do your own DD.. this is 100% rumors.....
Votes:
5
0
Yahoo Finance Community
02/18
Comment
One astute observer pointed on the other board noted that there is usually a little retail investor led run up in the share price between the time the earnings called is announced and the time when it takes place. These poor souls convince themselves that good news is coming on the call. Sometimes they are so deluded they think whatever they hear is good news. As knowledgeable investor digest the actual news and start selling shares, the retail investor just left holding the bag....
Yahoo Finance Community
02/18
Comment
I am contemplating the earnings call. Here's what you can expect:a $40 - $50 million loss on the refinancing agreement that will be carried as an extraordinary item.US sales of about $33 million, a $3 million increase over Q3 with a cost of sales and marketing around $25 million, so sad.Cash at year end 2024 and now dwindled to about $75 million if they tell you what current cash is.Sketchy updates on future milestones because they may not be coming.No updates on DSE takeover of manufacturing in Europe becase DSE has informed ESPR they are deferring this cost until 2027 or when Esperion goes bankrupt.Just a normal quarter!...
Yahoo Finance Community
02/18
Comment
Wait until the announcement is made. $2b upfront, 30% royalties, $1b milestones, and triple pill combo development with all sales, marketing, distribution and manufacturing by partner. Precedent has already been set , and this was prior to fda and Ema approvals. I might be off a few billion....
Votes:
5
0
Quantexa News
02/18
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Down 8.1% in January
Esperion Therapeutics, Inc. ( – ) was the target of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 31,240,000 shares, a drop o...
Quantexa News
02/19
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Down 8.1% in January
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) was the target of a significant decrease in short interest in the month of January. As of January 31st, there was short interest totalling...
Quantexa News
02/19
Short Interest in Esperion Therapeutics, Inc. (NASDAQ:ESPR) Decreases By 8.1%
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) was the target of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling...
Yahoo Finance Community
02/19
Comment
Yep, stay short at you own peril...and thank you for staying short, it will only help the longs.And if you are a paid short shill such as JAMES (and all of it's alter egos) then should start looking for a new boss own a new forum to hang out in. You will deserve whatever you get - KARMA can really be a ..... (rhymes with witch if you can figure that out)...
Votes:
2
0
Yahoo Finance Community
02/19
Comment
I am sad that Esperion has opened down again today but not surprised. With the date for the quarterly loss report now revealed, investors are left to ponder the many existential challenges that management will gloss over when they report. Items such as stagnant US sales at a point where the company is spending three times what it takes in, looming patent expiration on their one salable pill and new more potent alternatives now entering the market. So scary....
Yahoo Finance Community
02/19
Comment
Some say ESPR will run soon as the funds are fully loaded. Sounds reasonable considering 13f’s reported show huge increases of holdings and limited shorting by the big boys. Now the little shorts may scramble to cover before the run, but some will hope and pray....
Votes:
4
0
Yahoo Finance Community
02/19
Comment
Yes, the slow and steady rise to $20 appears to have begun. A nickel here, a shiny nickel there, and before you know it, $20 a share. Very exciting times. A US partnership would be game changing and will get us to $20 much quicker perhaps overnight....
Votes:
5
0
Quantexa News
02/20
Esperion Therapeutics Inc (ESPR) Shares Rise Despite Market Challenges
Esperion Therapeutics Inc (NASDAQ: ESPR)’s stock price has plunge by 1.60relation to previous closing price of 1.87. Nevertheless, the company has seen a 6.15% surge in its stock price over the last f...
Yahoo Finance Community
02/21
Comment
All small bio are facing headwinds. But as always, things will change, some will rise , and the market will figure out where there is value. It happened in tech, oil, uranium, gold, and small bio is in line but you have to be patient. ESPR will distinguish itself by becoming profitable, proving its blockbusters, and I suspect, new molecules and applications that will add many billions to the franchise value....
Votes:
3
0
Quantexa News
02/21
ESPR supported and digital product passports issued by YOKE
YOKE Industrial Corp. has implemented Digital Product Passports (DPP) across its entire range of lifting and rigging products to comply with the European Union’s Ecodesign for Sustainable Products Reg...
Yahoo Finance Community
02/21
Comment
I am sad, but not surprised, to see Esperion trading down again. We must remember that the price will not rise until there are positive signals that Esperion can survive 2025. Unfortunately, US sales have stagnated, the company continues to burn through more than a million dollars per business day than it takes in, and all European royalty revenue was sold off in the lates round of toxic financing. When you consider the patents are running out in a few years, there is little cause for celebration....
Quantexa News
02/22
https://seekingalpha.com/article/4760973-esperion-therapeutics-little-upside-potential-in-their-earlier-generation-drug
Pgiam/iStock via Getty Images I last covered Esperion Therapeutics ( NASDAQ: ESPR ) five years ago, and before that, I used to cover it regularly. Our general strategy, with some notable exceptions,...
Yahoo Finance Community
02/22
Comment
The seeking alpha article made me giggle. “Let me see what they have been up to these days.” Who would right this drivel ? It reminds me of Kurt’s simplistic writing style. Reality is milestones were not discussed and that is $130m. Israel was partnered, and Canada and possibly other territories, including US, can be partnered for cash up front, including billions for US. Revenue was not considered, just current or past cash burn which does not account for growth of sales, removal of manufacturing costs in Europe....
Votes:
3
0
Yahoo Finance Community
02/22
Comment
Also, even if MRK has a reasonable oral PCSK9, how about other big pharma? Do they all say, ok MRK, you get the full heart health market , the biggest in the world, even with a PCSK9 with known limitations-no inflammation reduction? No other big pharma will want an alternative with primary risk reduction of 30-40% and inflammation reductions of 20-30%? No educated author would be so naive....
Votes:
2
0
Yahoo Finance Community
02/22
Comment
Seriously, who writes “That is probably why, after its LDL-C drug was approved in 2020, I must have lost interest in Esperion..” . You don’t know why you stopped following ESPR? You have to guess at a reason? Seriously? Kurt wrote more coherent posts when he had gifs with bombers flying over. Somehow, i suspect this author wanted to attach a gif or hand sketch a drawing but it wasn’t allowed....
Votes:
2
0
Yahoo Finance Community
02/22
Comment
Seeking alpha author conveniently ignores the fact that mrk’s outcome trial will complete around 2030. Are you kidding me? Shorts are so desperate it’s palpable. And that is why I am fully loaded sitting next to my fire place drinking my hot cocoa. Their desperation strengthens my resolve with every silly post or article....
Votes:
4
0
Quantexa News
02/23
The EU Ecodesign Legislation: A Strategic Shift for Smartphone Manufacturers
Smartphone companies that embrace these changes can build stronger, longer-lasting relationships with their customers while reinforcing their commitment to environmental responsibility. SOURCE: IDC B...
Quantexa News
02/25
Eight key aspects to know about the EU Ecodesign for Sustainable Products Regulation
The new Ecodesign for Sustainable Products Regulation1 ("ESPR"), which entered into force on 18 July 2024, is set to significantly reshape the regulatory landscape for companies operating in the Europ...
Yahoo Finance News
02/26
Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Xeris Biopharma (XERS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release Zacks Equity Research W...
Quantexa News
02/26
Esperion Therapeutics Inc (NASDAQ: ESPR) Is A Bargain Stock You Should Consider.
In the last trading session, 5.87 million Esperion Therapeutics Inc (NASDAQ:ESPR) shares changed hands as the company's beta touched 1.03. With the company's per share price at $1.73 changed hands at...
Quantexa News
02/28
Sigma Planning Corp Increases Stock Holdings in Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Sigma Planning Corp boosted its position in shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Free Report ) by 1,455.8% in the fourth quarter, according to its most recent filing with the Securiti...
Yahoo Finance News
03/01
Is Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now?
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Is Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now? Laiba Immad Sat, Mar 1, 2025, 7:2...
Quantexa News
03/01
Is Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now?
We recently compiled a list of the In this article, we are going to take a look at where Esperion Therapeutics, Inc. (NASDAQ:ESPR) stands against the other small cap pharma stocks. Impact of US Tarif...
Quantexa News
03/02
Esperion Therapeutics (ESPR) Projected to Post Quarterly Earnings on Tuesday
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ) is expected to announce its earnings results before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of...
Quantexa News
03/02
Esperion Therapeutics (ESPR) Projected to Post Earnings on Tuesday
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) will likely be announcing its earnings results before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings of...
Quantexa News
03/03
Esperion Therapeutics (ESPR) Projected to Post Quarterly Earnings on Tuesday
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Tuesday, March 4th. Analysts expect the company to announce earnings o...
Quantexa News
03/03
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Rating of “Moderate Buy” by Brokerages
Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) has received a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat reports. One eq...
Quantexa News
03/03
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Recommendation of “Moderate Buy” by Brokerages
Shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) have been given an average recommendation of “Moderate Buy” by the six ratings firms that are presently covering the firm, Marke...
Yahoo Finance News
03/03
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and eze...
Quantexa News
03/03
ESPERION THERAPEUTICS, INC. Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
– Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales – ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics...
Quantexa News
03/03
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
March 03, 2025 at 08:00 AM EST ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with...
Quantexa News
03/03
ESPERION THERAPEUTICS, INC. Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
March 03, 2025 at 08:01 am EST ANN ARBOR, Mich. March 03, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with C...
Quantexa News
03/03
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement with CSL Seqirus (ASX:CSL) for the ex...
Quantexa News
03/03
Esperion Partners with CSL Seqirus for NEXLETOL® in Australia
Esperion and CSL Seqirus Collaboration in Australia Today, Esperion Therapeutics (NASDAQ: ESPR) announced a significant leap forward in its mission to tackle cardiovascular health challenges. They ha...
Quantexa News
03/03
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
Esperion Therapeutics, Inc. – Esperion to Receive an Upfront Payment and Near-Term Milestones Along with a Profitable Transfer Price on Product Sales – ANN ARBOR, Mich., March 03, 2025 (GLOBE NEWSWI...
Quantexa News
03/03
Esperion Bags $5 Mln CSL Seqirus Deal To Commercialize Cholesterol Drugs In Australia, New Zealand
Esperion Therapeutics ( ESPR ), Monday announced that it has entered into a license and distribution agreement with CSL Seqirus (CSL) to exclusively commercialize NEXLETOL and NEXLIZET in Australia an...
Polygon News
03/04
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
Esperion reported strong revenue growth in Q4 2024, driven by increased prescription demand and global expansion. The company is focused on continued revenue growth, reaching profitability, and portfo...
Yahoo Finance News
03/04
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Esperion Reports Fourth Quarter and Full Year 2024 Financial Results Esperion Therapeutics, Inc. Tue, Mar 4, 2025, 6...
Quantexa News
03/04
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. “The significant progress we and our partners ach...
Quantexa News
03/04
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
Esperion Therapeutics, Inc. – FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million – –Q4 Total Revenue Grew 114% Y/Y to $69.1 Million; Q4...
Quantexa News
03/04
ESPERION THERAPEUTICS, INC. Esperion Therapeutics: Q4 Earnings Snapshot
March 04, 2025 at 06:18 am EST ANN ARBOR, Mich. (AP) — ANN ARBOR, Mich. (AP) — Esperion Therapeutics Inc. (ESPR) on Tuesday reported a loss of $21.3 million in its fourth quarter. The Ann Arbor, Mic...
Yahoo Finance News
03/04
Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates Zacks Equity Research Tue, Mar 4, 2025, 6:10 AM...
Quantexa News
03/04
Esperion Therapeutics (NASDAQ:ESPR) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the con...
Quantexa News
03/04
Esperion Therapeutics stock surges over 9% on strong Q4 results
ANN ARBOR, Mich. -On Tuesday, Esperion Therapeutics (NASDAQ: ESPR ), the biopharmaceutical company, reported better-than-expected fourth quarter results and provided an upbeat outlook for 2025. The c...
Quantexa News
03/04
Esperion Therapeutics (NASDAQ:ESPR) Issues Quarterly Earnings Results, Beats Expectations By $0.04 EPS
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.10) EPS for the quarter, topping the consensus esti...
Quantexa News
03/04
Esperion Therapeutics (NASDAQ:ESPR) Posts Earnings Results, Beats Estimates By $0.04 EPS
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ) announced its earnings results on Tuesday. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, topping analysts'...
Quantexa News
03/04
Esperion Therapeutics (NASDAQ:ESPR) Releases Earnings Results, Beats Estimates By $0.04 EPS
Esperion Therapeutics ( – ) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.04, rep...
Quantexa News
03/04
ESPERION THERAPEUTICS, INC. Esperion Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2024
Esperion Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2024. For the fourth quarter, the company reported revenue was USD 69.11 million compared to USD 32.25 m...
Quantexa News
03/04
Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2024 Earnings Conference Call March 4, 2025 8:00 AM ET Company Participants Alina Venezia - Director of Investor Relations Sheldon Koenig - President an...
Quantexa News
03/04
Esperion Therapeutics (NASDAQ:ESPR) Given “Buy” Rating at HC Wainwright
Esperion Therapeutics ( – ‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Tuesday, reports. They presently have a $16.00 target price on the biopharm...
Quantexa News
03/04
Esperion Therapeutics' (ESPR) “Buy” Rating Reiterated at HC Wainwright
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently hav...
Quantexa News
03/04
Esperion Therapeutics Inc (ESPR) Stock Faces 6.77% Weekly Volatility
The stock of Esperion Therapeutics Inc (ESPR) has seen a -13.19% decrease in the past week, with a -12.71% drop in the past month, and a -38.52% decrease in the past quarter. The volatility ratio for...
Quantexa News
03/04
Esperion Bags $5 Mln CSL Seqirus Deal To Commercialize Cholesterol Drugs In Australia, New Zealand
(RTTNews) - Esperion Therapeutics (ESPR), Monday announced that it has entered into a license and distribution agreement with CSL Seqirus (CSL) to exclusively commercialize NEXLETOL and NEXLIZET in Au...
Quantexa News
03/04
Esperion's Strong Financial Performance and Strategic Initiatives Justify Buy Rating
Analyst Serge Belanger from Needham maintained a Buy rating on Esperion (ESPR – Research Report) and decreased the price target to $5.00 from $6.00. Serge Belanger has given his Buy rating due to a c...
Quantexa News
03/04
Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4
CEO Sheldon Koenig expects to drive further revenue gains and reach operating profitability through the expansion of its bempedoic acid products in the U.S. and Europe and global expansion into key ma...
Quantexa News
03/05
Esperion Therapeutics (NASDAQ:ESPR) Given “Buy” Rating at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a research report sent to investors on Tuesday, Benzinga reports. The firm currently has a $...
Quantexa News
03/05
Citizens JMP Reiterates Market Outperform Rating on Esperion Therapeutics (ESPR)
March 5, 2025 5:28 AM EST Citizens JMP analyst Jason N. Butler reiterated a Market Outperform rating and $4.00 price target on Esperion Therapeutics (NASDAQ: ESPR).The ... This is a premium only art...
Quantexa News
03/05
Pre-Market Earnings Report for March 4, 2025 : PLUG, WVE, NYAX, OLPX, PMTS, EVGO, ESPR, FSTR, YMAB, SOPH, STIM, AMLX
March 03, 2025 — 04:00 pm EST Written by NASDAQ.com The following companies are expected to report earnings prior to market open on 03/04/2025. Visit our Earnings Calendar for a full list of expect...
Quantexa News
03/06
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.75 Average Target Price from Analysts
Shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat.com...
Quantexa News
03/06
Esperion Therapeutics’ (ESPR) Buy Rating Reiterated at HC Wainwright
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They curren...
Quantexa News
03/06
HC Wainwright Reaffirms Buy Rating for Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics ( NASDAQ:ESPR – Get Free Report ‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They present...
Quantexa News
03/06
Esperion Therapeutics Inc (NASDAQ: ESPR): A Stock Worth Watching
Esperion Therapeutics Inc (NASDAQ:ESPR) shares, rose in value, with the stock price down by -6.78% to the previous day's close as strong demand from buyers drove the stock to $1.65. Actively observin...
Quantexa News
03/07
Esperion Therapeutics' (ESPR) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Esperion Therapeutics ( NASDAQ:ESPR – Free Report in a research note published on Tuesday morning, Benzinga reports. The brokerage currently has...
Quantexa News
03/07
Can You Get A Quick Recovery From Esperion Therapeutics Inc (NASDAQ: ESPR) Given A -140.24% drop From High?
During the recent session, Esperion Therapeutics Inc (NASDAQ:ESPR)'s traded shares were 0.85 million, with the beta value of the company hitting 0.82. At the last check today, the stock's price was $1...
Quantexa News
03/08
Analysts Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) PT at $6.75
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) have been given an average rating of “Moderate Buy” by the six research firms that are presently covering the company, MarketBeat...
Quantexa News
03/08
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Rating of “Moderate Buy” by Analysts
Shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are covering the company, Market...
Quantexa News
03/10
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $6.75 Average Target Price from Brokerages
Shares of Esperion Therapeutics, Inc. ( NASDAQ:ESPR – Get Free Report ) have received an average rating of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat.com reports. On...
Quantexa News
03/10
Brokerages Set Esperion Therapeutics, Inc. (NASDAQ:ESPR) Target Price at $6.75
Esperion Therapeutics, Inc. ( – ) has earned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the stock, reports. One analyst has rated the stock with a sell ra...
Quantexa News
03/10
SGS hosts webinar on sustainability trends and solutions in the E&E industry
Geneva (March 10, 2025) – SGS, the world's leading testing, inspection and certification company, is delighted to announce a free webinar, ‘Sustainability trends and solutions in the E&E industry', on...
Quantexa News
03/11
SGS hosts webinar on sustainability trends and solutions in the EE industry
Geneva (March 10, 2025) – SGS, the world’s leading testing, inspection and certification company, is delighted to announce a free webinar, ‘Sustainability trends and solutions in the E&E industry’, on...
